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Sum m ary
Asthma is a chronic inflammatory condition characterised by airway 
hyperresponsiveness, inflammatory infiltrates in the bronchial wall containing 
eosinophils, and elevated serum IgE levels to common inhaled allergens. Over the last 
twenty years, the prevalence of asthma and allergies has increased markedly which 
cannot be explained by changes in genetic predisposition. A greater understanding of 
the regulation of the inflammatory responses in asthma will assist in identification of 
potential targets for therapeutic intervention. In this thesis, I have used a murine 
model of allergic airways disease to investigate (i) the effects o f Toll-Like Receptor 2 
(TLR2) activation; and (ii) the role of Glucocorticoid-induced tumour necrosis factor 
receptor (GITR).
Toll-Like Receptors (TLRs) are primary sensors of both innate and adaptive immune 
systems where they play a pivotal role in the response directed against structurally 
conserved components of pathogens. Synthetic bacterial lipopeptide Pam3CSK4 
(BLP) is a TLR2 agonist capable of modulating Thl and Th2 responses. I examined 
the therapeutic effect of Pam3CSK4 on established airways inflammation in a murine 
model of asthma. In mice previously sensitised and challenged with OVA, 
Pam3CSK4 given intraperitoneally markedly reduced the total inflammatory cell 
infiltrate and eosinophilia in bronchoalveolar lavage fluid. Pam3CSK4 therapy was 
associated with a reduction in OVA-induced IL-4 and IL-5 secretion from thoracic 
lymph node culture, airway inflammation, bronchial hyperresponsiveness, and serum 
levels of IgE. Pam3CSK4 therapy was also associated with an increase in OVA-
2
induced IFNy, IL-12 and IL-10 production. However, the anti-inflammatory effect of 
Pam3CSK4 was independent of IL-10 or TGF(3 but critically dependent on IL-12, the 
production of which by dendritic cells was enhanced by Pam3CSK4 in vitro. The 
heightened levels of IL-12 in turn enhanced a specific Thl response and decreased 
Th2 activity.
Glucocorticoid-induced tumour necrosis factor receptor (GITR) is expressed at low 
levels on resting T cells, B cells, and macrophages but at high levels on regulatory T 
cells. Although GITR expression is up-regulated on CD4+ effector cells upon 
activation, the role of GITR in Thl and Th2 cell development is unclear. Here I show 
that activation of GITR signalling by anti-GITR antibody markedly enhanced the 
induction of both Thl (IFNy) and Th2 (IL-5) cytokine production by naive 
CD4+CD25' T cells, but had little or no effect on established Thl or Th2 cell lines or 
clones. Consistent with this observation, anti-GITR antibody significantly enhanced 
the expression of the key Thl (T-bet) and Th2 (GATA3) transcription factors in vitro. 
Administration of anti-GITR mAb also markedly exacerbated airway inflammation of 
a murine OVA model of asthma with elevated production of OVA-specific IFNy, IL- 
2, IL-4, IL-5, and IgE. Furthermore, adoptive transfer of CD4+GITR+ T cells 
effectively abolished airway inflammation induced in SCID mice reconstituted with 
CD4+GITR' T cells.
The findings in this thesis provide direct evidence that TLR2 and GITR are important 
mediators in murine allergic airways disease, suggesting that TLR2 agonists and 
GITR could represent potential targets for novel therapeutic agents in clinical asthma.
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i.n. intranasal
i.p. intraperitoneal
IPEX Immune dysregulation, polyendocrinopathy, entropathy, 
X-linked syndrome
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ko knockout
LPS lipopolysaccharide
mAb monoclonal antibody
MACs magnetic cell sorting
MALP-2 macrophage activating lipopeptide 2
MHC major histocompatibility complex
MLN mesenteric lymph node
MLR mixed leukocyte reaction
mRNA messenger ribonucleic acid
NK natural killer
NOD mice non-obese diabetic mice
OD optical density
OVA ovalbumin
PAMPs pathogen-associated molecular patterns
PBS phosphate buffered saline
PBMC peripheral blood mononuclear cell
PCR polymerase chain reaction
PE phycoerythirin
Penh enhanced pause
PG prostaglandins
PMA phorbol 12-myristate 13-acetate
PRR pathogen recognition receptor
R A G ; recombinase-activating gene deficient mice
RANTES regulated on activation, normal T-cell expressed and secreted
RT-PCR reverse transcriptase PCR
SCID severe combined immunodeficient mice
SPF specific pathogen free
STAT signal tranducer and activator of transcription
TAMRA 6-carboxy-tetramethyl-rhodamine
TCR T-cell receptor
Tg transgenic
TGF-p transforming growth factor-(3
Th T helper
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TIR Toll/IL-1 receptor
TLR Toll-like receptor
TMB S ^ ’^ S ’-tetramethylbenzidine peroxidase
TNF Tumour necrosis factor
Trl T regulatory T cell type 1
Treg regulatory T cell
WT wild type
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Chapter 1
General Introduction
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1.1 Asthma
1.1.1 Introduction
Asthma is a chronic inflammatory condition of the airways characterised by 
reversible airflow limitation, airway hyperresponsiveness (AHR) and inflammatory 
infiltrates in the airway walls containing eosinophils, mast cells, and T lymphocytes. 
Asthma is divided into atopic and non-atopic types, whereby atopic individuals have 
elevated serum IgE levels directed against particular allergens.
T helper (Th) lymphocyte subsets, defined by the cytokines they secrete are thought 
to play a key role in the initiation and perpetuation of allergic airway inflammation. 
Th2 cells, producing interleukin (IL)-4, IL-5 and IL-13, are thought to be o f particular 
importance. (1 ,2 ) The network of cell types and inflammatory mediators involved in 
asthma is complex and the current understanding is reviewed in references (3-5). This 
fascinating aspect of applied immunology is rapidly developing, and is a very active 
area o f research.
The aim of the work presented in this thesis is to gain further knowledge into the 
immunology of asthma, and lead to new therapeutic approaches in the treatment of 
asthma.
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1.1.2 Cellular basis of inflammation in asthma
1.1.2.1 Innate and adaptive immunity
The immune response o f mammals can be divided into two parts: innate and adaptive 
immunity. The innate immune response provides a defence against infection, which is 
rapid (within a few minutes), but non-specific and has no memory. The innate system 
utilises many mechanisms to protect us against pathogens. This defence extends from 
physical barriers (for example skin) to the recruitment of inflammatory cells (such as 
macrophages, mast cells, eosinophils, neutrophils, and dendritic cells). Thereafter, the 
immune system produces a more specific response mediated by T and B lymphocytes. 
These lymphocytes eradicate pathogens more efficiently, and provide immunological 
memory, which confers increased protection against subsequent re-infections. The 
innate and adaptive immune systems are not mutually exclusive, with many cells of 
the innate system also participating in the effector mechanism of the adaptive 
response. A number of cells of both the innate and adaptive immune system have been 
implicated in the pathogenesis of asthma. A summary of the interplay of these cells’ 
interaction in the allergic inflammatory response associated in asthma is described 
below, and is summarised in Figure 1.1.
1.1.2.2 T helper (Th) lymphocytes
An integral cell in adaptive immunity is the CD4+ T cell. Mosmann and Coffmann 
first described the presence of two functionally distinct CD4+ helper T cell subsets,
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Figure 1.1 Cells thought to be involved in the pathogenesis of asthm a
Th2 cytokines have a central role in the pathogenesis of asthma.
Adapted from Lewis et al, 2002; (6).
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namely Thl and Th2, in 1986 (7). Thl lymphocytes are characterised by their 
production of interferon (IFN)y, whereas Th2 lymphocytes secrete interleukin (IL) -4. 
ThO lymphocytes produce cytokines characteristic of both Thl and Th2 clones. 
Subsequent studies demonstrated that Thl cells are an integral part of the cell 
mediated immune response to intracellular organisms such as mycobacteria, 
leishmania parasites and viruses (8), and involved in the actions of macrophages and 
cytotoxic T lymphocytes (CTLs). In contrast to Th2 cells, the differentiation o f Thl 
cells is mainly dependent on IL-12, which signals through STAT-4-dependent 
pathways (9). Another transcription factor involved in Thl lineage and IFNy gene 
expression is T-bet which induces the transcription of the gene encoding IFNy (10). 
Thl cells are further characterised by the expression o f the chemokine receptors 
CCR1, CCR5 and CXCR3 (11, 12), and the receptors for IL-18 (13) and IL-12 (14).
Th2 cells are characterised by the production of IL-4, IL-5 and IL-13, (8), and 
expression of the chemokine receptors CCR3, and CCR4 (11, 15, 16), and orphan 
receptor T1/ST2 (13, 17). Th2 cell differentiation is mainly reliant on IL-4 and 
STAT-6-dependent signalling pathways which induce the Th2-specific transcription 
factor, GATA-3 (18, 19). The transcription factor, c-Maf, which trans-activates the 
IL-4 promoter, has an important role in the transcription of IL-4 (20). Th2 cytokines 
promote the activation of innate cells, such as mast cells and eosinophils, and can 
direct B cells to produce murine IgGl and IgE. These effector mechanisms are 
important in the elimination of extracellular parasites such as helminths (21). 
However, Th2-medited responses have also been implicated in pathogenesis of 
allergic responses, such as asthma.
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Asthma is characterised histologically by a predominance of Th2 lymphocytes (1). 
Bronchial biopsies taken from atopic and non-atopic asthmatics show elevated 
expression of IL-4, IL-5, and IL-13 (22), and increased expression of GATA-3, c- 
Maf, and STAT-6 (23). Murine models of asthma also support the importance of Th2 
lymphocytes in allergic inflammation. IL-4-deficient mice display reduced airways 
disease (24), whereas transgenic mice over-expressing IL-5 (25) or IL-13 (26) have 
more marked disease. In studies designed to demonstrate the importance of IL-4 in 
asthma, murine adoptive transfer of IL-4-deficient CD4+ cells have shown that IL-4 is 
not essential for developing allergic airways inflammation. Despite this, it was 
demonstrated that STAT6 and IL-4 receptor alpha were both necessary for the 
development of murine airways inflammation (27, 28). It has also been shown that the 
cytokine IL-13 receptor heterodimer utilises the IL-4 receptor alpha chain, and 
STAT6 pathway. Further work has shown that although IL-4 is essential for the 
initiation of Th2 polarisation, subsequent development of allergic airways disease 
may rely on IL-13. IL-13 can mediate the induction of AHR, pulmonary fibrosis, and 
goblet cell hyperplasia (29, 30). Another important Th2 cytokine, IL-5, is important in 
the differentiation, activation and survival of eosinophils (31). IL-5-deficient mice do 
not develop allergic airways inflammation (32). It is felt that the interplay of Th2 
cytokines, such as IL-4, IL-5 and IL-13, are important for the development of allergic 
airways inflammation.
The balance between Thl and Th2 cells is thought to be important in the development 
and propagation of asthma, especially when the two populations are counter- 
regulatory (7). Cytokines from Thl lymphocytes were originally thought to be 
protective of asthma by skewing the immune response from a Th2 towards a Thl
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profile (33). Furthermore, the observations that antigen-induced IFNy production was 
reduced in peripheral blood lymphocytes of asthmatics (34), and that IFNy and Tbet-1 
was critical for attenuating airways eosinophilia in murine models of asthma (35, 36) 
gave further support to this hypothesis. However, it has since been demonstrated that 
IFNy is produced by bronchoalveolar lavage (BAL) T cells (37) and may enhance 
airways inflammation (38). In an adoptive murine transfer model of asthma, it was 
shown that Thl cells did not reduce airways inflammation, but actually enhanced 
established disease through the activation and recruitment of neutrophils into the 
airways (39-41). These observations can be summarised thus; Th2 cells appear to be 
important in the initiation and maintenance of allergic airways inflammation, and can 
be regulated by Thl cytokines. However, once disease has been established Thl 
responses may contribute to the perpetuation of disease under certain circumstances.
Some of the T cell-related cytokines and their proposed actions in asthma are 
summarised in Table 1.1.
1.1.2.3 Dendritic Cells
Dendritic cells are the most effective “professional” antigen presenting cells (APCs), 
and have been shown to be necessary for disease development in murine models of 
asthma (42). The interactions between TcRs expressed by naive CD4+ T cells and 
MHC class II/peptide complexes on APCs can influence T cell differentiation 
[reviewed in (43)]. This was demonstrated by early work by Bottomly and colleagues, 
who showed that high density of peptide/MHC complexes promotes strong Thl- 
mediated immune responses, whereas low density of peptide/MHC complexes induce
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Cytokine Source Actions
IL-3
T hl/T h2 cells 
Eosinophils 
Basophil 
Mast cells  
Macrophages
Differentiation and activation o f  eosinophils, mast cells, 
basophils and neutrophils
IL-4
Th2 cells  
Eosinophils 
Mast cells  
Basophils
B -cell switch to IgE synthesis 
Th2 developm ent 
Mast cell developm ent 
Eosinophil and basophil activation 
M ucous secretion
IL-5
Th2 cells  
Eosinophils 
Mast cells  
Basophils
Eosinophil & Basophil differentiation, maturation, and 
activation
IL-6
T hl/T h2 cells 
M acrophages 
Endothelial cells
T and B -cell growth factor 
Cofactor for IgE synthesis
IL-9
Th2 cells  
Eosinophils 
Mast cells  
Basophils
Mast cell and Eosinophil developm ent 
AHR  
M ucous secretion
IL-10
T cells  
M acrophages
Suppresses T h l/T h2 function 
Favours regulatory T cell production 
B-cell switch to IgG4
IL-13
Th2 cells  
Eosinophils 
Mast cells  
Basophils
Mast cell developm ent 
B -cell switch to IgE  
Eosinophilia  
AHR  
M ucus secretion
IL-25 Th2 cells Favors Th2 developm ent and IL-4,IL-5,and IL-13 
production
GM -CSF
T hl/T h2 cells 
M acrophages 
Eosinophils 
Mast cells  
Basophils 
Fibrobasts & Epithelial cells
Differentiation and activation o f  eosinophils, neutrophils, 
and mast cells
IFNy Thl cells
Inhibits IgE synthesis,
Inhibits Th2 induction 
A ctivates eosinophils and macrophages
IL-12 Macrophages 
B cells
Favours Thl expansion  
Inhibits IgE synthesis
IL-15 M any non-T cells T cell growth factor
IL-18 Macrophages Induces IFN-y production by T cells, N K  cells  
Favours Thl expansion
IL-23 Various hem opoietic cells Cofactor for Th 1 developm ent, 
Activates DCs
IL-27 APC Favours T hl expansion
Table 1.1 Cytokines involved in asthma
Some of the cytokines important in the pathogenesis of asthma.
Adaptedfrom Larche et al, 2003; (5).
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strong Th2-mediated responses (44). In addition, it has been demonstrated that high 
affinity binding of peptide by TcRs and strong TcR-mediated signalling promotes Thl 
differentiation, whereas lower affinity binding and weak TCR signals promote Th2 
differentiation (45). Th cell induction by APC is dependent on the nature of antigen, 
the affinity of interaction of TCR and MHC, the co-stimulatory signals, the cytokine 
environment and the genetic background of the cells (46).
Potential APCs in the lung are alveolar macrophages, B-cells, epithelial cells, and 
dendritic cells. The lung macrophage is a poor accessory cell (47), and there is little 
data showing B cells or epithelial cells process and present antigen in the allergic 
airway. Hence, the most important APC in the lung is probably the dendritic cell.
Dendritic cells taken from the respiratory mucosal wall preferentially induces Th2 
cytokine production (48). Peripheral blood-derived dendritic cells taken from atopic 
donors secrete IL-13 after stimulation with protein allergens, and enhance Th2 cell 
development (49). Dendritic cell co-stimulatory signals, such as inducible 
costimulator (ICOS), may bind T cell surface molecules, such as inducible 
costimulator ligand ICOS-L, and promote Th2 responses (50, 51). However, ICOS 
along with IL-10 (produced from DCs) have been implicated as an important factors 
in tolerance induction to inhaled allergen in murine models of asthma (52, 53).
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1.1.2.4 Eosinophils
Antigen presentation and CD4+ T cell responses results in the recruitment and 
activation of the primary effector cells of the allergic response: the eosinophil, mast 
cell and basophil.
One of the most striking characteristic in atopic asthma is eosinophilic hyperplasia. 
Eosinophilic inflammation has always been regarded as a hallmark of both atopic and 
non-atopic asthma (54, 55). Recently, two different genetically altered “ eosinophil 
knockout mice” have been generated. One model was specifically designed to 
deliver a suicide signal only to eosinophils (56), whereas the other model took 
advantage of an unexpected observation that a deletion in the GATA-3 promoter site 
resulted in an eosinophil-free mouse (57). In the eosinophil suicide model, data were 
presented that eosinophils were an absolute requirement for the asthma-like 
phenotype in the mouse. Surprisingly, this was different from the other model, in 
which eosinophils seemed to play little, if any role in the initiation o f allergic 
inflammation. The two models appeared to agree that eosinophil might play a role in 
airway remodelling, which is in accordance with work showing that anti-IL-5 
antibody administration in human subjects reduces eosinophils and the deposition of 
several tissue matrix proteins (58). Despite this apparently contradictory or 
incomplete murine data, there is still a great deal of evidence suggesting eosinophils 
are important in asthma. Eosinophils are integral to the development of 
bronchoconstriction in the late asthmatic response (59); are increased in number in 
human atopic (60, 61) and non-atopic (62) lungs; and there is a correlation between 
BAL eosinophil numbers and severity of asthma (63).
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Eosinophils express CD23, low affinity surface receptors for IgE, and this might 
enhance migration to sites of pulmonary inflammation. Eosinophil degranulation can 
be induced by binding IgE to surface receptors on the eosinophil. Other factors such 
as IL-5, GM-CSF and complement component C3b on immune-complexes, along 
with ligation of IgG receptors can also degranulate eosinophils. This leads to the 
release of pro-inflammatory substances which include eosinophilic cationic protein 
(ECP), myelin basic protein (MBP), eosinophil derived neurotoxin (EDN), eosinophil 
peroxidase, reactive oxygen species, cytokines like IL-3, IL-5, IL-13 and GM-CSF, 
prostaglandins and leukotrienes. These inflammatory mediators promote the migration 
and activation of several other cell types into the lung and cause microvascular 
leakage, increased mucous production, induce bronchoconstriction and epithelial 
damage [reviewed in (64)]. In summary, eosinophils are important in the late 
asthmatic response (Figure 1.2) and tissue remodelling.
1.1.2.5 Mast cells and basophils
Eosinophils are important in the late allergic (asthmatic) response, whereas mast cells 
appear to be pivotal for the immediate response to an inhaled allergen (Fig. 1.2). Both 
mast cells and basophils are seen in bronchial biopses of asthmatic subjects (65), and 
express the high affinity IgE (FceRI) on their cell surface. Allergen-induced cross 
linking of these receptors by IgE causes the release of pre-formed mediators like 
histamine, proteoglycans, serine proteases, carboxypeptidase A. These mediators and 
newly synthetised mediators like prostaglandin D2, leukotriene C4, and platelet
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Figure 1.2 Early and Late Allergic Response
Release o f pre-formed inflammatory mediators (mainly from mast cells and 
basophils) leads to the early (acute) allergic response, which occurs within minutes o f 
inhaling allergen. Chemokines released by mast cells and other cells recruit and 
activate other other inflammatory cells contributing to the late allergic response.
Adaptedfrom Hawrylowicz et al,(66).
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activating factor (PAF) cause bronchoconstriction, vasodilatation, and mucosal 
oedema in the airways. Furthermore, these mediators, and others, will promote the 
migration and activation of other cells into the lung, which will then further 
exacerbate the inflammatory response. Mast cells also contribute to the late allergic 
response, and mediators like histamine, cytokines and proteases are felt to influence 
airways remodelling. In addition, mast cells produce IL-4 which could promote Th2 
cell differentiation and enhance Th2-mediated functions [reviewed in (67)].
1.1.2.6 B cells
IgE is important in the degranulation of mast cells. It has been shown that there is a 
highly significant relationship between total serum IgE and the prevalence of all 
asthma in humans (68). IL-4 and IL-13, released by Th2 cells, can induce B cells to 
class switch their immunoglobulin isotypes IgGl(mice) or IgG4 (humans), and IgE 
immunoglobulin production (69, 70). It is thought that B cells activated by Th2 cells 
produce and release IgE which then contributes to the effector mechanisms in asthma 
described above.
B cells can act as APCs in vivo (71), and hence there is a potential that they may have 
an additional role in allergic inflammation. However, to date there has been no studies 
specifically examining this in asthma.
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1.1.2.7 O ther cells involved in asthm a pathogenesis
Many other cells types are present in the airways and may have an important role in 
the pathogenesis of asthma. Airway epithelial cells are thought to be an important 
source of inflammatory mediators, for example regulated on activation, normal T-cell 
expressed and secreted (RANTES) and eotaxin. Neutrophils may also have an 
important role in airways inflammation, with severe and steroid-resistant asthmatics, 
or asthmatic subjects who smoke having marked airway neutrophilia. Macrophages 
can also secrete pro-inflammatory cytokines, for example IL-6 and TNFa, and 
immunoregulatory cytokines, for example IL-12, IL-15 and IL-18, which could 
potentially also participate in the pathogenesis of asthma. Regulatory T lymphocytes 
and NKT cells may have an important role in airways inflammation, and I intend to 
discuss this further in section 1.3.
With so many effector systems interacting in asthma pathogenesis, it would seem 
sensible that when trying to investigate such a disease one should aim for a cell type 
or immune system that is integral to all the effector systems. For this reason, I 
examined and will present data for two surface molecules: Toll-Like Receptor 2 
(TLR2) and Glucocorticoid-induced tumour necrosis factor receptor (GITR). TLR2 is 
found on cells of both the innate and adaptive immune system and been shown to be 
important in inflammation. GITR is important in the function of regulatory T cells 
(Tregs), which are integral in controlling immune responses. The next two sections 
will describe these in turn.
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1.2 Toll-Like Receptors
1.2.1 Introduction
Toll was first discovered when Drosophila ffuitfly embryos deficient in Toll 
displayed aberrant ventral-dorsal development, and diminished protection against 
fungal infection (72-74). Subsequent work revealed the presence o f a family of 
mammalian homologues to Toll, termed Toll-like receptors (TLRs) (75, 76), which 
recognize pathogens, or pathogen-derived products. TLR activation triggers both the 
early innate and adaptive immune responses. There are now at least 11 TLRs known 
in mice and 10 in humans (77-79), which recognise distinct structurally conserved 
components of pathogen-associated molecular patterns (PAMPs).
1.2.2 TLR ligands
TLRs act as primary immune sensors to recognize PAMPs displayed by various 
microbial components (Table 1.2) including gram-positive and -negative bacteria (78- 
82); DNA and RNA viruses (83-85); fungi (86) and parasites and protozoa (87-90). 
TLRs are type 1 transmembrane receptors that possess an extracellular leucine-rich 
repeat domain and cytoplasmic domain homologous with that of the interleukin 1 
receptor (IL-1R) family (75, 91). Upon stimulation, TLRs and IL-1R interact with the 
adapter molecule, myeloid differentiation factor-88 (MyD88), recruiting the IL-1R- 
associated kinase (IRAK), ultimately leading to the activation of the transcription
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factor nuclear factor-KB and inflammatory gene transcription. All TLRs characterised 
so far, except TLR3, signal through the adaptor protein MyD88. However some TLRs 
also appear to signal through a MyD88-independent pathway under specific 
conditions. An adapter protein named Toll/IL-IR domain-containing adapter inducing 
IFN-beta (TRIF) is involved in MyD88-independent TLR signalling pathways (92,
93), which specifically activates IFN regulatory factor 3 (IRF-3) and induces the IFN(3 
production.
TLR2 recognizes a wide variety of PAMPs from bacteria, yeast, fungi, and parasites, 
and is thought to act as a receptor by forming heterodimers with TLR1 or TLR6 (92,
94). TLR2/6 heterodimer binds gram positive cell wall components, such as 
peptidoglycan, and mycoplasmal lipopeptides that are diacylated, whereas 
TLR2/1 heterodimers recognises bacterial lipopeptides that are triacylated (92, 94-96).
TLR4 functions as a homodimer or homo-oligomers and detects lipopolysaccharide 
(LPS), a major cell wall component of gram negative bacteria (75, 82). Recognition of 
LPS also requires the association of LPS-binding protein (LBP) (97), CD 14 (98) and 
MD2 (99). MyD88-dependent and MyD88-independent pathways both mediate TLR4 
signalling (100, 101).
Flagellin, a monomeric constituent of bacterial flagella, binds TLR5 (80), and is 
important in microbial recognition at mucosal surfaces (102, 103). Virus recognition 
appears to be mediated by TLR3, 7, 8 or 9. TLR3 recognizes double-stranded RNA by 
a MyD88-independent pathway to induce IFNp production (104). In contrast, TLR7 
and 8 recognize single-stranded RNA from viruses triggering an immune response
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and IFN-y production (105). TLR9 recognizes unmethylated CpG motifs, which are 
found abundantly in prokaryotic genomes and DNA viruses (85, 106). There are two 
types of CpG DNA -  A/D type and B/K type- with A/D type CpG being the 
conventional motif, which induces IL-12 and TNFa. B/K type CpG DNA has a 
greater ability to induce IFNa, but not IL-12, from dendritic cells (106-108). In 
contrast to other TLRs, TLR7, TLR8, and TLR9 recognizes its ligand intracellularly, 
perhaps in acidic compartments like endosomes or lysosomes following bacterial or 
viral lysis (109). It is still unresolved as to whether TLR3 functions on the cell surface 
or intracellularly. Bladder epithelial cells expressing TLR11 respond specifically to 
uropathogenic bacteria, indicating a potentially important role for TLR 11 in 
preventing infection of internal organs of the urogenital system (79). TLR11 has only 
been identified in mice so far.
1.2.3 TLRs and the immune system
TLRs are a crucial link between the innate and adaptive immunity. Initial recognition 
of the highly conserved PAMPs on pathogens by the innate immune cells will cause 
release of chemokines, recruit cells to sites of inflammation, trigger phagocytosis with 
degradation and presentation of pathogen-derived peptides. TLRs are highly 
expressed on antigen presenting cells (APCs), which upon activation release 
inflammatory cytokines and express co-stimulatory molecules. Thus, not only do 
TLRs activate the innate system, they also initiate the development of an antigen- 
specific adaptive immune response (Fig. 1.3).
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TLR Ligands
TLR1
Tri-acyl lipopeptides (bacteria, mycobacteria) 
Soluble factors (Neisseria meningitidis) 
Modulin
TLR2
Lipoprotein/lipopeptides 
Peptidoglycan 
Lipoteichoic acid
Lipoarabinomannan (mycobacteria) 
Glycoinositolphospholipids (Trypanosoma cruzi) 
Glycolipids (Treponema maltophilum)
Porins (Neisseria)
Zymosan (fungi)
Listeria (Heat-killed bacteria)
LPS (Spirochetae)
Modulin
TLR3 Double-stranded RNA (virus)
Poly(I:C) (synthetic analogue o f double stranded RNA)
TLR4
LPS (Gram-negative bacteria) 
HSP60 (Chlamydia pneumoniae) 
HSP60 (host)
HSP70 (host)
Fusion protein (RSV)
Taxol (Plant)
Envelope proteins (MMTV) 
ES-62 (filarial nematode)
TLR5 Flagellin (bacteria)
TLR6
Di-acyl lipopeptides (mycoplasma) 
Modulin,
soluble tuberculosis factor STF
TLR7
GU rich Single-strand RNA (ssRNA) 
Imidazoquinoline (synthetic compounds) 
Loxoribine (synthetic compounds) 
Bropirimine (synthetic compounds)
TLR8 GU rich Single-strand RNA (ssRNA)
TLR9 CpG DNA (bacteria)
CPG ODN (synthetic oligonucleotides that contain unmethylated CPG dinuleotides)
TLR 10 ? (unknown)
TLR11 
(mice only)
Uropathogenic strains of E.coli (UPEC)
Table 1.2 Toll-like receptors and their ligands in humans and mice
Adapted from  (75, 76, 79, 91, 104-106, 110-113)
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1.2.3.1 TLRs and cells of the innate immune response
Pathogens recognition by TLRs induce the expression of selectins, chemokines and 
chemokine receptors that regulate cell migration to sites of inflammation (114). Innate 
cells like neutrophils, NK cells, mast cells, eosinophils, dendritic cells, macrophages, 
B cells, endothelial and epithelial cells express a variety o f TLRs which, upon binding 
of ligands, will generate pro-inflammatory signals and cytokines that will result in 
microbial killing (78, 96, 115-119). In the absence of TLRs, particularly TLR2/TLR4 
or MyD88, macrophages have shown impaired bacterial killing compared with wild 
type cells (119). Phagocytosis of bacteria including Escherichia coli, Salmonella 
typhimurium and Staphylococcus aureus has also been shown to be impaired due to 
defective phagosome maturation in these TLR-deficient mice (120). Hence, TLRs are 
important in the initial recognition, cell migration, phagocytosis, and clearance of 
pathogens by the innate system.
DCs express a large number of TLRs, however the precise pattern of TLR on different 
subsets of DCs remains unresolved. Human myeloid DCs express all 10 TLRs except 
TLR4 and TLR9 and can recognize bacterial, fungal and viral pathogens (121-124). 
Freshly isolated plasmacytoid DCs (pDCs) express TLR7 and TLR9, whereas CD1 lc+ 
human myeloid DCs (mDCs) express TLR1, TLR2, TLR3, TLR5, TLR6, and TLR8 
(121-124). Some groups found TLR7 was expressed on both pDCs and mDCs (121, 
124), whilst others found TLR7 on pDCs alone (122, 123). Mouse DC TLRs are more 
heterogeneous than human, with most TLRs expressed on most DC subsets, with the 
exception of CD8+ DC which lack TLR5 and TLR7 (125, 126).
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Figure 1.3 TLRs and innate and adaptive immunity
Innate immune cells recognise pathogens via TLRs. TLR activation will induce 
phagocytosis, pro-inflammatory cytokines production, co-stimulatory molecules 
expression, and pathogen peptide presentation to T cells. This will in turn lead to 
antigen-specific immunity (preferentially Thl responses).
Adaptedfrom Takeda et al (127).
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TLRs initiate adaptive immunity mainly through DCs. These cells capture microbial 
antigens in the peripheral tissues, mature, process the antigen into peptides, and then 
migrate to draining lymph nodes to present processed peptide to T cells. The 
activation of TLRs results in downregulation of inflammatory chemokine receptors 
(like CCR6) and upregulation of receptors for lymphoid chemokines (like CCR7), 
which encourages DC migration to lymphoid tissue (128, 129). TLR activation also 
increases the expression of CCR2, CCR5, and CCR7 on DCs; enhances the 
production of IL-12, tumour necrosis factor a  (TNF-a) and IL-6 by DCs; and up- 
regulates co-stimulatory molecules such as CD40, CD80 (B7-1), CD86 (B7-2) and 
MHC class II (128-132). These changes allow DCs to mature and present antigenic 
peptides to T cells more effectively.
Analysis of MyD88-deficient mice has demonstrated the critical role of TLRs in DC 
maturation and induction of adaptive immune responses. MyD88-deficient DCs 
stimulated with CpG DNA, but not LPS, failed to mature (101) as demonstrated by 
the lack of surface co-stimulatory and MHC molecules. Furthermore, these DCs failed 
to prime antigen-specific naive T cells in vitro. In TLR2 and TLR4-deficient mice, the 
expression of co-stimulatory molecules and MHC class II molecules, as well as pro- 
inflammatory cytokines were impaired in DCs upon simulation with PGN, LPS, or 
Lipid A (133). TLR9-deficient mice also failed to respond to CpG DNA, which 
resulted in decreased DC maturation, antigen presentation, with subsequent decreased 
splenocyte proliferation. Hence, TLRs are important in DC maturation and microbial 
antigen presentation to T cells.
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1.2.3.2 TLRs and cells of the adaptive im m une response
As well as initiating specific immune responses, TLRs are also critically involved in 
determining the Thl/Th2 balance (77). The density of antigenic peptide presented, the 
degree of co-stimulation, and the amount and nature o f cytokines and inflammatory 
mediators produced by DCs at the site of inflammation have been shown to influence 
T cell differentiation (134).
It has been shown that TLRs recognize PAMPs on pathogens and generate immune 
responses that are appropriate for their elimination (135). Prokaryotic, fungal, viral, or 
protozoan pathogens activate DCs through the engagement o f TLRs to stimulate IL- 
12 production and thereby direct the development of Thl responses leading to their 
clearance (136-138). LPS from Escherichia coli, a TLR4 agonist, promotes the 
production of IL-12p70 and was associated with Thl responses (139). CpG- 
containing bacterial DNA also initiated a strong Thl-biased response by inducing the 
co-stimulatory molecule CD40 and IL-12, which was dependent on TLR9 (140, 141). 
Double-stranded RNA (polyI:C, a mimic of viral RNA) is associated with Thl cell 
responses (142). It has been shown that MyD88-deficient animals developed a Th2- 
enhanced response (143). This suggests that the TLR-mediated MyD88 signalling 
pathway could contribute to Thl or Th2 cell induction. Thus, in addition to initiating 
Thl responses, TLRs are also important in Th2 differentiation by MyD88-dependent 
and -independent mechanisms. TLR activation of DCs can induce Th2 responses 
(139, 140, 144-147). It has also been shown that immature dendritic cells can induce 
both Thl and Th2 profiles depending on which TLR are activated (148). TLR4 
activation of immature DCs promoted the production o f the Thl-inducing cytokine
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IL-12p70 and the chemokine interferon-gamma inducible protein (IP)-10, which is 
associated to Thl responses. In contrast, TLR2 stimulation of these immature DCs 
failed to induce IL-12p70 or IP-10, but resulted in the release of the IL-12 inhibitory 
p40 homodimer which acts as an IL-12R antagonist, and favours Th2 development 
(148). Moreover, it has been shown that TLR2 triggering can promote Th2 
differentiation in vitro and in vivo (139, 146, 149). Flagellin, a TLR5 agonist, can also 
initiate a MyD88-dependent Th2 response through DC maturation and increased IL-4, 
IL-13, and IgGl production (150). Using TLR4-deficient mice, it has been shown that 
TLR4 is required for the induction of murine allergic airways disease (151). 
Interestingly, using the TLR4 ligand LPS, it has been shown that the dose of LPS can 
determine whether a Thl or Th2 response develops in vivo. In a murine model of 
asthma, LPS stimulation of DCs, at a low dose, enhances Th2 responses. However, 
when LPS was administered locally into the lungs at high dose a Thl response 
predominated (152). Thus, some Thl-inducing pathogens may also induce Th2 
development depending on the degree of TLR activation of the DCs.
As well as being found on innate cells, TLRs are also expressed on cells of the 
adaptive immune system. Recent results have shown a direct role of TLRs on T cell 
activation and function. Human T cells express cell-surface TLR2 after activation by 
anti-T cell receptor antibody and IFN-a (153). These activated T cells produced 
elevated levels of cytokines in direct response to the TLR2 ligand, Pam3CSK4, which 
is a Gram-positive bacterial lipopeptide. Another study showed that murine CD4+ T 
cells express TLR3 and TLR9, but not TLR2 or TLR4, and agonists of TLR3 and 
TLR9 increased T cell survival (154).
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Stimulation of TLRs on B lymphocytes directly can lead to T cell-independent 
activation and production of low-affmity immunoglobulin M (IgM) antibodies (155). 
Human memory B cells can produce antibodies in response to CpG stimulation 
independently of antigen-specific T cell help (156). In addition, TLR activation of T 
cell will result in the generation of signals that will influence B cell maturation and 
effector function.
In summary, it would appear TLRs can direct the adaptive Thl and Th2 immune 
responses by either directly interaction with T cells, or by acting indirectly via APCs. 
In addition, they can also directly or indirectly influence the humoral immune 
response.
1.2.3.3 TLRs and inflammatory disease
TLRs and Infectious Disease
TLRs play a critical role in protective immunity in vivo. Mice deficient in the TLR- 
associated adapter molecules MyD88 resulted in increased susceptibility to a wide 
variety of microorganisms including bacteria, such as Staphylococcus aureus (81), 
Listeria monocytogenes (157) and Mycobacterium avium (158); parasites, such as 
Leishmania major (159); fungal pathogen, such as Candida albicans (160, 161); and 
the intestinal nematode Trichuris muris (162). In addition to its protective role, TLRs 
also appear to contribute to inflammatory and immune disorders, such as sepsis, 
atherosclerosis, and asthma. Activation o f macrophages and neutrophils by the TLR4 
agonist LPS leads to enhanced production of pro-inflammatory cytokines, which are 
responsible for features of sepsis or septic shock (163). Studies examining a human
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TLR4 gene polymorphism, D299G, have shown that the polymorphism increases the 
risk of gram negative infections (164, 165), and sepsis (166).
TLRs and autoimmune disease
Clearly the TLR responses have evolved for protection, however, the development of 
some inflammatory diseases is influenced by TLRs include autoimmune diseases such 
as RA, SLE and EAE. In rheumatoid arthritis (RA), TLR2 and TLR4 are expressed at 
a higher level in the synovium of RA patients compared to healthy individuals. This 
increased TLR expression correlates with increased synovial levels of IL-12 and IL- 
18, which are thought to be important in the RA pathogenesis (167). TLR4 also 
contributes to the induction of experimental autoimmune encephalomyelitis (EAE), 
implicating innate immune mechanisms in the development of CNS autoimmune 
disease (168). Systemic lupus erythematosus (SLE) is a prototype non-organ specific 
auto-immune disease characterised by inefficient removal of apoptotic cells, and the 
normally sequestered nucleoproteins exposed on apoptotic cell membranes can trigger 
auto-reactive B cells to produce IgG auto-antibody. This process appears to involve 
antigen presentation by dendritic cells using a TLR9-dependent pathway (169). 
Mammalian DNA has some unmethylated CpG motifs, which are recognised by 
TLR9. Normally, self DNA is sequestered. However, in SLE the chromatin can be 
delivered to intracellular compartments that contain TLR9, which results in activation 
of these B cells which produce antibody against self DNA (170).
49
TLRs and atherosclerosis
In TLR4 or MyD88-deficient mice, there was a marked reduction in early 
atherosclerosis due to decreased macrophage recruitment to the arterial intima. In 
addition, individuals with the D299G polymorphism had reduced carotid artery 
atherosclerosis (171), and acute coronary events (172). This suggests that TLR4- and 
MyD88-mediated pathways may be involved in the development of atherosclerosis 
(173, 174).
TLR and other inflammatory disorders
The MyD88-dependent pathway appears critical in allograft rejection, because minor 
antigen-mismatched allograft rejection cannot occur in the absence of MyD88 
signalling (175). TLRs have been implicated in the initiation and perpetuation of 
allergic diseases, such as asthma. Exposure to the TLR4 agonist, LPS, has been 
correlated to the severity of asthma. Indeed, one study actually showed that in people 
sensitive to house dust mite, asthma severity correlated more closely to LPS levels 
than with the allergen itself (176). People with allergic asthma are more sensitive to 
the bronchoconstrictive effects of inhaled LPS (177). In contrast to these findings, 
exposure to TLR ligands in early childhood may decrease the incidence of asthma in 
later life (178, 179). It is hypothesised that this protection from asthma may be due to 
early TLR activation of regulatory T cells which may downregulate the immune 
response later in life. TLR ligands appear to be able to exacerbate or diminish asthma 
depending on the timing and nature of exposure. TLRs and asthma will be discussed 
further Chapters 3 and 4.
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Taken together, this evidence implies that TLRs are important in resolving infectious 
diseases, however the price for this is the tendency to promote autoimmune and 
chronic inflammatory diseases (180). Thus, the balance of the TLR-mediated 
pathways is probably involved in many aspects of immune system, from effector 
mechanisms to regulation.
1.2.3.4 TLRs and immunoregulation
Regulatory T cells (Tregs), including CD4+CD25+, Trl and Th3 cells, are cells that 
actively suppress immune reactions and play an important role in maintaining self- 
tolerance (see below). Several studies have indicated that DC activated by specific 
pathogens or their compounds, such as Mycobacterium vaccae, Plasmodium 
falciparum , Bordetella pertussis and Schistosoma mansoni, can induce regulatory T 
cells in the peripheral lymphoid organs which is dependent on IL-10 (181-184). 
Filamentous hemagglutinin (FHA) from Bordetella pertussis can stimulate DCs to 
produce IL-10 which can induce type 1 regulatory T (Trl) cells. Furthermore, IL-10 
production by Ag-specific T cells was significantly reduced, with an associated 
enhanced inflammation, in TLR4-defective mice. This suggests that TLR4 is 
important for IL-10-mediated generation of Trl cells (184). In another study, 
activation of TLR2 by schistosome-specific phosphatidylserine on dendritic cells was 
also essential for the induction ofIL-10-producing regulatory T cells (144).
The effect of TLR activation on CD4+CD25+ regulatory T cell function is receiving 
intense scrutiny in immunological research. In the setting of Candida albicans 
infection, the yeast can induce host immunosuppression through TLR2 signalling
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which was associated with an increased level of IL-10 and enhanced survival of 
CD4+CD25+ T cells (160). Furthermore, studies with virus-based vaccines have 
shown that viruses can trigger TLR signalling in CD8+ T cells in a manner that could 
bypass regulatory T cell-mediated suppression, and trigger antigen-specific T cell 
immune responses (185). These investigations therefore indicate that TLR signals 
may be involved in the suppressive function of CD4+CD25+ T cells during the course 
of infection.
The direct effect of TLR triggering on CD4+CD25+ T cells was demonstrated when 
LPS, from Salmonella typhimurium, enhanced the survival and suppressor function of 
CD4+CD25+ regulatory T cells. This phenomenon was independent of APCs (186). In 
contrast to this, another study has demonstrated that the TLR4 agonist, LPS, can act 
on CD4+CD25' effector cells to make them resistant to Treg suppression. This was 
independent of co-stimulation and was mediated by IL-6 and other soluble factors 
produced by DCs in response to TLR activation (187, 188). Furthermore, it has been 
shown that IL-6 and IL-1 produced by LPS-activated DCs can enhance the 
proliferative responsiveness of CD4+CD25+ T cells (188). Hence, TLR signals can 
manipulate regulatory T cell functions either by modulating DC function or directly 
acting on CD4+CD25+ T cells. More importantly, with the evidence to date, it would 
appear that TLRs can both enhance and abrogate the suppressor action o f CD4+CD25+ 
regulatory T cells.
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1.3 Regulatory T cells
1.3.1 Introduction
The adaptive immune system mounts defensive mechanisms against unanticipated 
pathogens by creating a diverse repertoire o f antigen receptors. With such a system, 
receptors will be randomly generated that recognise self components, and potentially 
cause self damage. Various mechanisms including clonal deletion, induction of 
tolerance, immuno-modulation by suppressive cytokines, and inactivation of 
autoreactive cells (189-191) have been proposed to prevent this potential problem. 
However, even in the 1960s it was suggested that a population of T cells could 
actively “suppress” the immune system. Richard Gershon (192) found a unique 
subpopulation of CD8+ T lymphocytes from mice which down-regulated the functions 
o f T cells, B cells, and APCs. This finding opened the field of so-called “suppressor T 
cells”. However, this CD8+ I-J restricted suppressor T cells fell into disrepute when 
the I-J gene was found not to exist by molecular sequencing of the MHC gene by 
Green & Webb (193).
It has since been demonstrated that the immune system is under T cell-mediated 
control. Firstly, Nishizuka et al showed that neonatal thymectomy of normal mice, 
resulted in autoimmune-mediated destruction of the ovaries (194). Secondly, Penhale 
et al then demonstrated that thymectomy of adult rats, which were subsequently 
subjected to sub-lethal X-irradiation, resulted in the development of autoimmune 
thyroiditis (195). More importantly, it was shown that subsequent inoculation with 
normal T cells, particularly CD4+ T cells, prevented the development o f this disease.
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This suggested the existence of a subset of CD4+ T cells within the normal population 
which possessed regulatory capacities (196-198).
Sakaguchi, et al using T cell depletion experiments demonstrated that the ability to 
suppress autoimmune disease was associated with the actions of CD4+CD5hl T cells 
(199). This regulatory subset was further defined by Powrie and colleagues who 
demonstrated that contained within the population of CD4+ T cells from normal mice, 
subsets of CD4+ T cells expressing low levels o f CD45RB were able to protect against 
chronic intestinal inflammation (200). Therefore, it would appear that a naturally 
occurring CD4+ subpopulation exhibited regulatory properties.
1.3.2 Naturally occurring CD4+CD25+ regulatory T cells
Sakaguchi et al showed that the removal of the thymus of mice 3 days after birth 
resulted in various autoimmune diseases (201, 202). Inoculation of the thymus-free 
mice with a mixed population of T cells from congenic mice prevented the 
development of autoimmune diseases if transferred before day 14 (203). It was also 
shown that a population of cells that naturally developed in the thymus could suppress 
this T cell-mediated autoimmune disease. Further adoptive transfer studies 
demonstrated that a subset of peripheral CD4+ T cells in normal adult mice, which 
expressed the IL-2Ra-chain (CD25), was critical for preventing autoimmune disease 
induced by CD4+CD25' T cells transferred into immune deficient mice (204). These 
regulatory T cells were also found in the thymus. The transfer of mature CD4+CD8' 
thymocytes (depleted of CD4+CD25+ T cells) induced a range of autoimmune 
diseases in syngeneic nude mice, which the co-transfer o f CD25+CD4+CD8'
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thymocytes prevented (205). CD4+CD25+ T cells, which constitute 5-10% of 
peripheral CD4+ T cells, are contained within the CD5hl and CD45RB10 fraction of 
CD4+ T cells, and appear in the periphery 3 days after birth, with their numbers 
increasing to adult levels by day 14 (203, 204). This agreed with the previous findings 
o f Sakaguchi, Powrie and colleagues - suggesting that peripheral immunological 
tolerance was maintained through the actions of CD4+CD25+ T cells.
1.3.2.1 Murine CD4+CD25+ regulatory T cell suppression in vitro
To analyse the suppressive function of CD4+CD25+ regulatory T cells, in vitro studies 
were devised. Co-culture of freshly-isolated CD4+CD25+ Treg cells, “effector” 
CD4+CD25' T cells, and APCs under limited TcR stimulation were established. 
Proliferation and cytokine production were used as end point measures of the 
suppressor function of Tregs. These in vitro studies have shown that CD4+CD25+ T 
cells are hypo-responsive, and able to suppress the activation of T cells to polyclonal 
stimulation (206-210). They have also demonstrated that suppression by CD4+CD25+ 
T cells is cell contact dependent. Supernatant collected from activated CD4+CD25+ T 
cells or mixture of CD4+CD25+ and CD4+CD25* T cells failed to suppress the 
proliferation of CD4+CD25* T cells in vitro (207-209). Furthermore, co-cultures of 
CD4+CD25+ and CD4+CD25' T cells separated by a semi-permeable membrane failed 
to demonstrate suppression (211).
CD4+CD25+ T cells initially require antigen specific TcR activation, however, once 
activated CD4+CD25+ T cells can suppress T cell responses in an antigen-independent 
manner (204, 212). Stimulation with OVA peptides induces a strong suppressive
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activity in CD4+CD25+ T cells from DO 11.10 transgenic mice, but fails to do so in the 
cells from non-transgenic littermates (204). Further studies have shown that in mixed 
lymphocyte reactions (MLRs), CD4+CD25+ T cells, activated by allogeneic stimulator 
cells, suppressed CD4+CD25' T cells of the same strain as well as CD4+CD25' T cells 
from a different strain of mouse (212). Therefore, the suppression of CD4+CD25+ T 
cells requires TCR stimulation but the activated cells exert their inhibition 
independent of antigen specificity. Despite this, the effects of CD4+CD25+ T cells 
have been shown to be dependent on APCs (207, 213).
1.3.2.2 Human CD4+CD25+ regulatory T cells
CD4+CD25+ T cells have also been isolated in human peripheral blood and thymus. 
They constitute around 5-15% of the peripheral CD4+ population, and are anergic to 
in vitro stimulation by anti-CD3 and anti-CD28 mAb. Human CD4+CD25+ T cells can 
inhibit effector T cell responses that have received antigenic or polyclonal stimulation 
(214-219), as seen in murine studies. It has also been demonstrated that human 
CD4+CD25+ T cells can convert effector T cells to regulatory T cells in the peripheral 
immune system, in a process called infectious tolerance (220-222). This process 
appears to be dependent on cell-contact, IL-10, and TGFp (221, 222).
1.3.2.3 Mechanisms of suppression by CD4+CD25+ regulatory T cells
As well as suppressing CD4+CD25' effector T cells, CD4+CD25+ T cells can also 
suppress other cell types. Some of these actions are summarised in Table 1.2.
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CELL ACTION ON CELL TYPE Ref.
CD8+
1. Proliferation and IFNy production suppressed
2. Action is APC-independent
3. IL-2 production and CD25 expression reduced
4. High concentrations of IL-2 did not break suppression
(210)
DC
1. Co-stimulatory markers - CD80 and CD86 -  downregulated
2. Reduced co-stimulation so that CD25" cells do not produce IL-2
3. Immature DCs (day 5-6, bone marrow derived) allow CD25' 
cells to be suppressed by CD25+ cells in vitro
4. Mature DCs (non TLR activated) can reverse CD25+-mediated 
suppression of CD25' cells
5. TLR-matured DCs can break anergy & cause proliferation of 
CD25+ cells
(213)
(188,
223,
224)
B cell *
1. Inhibits activation induced proliferation
2. Up-regulates Fas-L expression: inducing cell death
(225)
(226)
Table 1.3 Action of CD4+CD25+ T cells on different cell types
CD4+CD25+ regulatory T cells can reduce the magnitude of the immune response by 
many different routes.
* B cells may also act as APCs to recruit T cell help. Activated B ells express CCL4 
which induces migration of CD4+CD25+ T cells.
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The precise mechanisms behind the suppressor action of CD4+CD25+ T cells remain 
controversial. Several cytokines, cell surface markers and transcription factors have 
been implicated in the mechanism of CD4+CD25+ T cells. These are illustrated on 
Figure 1.4 and discussed below.
IL-2
The population of CD4+CD25+ T cells in the peripheral circulation is reduced from 5- 
10% in normal mice to 1-2% in IL-2, IL-2Ra, or IL-2Rp deficient mice. These 
knock-out mice died early due to severe lymphoproliferation and autoimmune 
diseases (207, 227-231). Adoptive transfer of CD4+CD25+ regulatory T cells from 
normal mice into IL-2Rp-/- mice prevented the lethal autoimmune diseases (231, 
232). Other work has shown that CD4+ T cells from IL-2-deficient mice protected 
mice from spontaneous experimental autoimmune encephalomyelitis, while CD4+ T 
cells from CD25-deficient mice did not. Thus, IL-2 derived from the recipient mouse 
drove expansion of IL-2-deficient cells, but was unable to drive the expansion of 
CD4+ cells from CD25-deficient mice (233). Further studies, through use of anti-IL-2 
mAb, have shown that IL-2 is necessary for the function of CD4+CD25+ regulatory T 
cells in vitro (234). In addition, CD4+CD25+ T cells proliferate in the presence of 
higher than normal (physiological) concentrations of IL-2 (207, 232). High 
concentration of IL-2 also abrogates the suppressive function of CD4+CD25+ T cells 
on the proliferation of CD4+CD25'T cells in vitro (235). Hence, overall IL-2 appears 
important in CD4+CD25+ T cell function.
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Figure 1.4 Expression of cell surface markers on naturally occurring 
CD4+CD25+ Treg cells.
Adaptedfrom Sakaguchi et al, (198).
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IL-10 and TGFfi
IL-10 and TGFp are produced in vitro by CD4+CD25+ T cells after stimulation with 
plate-bound anti-CD3 antibody and anti-CD28 antibody, or IL-2 (236, 237). Despite 
this, the suppressor action of CD4+CD25+ T cells was not abrogated by anti-TGFp or 
anti-IL-10 mAb in vitro (238, 239). However, administration of monoclonal 
antibodies against IL-10R or TGFp completely abrogated the therapeutic ability of 
CD4+CD25+ T cells to ameliorate murine colitis in vivo (240-242). In addition, TGFp 
is important in the CD4+CD25+ T cell-regulation o f CD8+ mediated diseases in vivo 
(243, 244). TGFp has also been shown to be critical in the generation o f Foxp3+ 
regulatory T cells (245-247). Hence, it is likely that IL-10 and TGFp are important in 
the function of CD4+CD25+ T cells in vivo, as well as in the function of other 
regulatory T cells (see below).
IL-6
IL-6, produced by TLR-activated dendritic cells, can render CD4+CD25' T cells 
resistant to suppression by CD4+CD25+ T cells (187). Furthermore, IL-6 and IL-1 
produced by TLR-activated DCs played an important role in breaking CD4+CD25+ 
regulatory T cell’s anergy (188). The exact role of IL-6 in CD4+CD25+ T cell function 
remains controversial.
CD25
CD25 (a chain o f IL-2R) is constitutively expressed at a high level on naive 
CD4+CD25+ T cells. As IL-2R is upregulated upon stimulation, all T cells (including 
CD25' effector cells) express CD25 upon activation. CD25+ does not confer
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regulatory properties, shown by the observation that activated effector cells do not 
normally act as Tregs (204).
CTLA-4
The Cytotoxic T Lymphocyte-associated Antigen-4 (CD 152, CTLA-4) is expressed 
on T cells, and binds B7-1 and -2 (CD80/CD86) on APCs with higher affinity than 
CD28. T cell activation, through TcR and CD28 signalling, increases CTLA-4 
expression on CD4+ T cells, which will then bind B7. CTLA-4 and B7 ligation cause 
T cells to de-activate, and cause reduction o f the immune response (248, 249). 
CD4+CD25+ T cells are the only CD4+ cells that constitutively express CTLA-4 in 
mice and humans. Blockade of CTLA-4 has been shown to lead to increased T cell- 
mediated immunity in several experimental models, including tumour immunity (250- 
253), parasite infection (254-257), and autoimmune diseases (248, 258, 259). In SCID 
mice colitis models, the protective and therapeutic effects of CD4+CD25+ T cells were 
abolished by treatment with anti-CTLA-4 antibody (242, 260). However, CD4+CD25+ 
T cells from CTLA-4 deficient mice, exhibited normal development and homeostasis, 
and also exerted their suppression on CD4+CD25'T cells and other cells in vitro (261, 
262). Studies using anti-CTLA-4 mAb raise the possibility that this antibody could 
simply block the normal downregulatory signal mediated by CTLA-4-B7 interactions 
on activated CD4+CD25' effector T cells. However, in vivo investigation has shown 
that monoclonal anti-CTLA-4 antibody has no direct effect on the CD4+CD25' T cells 
in the autoimmune colitis model (242). Together, the findings suggest that CTLA-4 
may be not the only signal required for the activation and function of CD4+CD25+ T 
cells.
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GITR
Gene microarray technology has identified more than twenty genes that were 
preferentially expressed on CD4+CD25+ over CD4+CD25' T cells. One of them is the 
glucocorticoid-induced tumour necrosis factor receptor (GITR). GITR, also known as 
TNFRSF18, is a type I transmembrane protein with high homology with other 
members of the TNFR family, including 4-1BB, CD27, and 0X 40 (263). It is 
predominantly expressed on CD4+CD25+ T cells and on CD4+CD8'CD25+ 
thymocytes. However, like CD25, GITR is also upregulated on naive T cells after 
activation, and these stimulated effector cells did not exhibit regulatory function. 
GITR is expressed and up-regulated on CD25+ Tregs, effector T cells, B cells and 
macrophages. It binds GITR ligand (GITR-L) which is on DCs, macrophages and B 
cells but not T cells (264, 265). GITR binding GITR-L or mAb causes activation of 
the CD4+CD25+ Tregs which abrogates their suppressive function (264, 265). Other 
investigators have found that GITR-L binds the effector T cells and makes them 
resistant to the suppressive action of Tregs (266). GITR activation on effector T cells 
has also been found to be a co-stimulatory signal on T cells, causing increased 
proliferation and cytokine production.
So far, no reliable cell surface marker that distinguishes Tregs from activated effector 
cells has been identified. In mice a transcriptional factor, Foxp3, is exclusively 
expressed at high levels in CD4+CD25+ regulatory T cell in both the thymus as well as 
the periphery, but not on activated CD4+CD25' effector T cells (213, 267).
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Foxp3
The X-linked forkhead/winged helix transcription factor, Foxp3, is required for 
CD4+CD25+ regulatory T cell development and function (267-271). A mutation in 
human FOXP3 is responsible for IPEX (immune dysfunction regulation, 
polyendocrinopathy, enteropathy, X-linked syndrome), which is associated with 
autoimmune diseases in multiple organs (272-275). In mice a similar disorder is seen 
in scurfy mice, which have a mutation in Foxp3 (274). Retroviral transformation of 
CD4+CD25' T cells with Foxp3 was sufficient to impart CD4+CD25' T cells with 
suppressive activity (267). These transformed CD4+CD25' T cells were anergic and 
suppressed the proliferation of other T cells in vitro, independent o f the production of 
TGF-p or IL-10. Furthermore, the profile of surface markers including GITR, CTLA- 
4, and CD 103 were comparable to those found in naturally occurring CD4+CD25+ 
regulatory T cells (276-278). These Foxp3-induced CD4+CD25' T cells were also able 
to suppress the development o f autoimmune disease like IBD in vivo (267, 269, 271). 
Thus, Foxp3 (FOXP3 in humans) appears to be an important gene in the development 
and function of CD4+CD25+ regulatory T cells. However, how Foxp3 is involved in 
immune suppression is still unknown.
Neuropilin-1 (NrPl)
Since Foxp3 is a nuclear protein, it has limited value as marker to identify 
CD4+CD25+ regulatory T cells in vitro. From gene expression profiling, neuropilin-1 
was identified as a protein linked to Foxp3 expression. RT-PCR results reveal that 
Foxp3 mRNA correlates with the NrPl expression on CD4+ T cells and is over­
expressed on the surface of CD4+CD25+ T cells. NrPl is expressed at a lower level on 
CD4+CD25' T cells and is even further down-regulated upon T cell activation.
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Therefore, NrPl may be an additional surface marker to distinguish CD4+CD25+ 
regulatory T cells from recently activated CD4+CD25+ non-regulatory T cells (279).
Integrin ctEpi
The integrin oieP7 was first identified by its expression on more than 90% of CD8+ T 
cells in the intestinal mucosa, and approximately 40-50% of CD4+ intestinal T cells 
(280, 281). otE-integrin is expressed on CD4+CD25+ T cells, as well as on a small 
proportion of CD4+CD25‘ murine T cell population. oie+CD4+CD25+ T cells, 
comprising about 4% of all CD4+ T cells and 25% of CD25+CD4+ T cells, were 
shown to have the greatest suppressor function in vitro (282). The integrins ot4 Pi and 
a,4 p7 receptors that direct T cell migration to inflamed tissues and to mucosal sites 
(283, 284). In human studies, peripheral CD4+CD25+ T cells fall into two categories 
on the basis of integrin a /p  expression. (X4P7+ CD25+ regulatory T cells suppress 
effector T cells in vitro and aid induction of distinct secondary IL-10-producing Trl 
cells, whereas a 4 Pi+ CD4+CD25+ T cells induce TGF-p-producing Th3 cells. These 
induced regulatory T cells cooperated with CD4+CD25+ regulatory T cells to inhibit 
activation of other CD4+ T cells (285).
Lymphocyte activation gene-3 (LAGS, CD223)
The MHC class II ligand, lymphocyte activation gene-3 (LAG-3 or CD223), was 
found to be selectively expressed on CD4+CD25+ regulatory T cells and peripherally 
induced regulatory T cells (286). LAG-3, as a negative regulator, inhibited antigen- 
driven T cell expansion in mice (287, 288). Furthermore, the suppressive activity of 
CD4+CD25+ T cells on CD4+CD25* T cell activation can be blocked by anti-LAG-3 
antibodies both in vitro and in vivo. Deficiency of LAG-3 inhibited the regulatory
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activity of CD4+CD25+ T cells, whereas forced expression of LAG-3 induced 
suppressor activity. LAG-3 can also be released as a soluble form (sLAG-3), which 
activated antigen-presenting cells through MHC class II signalling, leading to 
increased antigen-specific T-cell responses in vivo (289, 290). Thus, sLAG-3 may be 
a competitor for ligands binding the membrane form of LAG-3.
Programmed death receptor-1 (PD-1)
Recent gene chip analyses have demonstrated that programmed death receptor-1 (PD- 
1) mRNA is highly expressed in CD4+CD25+ regulatory T cells and anergic T cells, 
suggesting it may be involved in regulating T cell tolerance by two mechanisms 
(291). PD-1-deficient mice developed lupus-like glomerulonephritis, arthritis and 
autoimmune-dilated cardiomyopathy, suggesting a regulatory role for PD-1 in 
controlling lymphocyte responses (292). Although higher ratios o f human 
CD4+CD25+ T cells were required to suppress proliferation, if the PD-L1 receptor was 
blocked, regulatory T cell function was still shown to persist in the absence of the PD- 
1/PD-L1 pathway (215).
CD28
The CD28/B7 costimulation is necessary for the initiation of T cell responses and IL-2 
production. Mice deficient in either CD28 or B7 have reduced numbers of 
CD4+CD25+ T cells in both the thymus and the periphery (293, 294). CD28 co­
stimulation of TcR-signalled, CD4+CD8+ thymocytes initiated CD4+CD25+ T cell 
differentiation by directly inducing Foxp3 expression, and by up-regulating GITR and 
CTLA-4 expression, which was independent of IL-2 (295). Furthermore, peripheral 
CD4+CD25+ T cells require CD28 co-stimulation of CD4+CD25' T cells to maintain
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the IL-2 milieu, which is needed for Treg survival (293, 296). Studies have shown that 
CD28-deficient CD4+CD25+ T cells were less potent suppressors compared with 
those from wild-type mice. In addition, CD4+CD25+ regulatory T cells are anergic in 
the normal state, but can proliferate in vitro with TcR stimulation when anti-CD28 
antibody is also present (207). These expanded CD4+CD25+ T cells exhibited a 
stronger suppressive ability after resting (297).
Perforin & Granzyme
These are enzymes that are important for the cytolytic activity of CD8+, NK and NKT 
cells. Human CD4+CD25 +FOXP3+ cells can be activated by anti-CD3 and anti-CD46 
Ab to express granzyme A, and kill activated CD4+ and CD8+ T cells by a perforin- 
dependent mechanism (298).
The above findings may suggest CD4+CD25+ Treg cells are a homogenous population 
that suppress immune cells by a several mechanisms. The evidence could also indicate 
that CD4+CD25+ Treg cells are a heterogeneous population that suppress cells by a 
number of distinct pathways. The interaction and regulation o f these molecular and 
signalling pathways involved Treg cells suppression is an area of active research and 
is still being unravelled.
1.3.3 Other CD4+ Regulatory T cells
CD4+CD25+ Treg cells are thought to “naturally occurring” as they are initially found 
in the thymus and thought to exit into the periphery around day 3 in mice (203, 205). 
In addition to these Tregs, there is growing evidence to suggest suppressor cells can
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be induced in the periphery from conventional CD4+CD25- T cells (184, 299-301). 
These cells are also anergic under normal stimulatory conditions, and can inhibit 
immune cell function (Table 1.3).
1.3.3.1 T rl cells
The generation of Type-1 CD4+ regulatory (Trl) cells were first described by Groux 
et al in a murine model of inflammatory bowel disease (299). T cells from naive OVA 
TcR-transgenic mice, repeatedly stimulated with OVA and IL-10 in vitro, 
differentiated into a T cell population, which produced high level of IL-10, moderate 
amounts of IFN-y and IL-5, and small amounts of IL-2 and IL-4. Trl have been 
shown to produce moderate amounts of TGFp in some studies, but not in others. 
These Fojcpi-negative cells can suppress n'iave, and Thl and/or Th2 responses in vivo 
in an antigen-specific manner (301-303). The suppressive effects of Trl cells can be 
reversed by neutralizing anti-IL-10 mAb or anti-TGFp antibody, or both (299, 304). 
This result indicates that the inhibitory capacity o f Trl cells is mainly mediated 
through the production of the immunosuppressive cytokine, IL-10. Further work has 
demonstrated that Trl cells can be generated in CD4+ T cells culturesthat have been 
supplemented with Vitamin D3 and dexamethasone, or have had CD40-CD40L 
blockade, or been activated by immature dendritic cells (301-303, 305).
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CD4+CD25+ Trl Th3
Origin Thymus Periphery Periphery
Phenotype
CD25 +++ +/- +/-
GITR ++ - -
CTLA-4 +++ + +
Foxp3 ++ _ * +
Cytokine production
IL-10 Yes Yes -
TGFP Yes - Yes
IL-2 - +/- -
Induced by - IL-10 T GF - p/IL-10/IL-4
Ag Specificity self Tissue/foreign Ag Tissue/foreign Ag
Mode of action
in vitro Cell contact 
IL-10, TGFP
IL-10, TGFP TGFP
in vivo Cell contact IL-10, TGFP TGFp
Table 1.4 Comparison of CD4+ Regulatory T cells
* Recent description of IL-10 secreting Tbetl-positive ybjcpi-positive Tr cells has 
been made (278) -  see below.
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1.3.3,2 Th3 cells
Th3 cells w ere  initially  described by C hen  e t a t  CD4* T  cells from  m esenteric lymph 
nodes o f  m ice given oral m yelin  basic protein (M R P), suppress M BP’-speciflc EA E in 
vivo, in a T G Fp-dependent m anner (306, 307). Th3 regu latory  cells secrete TG Fp, 
provide help* for IgA  synthesis, and can suppress bo th  T h l and Th2 cells (245, 308)-
1.3.,3.3 O ther IL -10 producing T  cells
In addition  to  th e  cell's d iscussed above, there are a  num ber o f  o ther cell groups tha t 
also exhib it suppressor function. It has been dem onstrated tha t pulm onary  DCs; 
produce IL -10 in response to  resp iratory  allergen- T hese D C s can  induce T regs in the  
lung th a t b locks asthm a in a m urine modlel- This in teraction is dependent on IL-1Q> and 
ICOS- ICOS ligand pathw ay (.52, 53). F urther studies have dem onstrated tha t these 
Tregs are T b e tl-ex p ressin g  and  are FoxpS  positive.. These cells h av e  been show n to 
effectively block m urine asthm a in vivo  (278).
1.3.4 O ther regulatory cells
CD8+ Tr cells
CD8:+ T  cells norm ally  ac t as effector cells in response to intracellular infections. 
There is also  som e evidence suggesting tha t these cells have regulatory  function- CDS' 
/_ mice develop experim ental allergic encephalom yelitis (EAE) in a m ore severe and
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chronic manner, than do wild type mice (309). In addition, CD8+ T cells residing in 
the gut appear to have a regulatory role in intestinal immune responses (310) and 
antigen-specific CD8+ cells inhibited IgE production and IL-4 production in a murine 
model of asthma (311).
TCR yS+ cells
TCR y8+ cells are important in the induction and regulation of the mucosal immune 
response (235, 312). TCR y8+ murine intra-epithelial lymphocytes have a role in 
tolerance induced by orally administered sheep red blood cells (313). Elimination of 
TGFp and IL-10 producing TCR y5+ T cells from mice with tumours augments CTL 
and NK (NK) cell activities leading to tumour regression (314).
NKT cells
NKT cells express surface markers characteristic of both T cells and NK cells, and are 
either CD4+ or CD4'CD8'. These cells have a limited TcR repertoire (expressing ap 
TcR) and recognise glycolipid antigens presented by the non-polymorphic MHC class 
I-like CD Id. When activated, these NKT cells produce large quantities of IL-4 and
IFNy, and have been shown to exert a suppressive effect in a variety o f experimental
autoimmune diseases (315-317). LFA-l/ICAM-1 or CD28/B7 blockade, and TGFp 
have been proposed as mechanisms for the suppressive function of NKT cells (318, 
319), however their mode of action remains unclear. In addition to regulating immune 
responses, it was demonstrated that NKT cells can produce high levels of IL-4 and IL- 
| 13 in response to allergen, and can actually induce airways hyperresponsiveness in a
\ murine model o f asthma (320).
I
i
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In summary, there are a several suppressor CD4+ T cells with common features. It 
may be that these form a spectrum of CD4+ Tregs, and the environment and nature of 
immune response that they control may direct the Treg phenotype displayed. 
Potentially, CD4+CD25+ Treg, Trl, Th3 and other regulatory T cells could co-operate 
in vivo to prevent autoimmune reactions and over-active immune responses (321). 
CD4+CD25+ regulatory T cell are arguably the best studied regulatory T cells, 
principally because of the easy with which these cells can be obtained ex vivo. For this 
reason, CD4+CD25+ regulatory T cells have a great deal of evidence behind their 
suppressor function in vitro-, in experimental inflammatory disorders; and in transfer 
experiments in vivo.
1.3.5 CD4+CD25+ regulatory T cells and disease
Cells that can regulate the immune responses have enormous clinical importance. 
Controlling the suppression of the immune system could assist the treatment of 
transplant rejection, autoimmune and allergic disease; whilst decreasing suppression 
could help in cancer therapy or treatment of persistent infections.
CD4+CD25+ regulatory T cells and transplantation tolerance 
Transplant rejection and tolerance is a T cell-dependent event. Removal of 
CD4+CD25+ T cells from donor cell transfers, or in vivo CD25+ cell-depletion of the 
recipients before transplantation resulted in increased graft-versus-host disease in 
several animal models. Pre-treatment with anti-CD4 antibody plus regulatory 
CD4+CD25+ T cells can suppress the rejection of skin grafts mediated by naive
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CD4+CD45RBhlgh T cells (322, 323). Furthermore, a therapeutic effect has also been 
obtained by adding regulatory T cells to donor T cells in GVHD (324). A novel 
human to mouse trans vivo model has identified donor reactive immune responses in 
kidney and liver transplant patients. The results show that the delayed type 
hypersensitivity reaction was weaker in tolerised patients, and this response 
suppression was dependent on IL-10 and TGFp. In addition, kidney transplant 
patients with no history of acute rejection demonstrated little response to mismatched 
allopeptides, as compared to patients that had suffered episodes of acute rejection, and 
this regulation was mediated by CD4+CD25+ T cells (325, 326).
CD4+CD25+ regulatory T cells and tumour immunity
In humans, high levels of CD4+CD25+ regulatory T cells have been found in lung, 
ovarian, breast and pancreatic tumour specimens (327, 328), which may impede the 
generation and activation of tumour effector T cell responses. A study addressing the 
role of CD4+CD25+FQAP3+ T cells in ovarian carcinoma, found that human tumour- 
specific CD4+CD25+ regulatory T cells suppressed specific anti-tumour immunity in 
vitro, and reversed the inhibition of tumour growth induced by adoptive transfer of 
tumour-specific effector T cells (329).
CD4+CD25+ regulatory T cells and inflammatory bowel disease 
Evidence shows that CD4+CD25+ Tregs prevent the development of murine colitis by 
directly inhibiting effector T-cell proliferation and pro-inflammatory cytokine 
production (211, 240, 330). Furthermore, IL-10 and TGF-P play an important role in 
the prevention of intestinal inflammation (240, 331). CD4+CD25+ T cells can also 
treat established colitis induced in SCID mice (242). The therapeutic role of
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CD4+CD25+ regulatory T cells was strongly dependent on CTLA-4, IL-10, and TGFp 
(242, 332).
CD4+CD25+ regulatory T cells and rheumatoid arthritis
Rheumatoid arthritis is characterised by synovium infiltrated by activated CD4+ and 
CD8+ T cells, B cells, plasma cells, neutrophils and macrophages. Depletion of 
CD4+CD25+ T cells in susceptible DBA/1 mice resulted in significantly increased 
severity and incidence of disease (333), and enhanced Ag (type II collagen)-specific 
proliferation of splenocytes in vitro (333). These effects were reversed by adoptively 
transferring CD4+CD25+ T cells isolated from syngeneic naive mice. However, 
CD4+CD25+ regulatory T cells are not important in controlling autoimmune arthritis 
in a proteoglycan-induced murine arthritis model (334). In humans, it was found that 
CD4+CD25hlgh T cells isolated from the peripheral blood of patients with active RA 
were anergic and were unable to regulate pro-inflammatory cytokines released by 
effector T cells and monocytes in vitro, when compared to cells isolated from healthy 
individuals (335).
CD4+CD25+ regulatory T cells and diabetes mellitus
Diabetes mellitus is mainly caused by beta islet cell autoreactive CD4+ and CD8+ T 
cells, particularly those cells producing Thl-type cytokines IFNy, IL-12 and TNFa. 
As to whether there is deficiency in CD4+CD25+ T cells in patients with type 1 
diabetes remains controversial. However, the in vitro suppressive function of these 
cells isolated from diabetic patients on T cell proliferation was reduced when 
compared to healthy control subjects (336, 337). Using the non-obese diabetic (NOD) 
mice as a model of type 1 diabetes, it has been shown that CD4+CD25+ regulatory T
cells can inhibit IFNy production and prevent diabetes (338). In these studies, 
CD4+CD25+ regulatory T cells were localised in the pancreas-associated tissues, and 
it was demonstrated that decreased numbers of CD4+CD25+ T cells in these locations 
correlated with acceleration to diabetes. Reconstitution with pancreatic lymph node­
derived CD4+CD25+ T cells prevented diabetes progression. It was also shown that 
although CD4+CD25+ Tregs did not inhibit CD8+ T cell recruitment to the islets, they 
did delay or suppress the anti-islet CD8+ T cell differentiation into effector CTL 
(339).
CD4+CD25+ regulatory T cells and infectious disease
The persistence of pathogens in the host is seen in infectious diseases like 
tuberculosis, leishmaniasis, toxoplasmosis, and many viruses. CD4+CD25+ regulatory 
T cells may inhibit the clearance of such pathogens by suppressing effector T or 
innate cells. CD4+CD25+ regulatory T cells have been shown to prevent the complete 
elimination of Leishmania parasites in both resistant and susceptible mice (242, 340). 
Moreover, reactivation of disease was associated with a local increase in CD4+CD25+ 
T cell numbers. In another study, it was shown that the transfer o f CD4+CD25+ T cells 
purified from chronically infected mice into resistant mice was sufficient to trigger 
disease reactivation (341). CD4+CD25+ regulatory T cells also have been shown to 
suppress effector T cell responses, and contribute to pathogen persistence in 
experimental and clinical infections, including Pneumocystis carinii (342), Candida 
albicans (160, 343), Helicobacter pylori (344), human cytomegalovirus (345), HIV 
(345), and Hepatitis C infection (8, 346, 347). Thus, CD4+CD25+ regulatory T cells 
have a protective role in infection by limiting pathogen-induced immunopathology, 
whilst also allowing the development of pathogen-induced immunological memory.
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However, the multiple mechanisms underlying pathogen persistence still need further 
investigation.
CD4+CD25+ regulatory T cells and Th2-mediated disease
Patients that specifically lack CD4+CD25+ regulatory T cells develop severe eczema, 
have elevated IgE levels, display blood eosinophilia, and have food allergies. 
Therefore, it seems likely that regulatory T cells play a role in controlling the 
development of allergic disease and asthma (348). Furthermore, CD4+CD25+ 
regulatory T cells have been shown to suppress immature dendritic cells, rendering 
the DCs unable to induce Th immunity (223). Murine asthma work has produced 
conflicting data. Some investigators demonstrated that CD4+CD25+ T cells worsened 
the allergic phenotype in mice, by preferential inhibition of Thl cells by Tregs (349), 
whilst others have found that CD4+CD25+ regulatory T cells can suppress Th2- 
mediated inflammation, without affecting airways hyperresponsiveness (350, 351). In 
humans, CD4+CD25+ cells from the peripheral blood of atopic and non-atopic 
individuals has demonstrated that the suppressive activity o f such cells is reduced in 
atopic individuals, implying that the disordered activity o f Tregs may allow 
development of allergic disease (352).
In summary, CD4+CD25+ regulatory T cells have a critical role in the control of 
immune responses, probably working in close cooperation with other peripheral 
induced regulatory T cells and/or immunosuppressive cytokines in vivo. Dysfunction 
or deficiency of regulatory T cells could potentially be a cause of autoimmune 
diseases. However, activation of regulatory T cells is not always beneficial to the host. 
Regulatory T cells also inhibit show anti-pathogenic and anti-tumour immunity, and
may weaken vaccine induced-immunity. By gaining further knowledge of regulatory 
T cells, it may be possible to manipulate Tregs to suppress overactive immune 
responses in autoimmune, allergic and graft-versus-host diseases, whilst not 
compromising anti-tumour or anti-pathogen immunity. Hence, by carrying out basic 
scientific research one would hope to translate these works from bench to bedside.
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1.4 Hypothesis
As demonstrated above, there is a complex network of cells and factors that interplay 
in pathogenesis of asthma, and there is a substantial body of evidence supporting the 
importance of regulatory T cells and Toll-Like Receptors in inflammatory diseases.
As previously discussed, there are numerous ways in which to investigate such a 
complicated disease like asthma. However, the approach I have taken is twofold. 
Firstly, I propose to investigate the TLR2 system that is expressed and shown to be 
important in the function of many of the cells involved in allergic airways 
inflammation. TLR2 activation will affect effector cells of both the innate and 
adaptive immune system, as well as potentially affecting Tregs. I postulate that TLR2 
activation will ameliorate murine asthma, by either down-regulating or skewing 
effector Th responses, or by activating regulatory T cells.
Secondly, I propose to look at a surface molecule that is known to be important in the 
function of regulatory T cells, but also as a co-stimulatory molecule of effector T 
cells. Hence, I postulate that GITR activation in murine asthma may exacerbate the 
phenotype by abrogating Treg function, and by enhancing the Th2 effector response.
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1.5 Aims of the project
Hence, the aims of this project are:
1. To examine the effects of TLR2 activation in a murine model of allergic 
airways inflammation.
2. To examine the role of GITR activation in a murine model of allergic airways 
inflammation.
I will employ a range of in vitro and in vivo techniques to address these questions. The 
project will not only provide vigorous training in advanced immunology for a PhD 
program, but the results obtained should also shed light on the characteristics and 
function on this crucial area of immune regulation, leading to potential novel 
therapeutic approaches to a range of inflammatory diseases.
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Chapter 2
Materials and Methods
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2.1 Mice
BALB/c mice (H-2d, IgMa), 129/Sv (H-2b, IgMa), and severe combined 
immunodeficient mice (SCID, C.B-17 of the BALB/c background) were purchased 
from Harlan Olac (Bicester, Oxon, UK). DO 11.10 mice (I-Ad), transgenic for TcR 
specific to OVA peptide (sequence 323-339), were on a BALB/c background and bred 
in the Central Research Facilities (CRF), University of Glasgow. IL-12 p40 knockout 
(ko) mice (on a BALB/c background) and IFNy ko mice (on a 129/Sv background) 
were bred in the Central Research Facilities (CRF), University of Glasgow, and 
kindly supplied by Prof. A. M. Mowat (Division of Immunology, Infection, and 
Inflammation, University of Glasgow, Glasgow, U.K).
All mice were housed and treated in the Biological Service facilities in the University 
of Glasgow according to the UK Home Office guidelines under pathogens free 
condition. SCID mice were kept in micro-isolator cages with filtered air and fed 
sterilized foods. Mice were used at 6-10 weeks of age. Procedures were carried out 
under Project License 60/3119, procedure number 9.
2.2 Reagents and Buffers
The reagents either purchased or donated are summarised in Tables 2.1-2.3. Details of 
buffers are given Table 2.4.
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Cytokine Supplier Source Concentration Use
GM-CSF R&D Systems 
Oxon, U.K.
Murine 30 ng/ml BMDC
Culture
CSF-1 R&D Systems Murine 20ng/ml BMM
Culture
IL-2 GlaxoSmithKline 
Stevenage, U.K.
Human 10 ng/ml Cell culture 
maintenance
IL-4 R&D Systems Mouse 10 ng/ml Th2
polarisation
BMDC culture
IL-12 Genetics Institute, 
Cambridge, MA
Mouse 5 ng/ml Thl
polarisation
Table 2.1 Cytokines used for in vitro culture
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Antibodies 
(Clone No.)
Source Isotype Concentration Use
Anti-CD3 
(145-2C11)
BD Bioscience Hamster IgGl 0.5 - 5 pg/ml T cell activation
Anti-CD28
(37.51)
BD Bioscience Syrian 
Hamster IgG2
1 pg/ml Co-stimulation of  
T cells
Anti-CD 16/32 
(2.4G2)
BD Bioscience Rat IgG2b 0.5 pg/ lOOpl Fc receptor 
blocking
FITC or PE- anti- 
CD4 (RM4-4/5)
BD Bioscience Rat IgG2a 0.5 pg/lOOpl FACS
PE-anti-CD25
(PC61/7D4)
BD Bioscience Rat IgG2b 3.6 pg /I xlO8 
cells
T cell separation 
FACS
* Anti-IL-IOR 
(1B1.3A)
DNAX, Palo 
Alto, CA
Rat IgGl 1 mg/mouse in vivo 
experiments
Anti-IL-12 
(rm IL-12)
R&D Systems Goat IgG 0.1 pg/ml Drive Thl cells
** Anti-IL-12 ATCC 
Manassas, VA
Rabbit IgG 1 mg/mouse in vivo 
experiments
Anti-IFN-y
(XMG1.2)
BD Bioscience Rat IgGl 300 ng/ml Drive Thl cells
** Anti-TGF-P 
(1D 11.16.8)
ATCC 
Manassas, VA
Bovine IgGl 1 mg/mouse in vivo 
experiments
*** Anti-GITR 
(DTA-1)
Generated in 
house
Rat IgGl 1 mg/mouse in vivo 
experiments
FITC-GITR
(108619)
R&D Systems Rat IgG2a 1:10 dilution 
(Kit)
FACS
FITC-conjugated 
mouse anti-rat IgG 
F(ab’)
Jackson
Immuno-
Research
Lab
F(ab’)2
fragment
1:125 dilution GITR cell 
separation
FACS
Table 2.2 Antibodies used for in vivo and in vitro experiments
* Anti-IL-IOR was kindly provided by Dr. K. Moore (DNAX, Palo Alto, CA).
** Anti- IL-12 was a polyclonal rabbit anti-mouse IgG antibody prepared from clone Rab74.6 and anti- 
TGFp monoclonal antibody was prepared from clone ID 11.16 (both ATCC, Atlanta GA).
*** Anti-mouse GITR mAb was prepared from the DTA-1 hybridoma, kindly donated by Prof. S. 
Sagakuchi (Department o f Experimental Pathology, Kyoto University, Japan).
All control IgG were purchased from Sigma-Aldrich.
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R egen t S u pplier Use
2,2,2-tribromoethanol Sigma-Aldrich, 
Poole U.K.
Mouse anaesthesia
2% Alhydrogel Brentag Biosector, Denmark Mouse sensitisation
2-Mercaptoethanol Sigma-Aldrich T cell culture
Amyl alcohol Sigma-Aldrich Mouse anaesthesia
Anti-PE microbeads Miltenyibiotec, Auburn, CA CD25+ T cell separation
Anti-rat IgG microbeads Miltenyibiotec GITR cell separation
CD4 separation kit Miltenyibiotec CD4+ T cell separation
Concanavalin A Sigma-Aldrich Cell culture
Extravidin-peroxidase Sigma-Aldrich ELISA
Foetal calf serum 
(FCS)
Harlan, Loughborough, UK Cell culture
L-glutamine Invitrogen, Paisley, U.K. Cell culture
OVA 
(fraction V)
Sigma-Aldrich Mouse sensitisation, 
challenge & cell culture
Synthetic lipopeptide 
Pam3CSK4/BLP
EMC Microcollections, 
Germany
In vitro & in vivo 
experiments
PBS Invitrogen, Paisley, U.K. Cell culture
Penicillin Invitrogen, Paisley, U.K. Cell culture
Peptidoglycan 
(from S. aureus)
Sigma-Aldrich In vivo experiments
qPCR core kit Eurogentec, Hampshire, U.K. Real time PCR
RNA-Bee Ams Biotechnology 
Oxon, U.K.
RNA extraction
Streptomycin Invitrogen 
Paisley, U.K.
Cell culture
Superscript II RNaseH 
reverse transcriptase
Invitrogen 
Paisley, U.K.
RT-PCR
TMB Insight, KPL, 
Middlesex, U.K.
ELISA
TURBO DNA-free kit Ambion, 
Huntingdon, U.K.
Removal o f genomic DNA  
contamination
UNG Eurogentec Real time PCR
Table 2.3 Other reagents
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Buffer Constituents
Phosphate buffered Saline (PBS)
0.24g KH2P 0 4 
0.2g KCL 
1.44g NaH2P 0 4 
8g NaCL
Add to 800ml ddH20 , stir and allow to dissolve, then pH to 
7.0 and make up to a final volume o f 1 litre.
FACS buffer
1 xPBS  
2% FCS 
0.05% sodium azide
MACS buffer
1 xPBS  
2% FCS 
100 IU/ml penicillin 
100 pg/ml streptomycin 
sterilised with 0.22pM cellulose Acetate filter (VWR 
International)
Coating buffers for cytokine ELISA
1) 0.1 M NaHC03: 1.68g in 200ml distilled H20, pH-adjusted
to 8.4
2) 0.05 M carbonate/bicarbonate buffer: 50mM NaHC03, 
50mM Na2C 0 3, 
pH-adjusted to 9.4
3) 0.1 M carbonate/bicarbonate buffer:
0.1 M NaHC03, 0.1 M Na2C 0 3, 
pH-adjusted to9.5
Blocking buffer for cytokines 
ELISA
PBS & 10% FCS
Washing buffer for ELISA 0.05% Tween-20 in PBS, 
pH-adjusted to 7.4
IgG purification Buffer A 1:4 (v/v) ratio o f 1 M NaH2P 0 4 & 0.5 M Na2H P04, sterilised 
with 0.22pM cellulose Acetate filter (VWR International)
IgG purification elution buffer 0.1M glycine: 3.75g in 100ml distilled water, 
pH-adjusted to 2.5
Tris buffer for IgG storage 2M Tris Buffer: 12.1 lg  tris base, 
pH-adjusted to 9, and sterilised with 0.22pM cellulose 
Acetate filter (VWR International)
Table 2.4 Buffers
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2.3 Cell culture
2.3.1 Cell maintenance
Cells were cultured in complete medium, which consisted of RPMI 1640 medium 
supplemented with 2 mM L-glutamine, 100 IU/ml penicillin, 100 pg/ml streptomycin, 
50 mM 2-mercaptoethanol, and 10% heat-inactivated foetal calf serum (FCS). FCS, 
which had been Mycoplasma screened by the manufacturer, was heat-inactivated at 
56°C for 30 minutes. Cultures were incubated at 37°C in a humidified incubator 
supplemented with 5% CO2 .
Viable cells were counted with a Neubauer haemocytometer (Weber Scientific 
International Ltd, UK) on a Nikon Labphot microscope, staining with 0.1% (w/v) 
trypan blue. During cell purification and washing, cells were centrifuged at 1400 rpm 
at 4°C unless otherwise stated.
2.3.2 Lymphocyte function assay -  cell proliferation
Proliferation was assessed by culturing cells in triplicate in U-bottom 96 well plates 
(Nunc, Roskilde, Denmark) for 72 h. The final volume per well was 200 pi. Plates 
were pulsed with [3H]thymidine (1 pCi/well, Amersham Life Science, Bucks, UK) for 
the last 8 h of culture. Plates were harvested onto a glass fibre filter (Wallac, Milton 
Keynes, UK) using a 295-0054 Betaplate™ 96 well harvester (Wallac). [3H]-
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thymidine incorporation was measured using a Matrix 96 Direct Beta Counter 
(Wallac).
2.3.3 Cultures for cytokine assessment
Cytokine production was assessed by analysing supernatants from 24 well flat bottom 
plates or from 96 well plates (either U-shaped or flat bottom) after 72-96 hours of 
culture. Supernatants were stored at -20°C until cytokine analysis by ELISA was 
performed.
2.4 T Cell isolation
T cells were purified from murine lymph nodes by using magnetic beads. In brief, 
single cell suspension was prepared by forcing LN cells through 100 pm Nytex 
membrane (Cadisch & Sons, London, UK) twice using a 10 ml disposable syringe in 
the presence of RPMI-1640 medium. Cells were counted and then incubated with 
either non-conjugated rat, biotinylated, or PE-conjugated monoclonal antibodies.
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MACs buffer (Table 2.4) was added to make the reaction volume 40 pi per 10 total 
cells. After 20 minutes on ice, anti-rat, anti-biotin or anti-PE microbeads were added 
and incubated for another 20 minutes on ice. T cells were then washed twice and 
centrifuged at 200 g for 10 minutes. Thereafter T cells were separated by either 
negative or positive selection using an AutoMACS machine (Miltenyi Biotech) (353).
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2.4.1 Negative selection of CD4+ T cells
CD4+ T cells were purified from BALB/c lymph nodes by negative selection using 
magnetic beads. Cells were incubated with a cocktail of biotin-conjugated monoclonal 
antibodies [against CD8 a (Ly-2, Rat IgG2a), CD l ib  (Mac-1, Rat IgG2b), CD45R 
(B220, Rat IgG2a), DX5 (Rat IgM) and Ter-119 (Rat IgG2b)], at a concentration of 5 
pi antibody per 107 total cells. Anti-biotin microbeads (10 pi per 107 cells) were added 
and CD4+ T cells were then separated by negative selection.
2.4.2 Positive selection of CD4+CD25+ T cells
CD4+ cells were then further separated into CD25+ and CD25' populations by 
tfwfoMACS using PE-labelled anti-CD25 Ab and anti-PE Ab conjugated with 
microbeads. Briefly, 1 x 108 CD4+ T cells were incubated with PE-anti-CD25 
antibody (3 pg) for 15 minutes at 4°C in the dark, and then washed twice with 20 x 
volume of MACS buffer (Table 2.4). The cells were then incubated with 35 pi anti-PE 
microbeads for 15 minutes at 4°C in the dark. The cells were re-suspended in 2 ml 
MACS buffer, and then separated by positive selection using the autoMACS machine. 
The purity of each final cell preparations was determined by staining cells with 
murine anti-CD4-FITC and anti-CD25-PE Ab and analysed by FACSCalibur using 
CellQuest software (BD). The purity of CD4+CD25’ T cells was routinely >97%, and 
CD4+CD25+ T cells >94%.
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2.4.3 Positive selection of CD4+G ITR+ cells
CD4+ T cells were also further separated into CD4+GITR+ and CD4+GITR' 
populations by positive selection using rat anti-GITR mAb (DTA-1 hybridoma) and 
anti-rat IgG Ab conjugated with microbeads. The purity of cell preparations was 
determined by FACS analysis using rat anti-GITR mAb and FITC-conjugated mouse 
anti-rat IgG F(ab ’ )2  fragment, and was routinely >90%.
2.5 Specific in vitro culture protocols
2.5.1 Anti-GITR mAb production
A hybridoma cell line producing rat IgG2a against mouse GITR was generously 
gifted by Professor Shimon Sakaguchi (Department of Experimental Pathology, 
Kyoto University, Japan), Antibody was generated as previously described (264). 
Briefly, hybridoma cells were cultured for 3 days in normal complete medium 
supplemented with 10% FCS. The cells were then washed in PBS, and cultured for a 
further 3 days in RPMI medium supplemented with immunoglobulin (Ig) -deplete 
FCS (Harlan, Loughborough, UK). The supernatant was then collected and frozen at - 
20°C, until antibody purification was performed. A protein G Sepharose 4 Fast Flow 
column (Pharmacia Biotech) was used for IgG purification. Prior to use the protein G 
column was washed with 20% ethanol (v/v), and balanced with 400ml of Buffer A 
(Table 2.4). Two and a half litres of supernatant was loaded at 4°C onto the protein G 
column. After removing low affinity proteins bound to the column with 200ml of
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Buffer A, the antibody was washed off the column with an elution buffer. 2 ml 
aliquots were collected and mixed with 20 pi 2M tris HC1 (Table 2.4). The protein 
concentration of each elute was estimated by measuring optical density (O.D.) at 280 
nm. The aliquots with the highest O.D. values were then dialysed overnight in PBS 
(pH 7.4) at 4°C. The samples of antibodies were then stored at -20°C until used. The 
protein concentration for each aliquot was using Coomassie Protein Assay (Pierce, 
USA). Aliquots of antibody were routinely tested for LPS using an endotoxin kit 
(Sigma-Aldrich).
2.5.2 Regulatory T cell suppressive function assays in vitro
CD4+CD25+ and CD4+CD25‘ T cells were separated from naive BALB/c mice using 
an ^wtoMACS machine (as described above). Suppressor function assays were set up 
in 96-well U-bottom plates, with “effector” CD4+CD25' T cells (1 x 104 cells/well) 
being cultured with “regulatory” CD4+CD25+ in a 1:1 ratio. Soluble anti-CD3 
antibody (1 pg/ml), and mitomycin C-treated (50 pg/ml) CD4' spleen or lymph nodes 
cells (5 x 104 cells/well) were used as antigen presenting cells (APC). In some 
experiments, either 10 pg/ml control rat IgG Ab or anti-GITR mAb were added to 
cultures. Cells were cultured at 37°C in 5% CO2 for 3 days, and proliferation and 
cytokine production was assessed.
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2.5.3 Polarisation of T helper cells
CD4+ T cells or CD4+CD25' T cells were separated as above. Cells (1 x 106 cells) 
were then cultured in conditions to generate ThO (pluripotent), T hl, or Th2 cells. For 
ThO cell induction, cells were cultured with complete medium alone. Thl cells were 
generated by culturing with murine IL-12 (10 ng/ml) and anti-IL-4 antibody (1 
pg/ml). Th2 cells were produced by culturing with murine IL-4 (10 ng/ml), anti-IFNy 
(500ng/ml), and anti-IL-12 antibody (1 pg/ml). At the end of a 3 day culture, the 
supernatants were collected and stored at -20 °C for cytokine analysis. The cells were 
rested for 3-4 days in medium containing IL-2 (10 ng/ml; BD PharMingen), and re­
cultured in the conditions described above. After 2 cycles of culture the supernatants 
were again collected and stored at -20°C for cytokine analysis. The cells were 
phenotyped for Th 1 or Th2 by cytokine secretion and CD44 and CD62L expression. 
More than 95% of the cells were CD44+CD62L' and produced the expected type 1 or 
type 2  cytokines.
Where indicated, 10 -  100 pg/ml control rat IgG Ab or anti-GITR mAb was added to 
cell culture at the same time as the Th polarising cytokines and antibody. In some 
experiments, Pam3CSK4 (10 or 100 ng/ml) was added to the Th polarisation culture 
conditions. Cells were stimulated with graded doses o f soluble or plate bound anti- 
CD3 mAb (0.5-5 pg/ml), as indicated in the text.
For antigen-specific stimulation, T cells were purified from DO 11.10 mice - 
transgenic for TcR specific to OVA peptide (sequence 323-339). The OVA-specific
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CD4+ T cell or CD4+CD25' T cells were cultured in the conditions described above, 
except that 0.3 pM O V A 3 2 3 - 3 3 9  peptide was used instead of anti-CD3 mAb.
2.5.4 Bone marrow derived dendritic cell (BMDC) and bone marrow derived 
macrophage (M) cell generation
BMMs and BMDCs were generated as described previously (354, 355). Briefly, 
femurs and tibiae of mice were removed and separated from the surrounding muscle 
in sterile conditions. Bone marrow was flushed out with RPMI-1640 medium using a
1 / 95 ml syringe with 26 G “brown” needle, and cell clusters were washed and passed 
through Nitex twice. For dendritic cell generation, cells (2 x 106 /ml) were seeded into 
6 -well plate with complete medium in the presence of GM-CSF (30 ng/ml) and IL-4 
( 1 0  ng/ml), and incubated for 3 days at 37°C in 5% CO2 . Half of the culture medium 
was then replaced with fresh complete medium supplemented with GM-CSF and IL- 
4, and cells were cultured for another 3 days. Non-adherent cells (DCs) were then 
removed and washed by cold RPMI. For macrophage cell generation, cells (5 x 106 
/ml) were cultured in a total volume of 1 0  mis complete medium supplemented with 
CSF-1 (20 ng/ml) in petri dishes. After 3 days half the medium was replaced with 
fresh medium supplemented with CSF-1, and adherent cells were scraped off the 
bottom of ice-cooled petri dishes after a further 3 days culture.
The macrophage and dendritic cells were cultured at 1 x 106 cell/ml with 0.3 pM 
OVA323-339 peptide and Pam3CSK4 (10 or 100 pg/ml) for 12 h. Supernatants were 
collected and stored at -20°C for cytokine analysis. The residual cells were then 
washed and cultured with 1 xlO6 CD4+ T cells (purified from DO 11.10 transgenic
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mice), 0.3 pM OVA323-339 peptide and Pam3CSK4 (10 or 100 pg/ml) for a further 12 
h. Supernatants were collected and stored at -20 °C for cytokine analysis.
2.6 Murine model of allergic asthma
Murine models of allergic asthma are widely used (reviewed in (356)). Mice are 
sensitised to protein allergens with adjuvant and subsequently re-challenged 
repeatedly with allergen into the airways. This leads to the development of airway 
eosinophilia and airway hyperresponsiveness. Female BALB/c mice (6 - 8  weeks old) 
were used except in studies involving IL-12 and IFNy gene knockout (ko) mice. 
Female 129/Sv mice were used as control mice for IFNy ko experiments.
Avertin (357) was used as an anaesthetic during all experiments. A stock solution was 
made by dissolving 2,2,2 tri-bromoethanol in a 1:1 ratio (w/v) with amyl alcohol. This 
was stored at 4°C until immediately before use when a working solution was made by 
diluting the stock 1:40 in LPS-ffee sterile PBS.
2.6.1 Induction of airway eosinophilia in mice
Mice were sensitised to ovalbumin (OVA), as described in Figure 2.1 by modification 
o f a previously published protocol (358). All OVA solutions were filter sterilised prior 
to use (Millex-GV 0.22 pm, Millipore, Livingston, UK), and aliquots were routinely 
tested for LPS using an endotoxin kit (Sigma-Aldrich). An alum suspension 
(Alhydrogel 2%) was used as an adjuvant. To adsorb the OVA to the alum, a 1 mg/ml
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solution of OVA in PBS was added to an equal volume of the alum suspension and 
mixed using a vortex mixer. Mice were immunised intraperitoneally (i.p.) on day 0 
and 14 with 100 pg OVA in an alum suspension made up to a volume of 200 pi. On 
day 14, mice were anaesthetised with 250 pi of avertin, and 100 pg of OVA in 40 pi 
o f PBS was administered intranasally (i.n.). Mice were again anaesthetised before 
being challenged i.n. on each of the days 25, 26, and 27 with 10 pg OVA in 40 pi of 
PBS. Control mice were given PBS in place of OVA in both the sensitisation and the 
challenge stages.
2.6.2 Physiological measure of airways hyperresponsiveness -  Enhanced Pause
Whole Body Plethysmography is a technique that has been used to monitor lower 
airways resistance in unrestrained conscious mice. Enhanced Pause (Penh) is a 
function of the small pressure differences observed in the chambers housing mice 
compared to a reference chamber. Penh was measured at 12.5 to 50 mg/ml 
methacholine on day 28, as previously described (359). Briefly, mice were placed in a 
4 chamber plethysmography unit (EMMS, England, U.K.), and left undisturbed for a 
30 minute acclimatisation period. Mice were then challenged for 2 minute periods 
with saline (control) or graded doses of methacholine. Airways hyperresponsiveness 
was then estimated as Penh, using EMMS EDAQ® software.
2.6.3 Immunological measures of allergic airways disease
Mice were sacrificed on day 29 by administration of a fatal dose of avertin. Blood, 
bronchooalveolar lavage, lymph nodes and spleen were harvested and kept on ice
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until processed (see below).
In some experiments, disease-modifying agents were administered. The amounts, 
timings and routes of delivery of these compounds are outlined in the relevant results 
chapter.
2.6.4 Bronchoalveolar lavage (BAL)
The thorax was opened carefully and blood was taken by cardiac puncture. The 
trachea was then exposed and a small transverse incision made in it immediately 
below the level o f the larynx. Polythene tubing (0.58mm ID, 0.78mm OD; VWR 
International) threaded over a 23 gauge ‘blue’ needle was inserted into the trachea and 
held in place using 12 cm blunt forceps. The lungs were then lavaged by sequentially 
inserting and withdrawing two volumes of 0.8ml of PBS, ensuring that both lungs 
were seen to inflate during the lavage process and that there was no leakage of lavage 
fluid from the trachea. The two lavage samples from each mouse were pooled in a 1.5 
ml microcentrifuge eppendorf tube (Thistle Scientific, Uddingston, UK) and kept on 
ice until processing. The volume of each sample was estimated by weighing each 
sample and subtracting the weight of an empty eppendorf. The BAL fluid was 
centrifuged at 1400 rpm for 5 minutes to pellet the cells and the supernatant removed. 
Supernatants were frozen at -20°C until analysis. The cells were re-suspended in 1ml 
of PBS, and the cell numbers were counted. The absolute cell count per lavage was 
divided by the lavage volume to standardise the cell count per ml of lavage fluid.
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Figure 2.1 Experimental protocol used to induce allergic airways 
inflammation.
Mice were injected i.p. with 100 pg OVA and 100 pi 2 % Alum on day 0 and 14. The 
mice were boosted i.n. with 100 pg OVA on day 14. All the mice were then 
challenged i.n. on 3 consecutive days beginning on day 25. Penh was determined on 
day 28 and mice were sacrificed on day 29. Serum, BAL and lymphoid cells were 
collected and lung histology studied.
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2.6.4.1 BAL differential cellularity
The BAL cellularity was investigated by preparing and staining slide cyto-centrifuge 
preparations using a Shandon Cytospin. Approximately 1 x 105 cells were centrifuged 
at 400 rpm for 6  minutes then fixed in methanol for 10 minutes. The cell preparations 
(cytopreps) were stained with Diff-Quik (Triangle Biomedical Sciences, 
Skelmersdale, UK), a staining kit for rapid Romanowsky staining. Differential cell 
counting was done using standard morphological criteria (Fig. 2.2). Four hundred 
cells were counted per slide. Differential cell counts were expressed as a percentage 
of the number of cells then multiplied by the total cell count per ml to give an absolute 
cell number.
2.6.5 Lung histology
After BAL sampling, the lungs were removed and the lungs inflated with 1ml of 10% 
neutral buffered formalin (10% (v/v) of 37% aqueous solution of formaldehyde 
(Aldrich), in 30mM NaFLPCU.FLO, 45 mM Na2HP0 4 , pH 7). The trachea was tied 
with 2-0 silk suture (Ethicon, Edinburgh, UK) and the lungs immediately immersed in 
10% neutral buffered formalin for at least 72 hours. After fixation, the left lung was 
then dissected free, embedded in paraffin and 6  pm sections cut (kindly performed by 
Mr. Roderick Ferrier, Department of Pathology, Western Infirmary, Glasgow). 
Sections were stained with haematoxylin and eosin (H&E). Sections were examined 
at x 2 0  -  1 0 0  magnification and peri-bronchial and peri-vascular inflammation 
assessed.
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2.6.6 Lymphoid cell culture
Thoracic lymph nodes and spleens were obtained by careful dissection, and stored in 
complete RPMI on ice until processing. A single cell suspension was obtained by 
gently pressing lymph nodes and spleens through sterile Nytex using a 5 ml syringe 
plunger. The cell suspension was washed three times in complete RPMI, passed again 
through Nytex to remove cellular aggregates and debris. After re-suspended in 
complete medium, cells were count using a haemocytometer.
Proliferation assays using thoracic lymph node cells and spleens were performed in 
triplicate in U-bottom 96 well culture plates at 2 x 105 cells/well in 100 pi complete 
medium. Additional cell stimulating agents or medium were added in volumes of 100 
pi to give a final culture volume of 200 pi per well. Cells were stimulated with a final 
concentration of 100 -  1000 pg/ml OVA or 2-5 pg/ml Concanavalin A. Cell culture was 
allowed to proceed for 72 hours.
Cytokine production by lymphoid cells was measured using supernatants derived 
from parallel cultures set up in 24 well flat-bottom plates (Nunc). These culture 
supernatants were harvested after 96 hours. Supernatants were frozen at -20°C until 
cytokine levels were measured by ELISA.
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Figure 2.2 Typical bronchoalveolar cytospin preparations.
PBS-sensitised and -challenged mice demonstrated that macrophages were the 
predominant cell type in BAL. OVA-sensitised and -challenged mice displayed BAL 
eosinophilia and macrophages.
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2.7 Peritoneal lavage of mice
In some experiments, peritoneal lavage was performed to determine the differential 
cellularity. Mice were terminated by dislocation of the neck, and their peritoneal 
cavities exposed by careful dissection. 5 mis of sterile PBS was instilled into the 
peritoneum using a 20 G “yellow” needle. After 15 seconds, the fluid was slowly 
removed and stored on ice until processing. The volume of each sample was 
estimated, and the peritoneal fluid was centrifuged at 1400 rpm for 5 minutes to pellet 
the cells. The supernatant was removed, and the cells were re-suspended in 1ml of 
PBS. The cell numbers were counted, and the absolute cell count per lavage was 
divided by the lavage volume to standardise the cell count per ml of lavage fluid. 
Peritoneal fluid cellularity was investigated by preparing and staining slide cyto- 
centrifuge preparations using a Shandon Cytospin (as described above in Section 
2.6.4.1, p96). The cell preparations (cytopreps) were stained with Diff-Quik. 
Differential cell counting was done using standard morphological criteria. Four 
hundred cells were counted per slide. Differential cell counts were expressed as a 
percentage of the number of cells then multiplied by the total cell count per ml to give 
an absolute cell number.
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2.8 Flow cytometry
2.8.1 Cell surface markers
Freshly purified or activated cells (5 x 105 cells) were re-suspended in 100 pi FACS 
buffer (PBS with 2% FCS and 0.05% NaN3) in 12 x 75 mm polystyrene tubes (Falcon 
BD, Oxford, UK), and incubated with anti-CD 16/32 antibody (FcR block, 0.5 p g /100 
pi) for 15 minutes at 4°C in order to block non-specific Fc bindings.
Samples were stained with directly conjugated antibodies: aCD4 (PE), aCD4 (FITC), 
aCD25 (PE), aGITR (FITC), aCD69 (FITC), and ccCD44 (FITC), together with 
appropriate isotype controls were prepared, and incubated in the dark for 30 minutes 
at 4°C in FACS buffer. After one wash, cells were re-suspended in 500 pi FACSFlow 
and analysed with a FACSCalibur flow cytometer (Becton Dickinson) equipped with 
a 488 nm Argon laser and a 635 nm red diode laser, data were analyzed by Cellquest 
software (BD).
In initial experiments with GITR staining, a directly conjugated antibody was not 
available. Hence, indirect staining was performed with rat anti-GITR mAb (lpg/ 5 x 
105 cells) binding the cells and FITC-conjugated mouse anti-rat IgG F(ab’) (1:125, 
(v/v)) used as a secondary label.
100
2.9 Enzyme linked immunosorbance assay (ELISA)
2.9.1 Cytokine assays
The concentration of cytokines in cell culture supernatants, lung lavage fluid, and 
serum were determined by ELISA with paired antibodies (BD. PharMingen). Details 
o f the concentrations of antibodies used and the lower limit of detection of each assay 
are given in Table 2.4. Immulon 4 plates (Thermo Labsystems, Franklin, USA) were 
incubated overnight at 4°C with the appropriate concentration of capture antibody in 
0.1 M NaHC0 3  coating buffer. Plates were then washed 3 times with ELISA washing 
buffer (Table 2.4). For each wash, wells were filled with washing buffer and allowed 
to stand for at least 1 minute prior to removal of the wash buffer. Plates were washed 
4-6 times between each of the subsequent steps. Non-specific binding was reduced by 
incubating 1-2 h with ELISA blocking buffer (200 pi/ well) at room temperature. 
Culture supernatant (50 pl/well) were then added to the plate in triplicate. Serial two­
fold dilutions of recombinant cytokines were used as standard in duplicate. The plates 
were incubated for 2  h followed by a matched biotinylated antibody (detection 
antibody) for 1 h at room temperature. Extravidin Peroxidase (1:1000 dilution) was 
added, and the plates were incubated for 30-45 minutes at 37°C. 100 pi TMB 
(3’,3’,5’5’- tetra -methylbenzidine) Microwell Peroxidase Substrate was then added. 
Plates were incubated in the dark for 5-30 minutes depending on the rate of 
development of colour. The plates were then read at 630 nm on a MRX II microplate 
reader (Dynex Technologies, U.K.), always within 1 hour o f the TMB being added. 
In some experiments, IL-10, IL-13 and TGF0 detections were performed by Cytoset
Kit (Biosource, UK) according to the manufacturer’s instructions.
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2.9.2 M urine serum immunoglobulin measurements
2.9.2.1 Serum OVA-specific IgG l, IgG2a and IgE levels
Blood collected from mice coagulated at room temperature for 6  hours. Therafter, 
samples were centrifuged at 14,000 rpm for 30 minutes and sera aliquoted off. Murine 
serum OVA-specific IgGl, IgG2a and IgE levels were determined using a 
modification of the ELISA protocol described above, and of a previously published 
method (360). At least five washes with ELISA wash buffer (Table 2.4) were done 
between each step of the protocol. Immunolon 4 micro-ELISA plates were coated at 
4°C overnight with 50 pi of a 10 pg/ml solution of OVA in a coating buffer of 0.05 M 
carbonate/bicarbonate buffer. The plates were then blocked with 200 pi of ELISA 
blocking buffer (Table 2.4) for 1 hour at room temperature. Serum was diluted 
appropriately in wash buffer, then 1 0 0  pi of the diluted serum added across the top 
row of the plate, leaving column 12 with buffer alone. The starting dilutions were 1 in 
250 for serum IgGl assays, 1 in 50 for Ig2a assays and 1 in 20 for OVA-specific IgE 
assays. The samples were then serially diluted with wash buffer through rows two to 
eight of the plate. IgGl samples were diluted 1:3 each time and IgG2a and IgE assays. 
The samples were then serially diluted with wash buffer through rows two to eight of 
the plate. IgGl samples were diluted 1:3 each time and IgG2a and IgE samples diluted 
1:2. Samples were then incubated at room temperature for l lA hours. Biotinylated 
anti-mouse IgG l, IgG2a and IgE (BD Biosciences) antibodies were added to the 
appropriate plates at a concentration of 0.5 pg/ml in 50 pi wash buffer. The plates 
were incubated for 1 hour at room temperature. Thereafter, 50 pi of a 1:1000 dilution 
o f ExtrAvadin in wash buffer was added to each well and incubated
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Cytokine
Capture
Antibody
(pg/ml)
Detection Antibody 
(pg/ml)
Lower Limit of Detection 
of Assay (pg/ml)
IL-2 2 1 40
IL-4 2 2 30
IL-5 2 2 30
IL-12 2 0.5 40
IFN-y 1 0.5 40
Table 2.5 Antibodies used in murine cytokine ELISAs.
The antibodies used for the quantification of murine cytokines by ELISA in cell 
culture supernatants.
All antibodies were purchased from BD Biosciences, Cowley, UK.
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for 30 minutes at room temperature. The IgG plates were developed using 100 pi of 
TMB substrate and then read at 630 nm, as described in section 2.8.1 above. In the 
case of OVA-specific IgE, the reaction was stopped at 30 minutes by the addition of 
50 pi 1 M H3PO4. Plates were then read at 450 nm with 570 nm correction. The mean 
optical density for a designated serum dilution for each of OVA-specific IgG l, IgG2a 
and IgE was recorded to give a comparison of the serum levels of these antibodies 
among different treatment groups.
2.9.2.2 Measurement of serum total IgE levels
Total murine serum IgE levels were measured using commercial ELISA kit (OptEIA, 
BD Biosciences) following the manufacturer’s guidelines. The working volume was 
100 pi. At least 4 washes were performed between each step. Immunolon 4 micro- 
ELISA plates were coated with a 1:250 dilution of capture antibody in 0.1 M 
carbonate/bicarbonate buffer (0.1 M NaHC0 3 , 0.1 M Na2C0 3 , pH 9.5) and incubated 
at 4°C overnight. Plates were blocked by incubating with 200 pi of ELISA blocking 
buffer for 1 hour at room temperature. Mouse serum samples diluted 1:200 in ELISA 
wash buffer and then incubated for 2 hours at room temperature. Samples and the 
supplied IgE standard were tested in duplicate. The standard curve ranged form 1.6 
ng/ml to 100 ng/ml. Detection antibody and detection agent, both at a dilution of 
1:250 in ELISA buffer, were then added and samples incubated for 1 hour at room 
temperature. TMB substrate was used to develop the ELISA. This reaction was 
stopped at 30 minutes by the addition of 50 pi 1 M H3PO4. Plates were then read at 
450 nm with 570 nm correction.
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2.10 Reverse transcription -  polymerase chain reaction (RT-PCR)
Real time PCR was used when investigating the mechanism behind the effects of anti- 
GITR mAb on CD25' effector T cells in vitro. By quantifying the messenger RNA 
signals, we examined the stage of protein synthesis at which anti-GITR mAb was 
having its effect.
2.10.1 RNA purification
Total RNA was extracted from freshly purified or activated T cells. Cells (0.5-1 x 106) 
were re-suspended in 400 pi RNA-Bee (Table 2.3) by pipetting up and down. RNA- 
Bee is a reagent that isolates and preserves RNA. Samples were treated immediately 
or stored at -70°C before processing. Frozen samples were thawed on ice and 50 pi of 
Choloroform (Sigma-Aldrich) added. The mixtures were then incubated on ice for 15 
minutes. RNA, DNA and protein were separated by centrifugation at 14,000 rpm at 
4°C for 15 minutes. The upper aqueous phase was removed into a clean RNAase-free 
eppendorf tube (Ambion) and an equal volume of cold RNAase-free 2-isopropanol 
added. Samples were incubated at -20°C for 1 h before centrifuging as above. The 
RNA containing pellet was washed in 100 pi ice cold RNAase-free 70% ethanol and 
re-suspended in 20-50 pi cold RNAase-free water depending on the original cell 
numbers.
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2.10.2 DNase treatm ent
The RNA preparations may have genomic DNA contamination that could potentially 
be amplified in later steps. Therefore, TURBO DNA-free™ kit (Table 2.3) was used 
to remove genomic DNA. Briefly, 1-2 units TURBO DNase were added to 20 pi of 
RNA in the presence of the TURBO DNAse buffer, and incubated in a 37°C water 
bath for 1 h. DNAse inactivation regent (2 pi) was then added for 2 minutes at room 
temperature, and removed by centrifuging at 14,000 rpm for 1 minute. RNA samples 
were transferred into RNAse- free tube to perform RT-PCR.
2.10.3 Reverse Transcription PCR
Cloned (c) DNA was synthesized using superscript II RNase H-reverse transcriptase 
and 0 1 igodTi2-i8 (Invitrogen) was used as primers. Briefly, 1-5 pg RNA was 
incubated with 1 pi Oligo (500 pg/ml) and 1 pi dNTP mix (10 mM) in a total volume 
of 12 pi. The mixture was heated at 65°C for 5 minutes and quickly chilled on ice. 
Samples were reverse-transcribed using 1 pi (200 units) Superscript II reverse 
transcriptase with 4 pi 5 x first-strand buffer, 1 pi 0.1 M DTT, 1 pi distilled H2O at 
42°C for 50 minutes and then inactivated by heating samples at 70°C for 15 minutes. 
Negative control samples (without first-strand synthesis) were prepared in the absence 
o f reverse transcriptase.
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2.10.4 Prim ers and probe design
Oligonucleotide primers and fluorescent probes were designed to the interest genes 
using the PrimerExpress™ 1.5 program. Sequence of interest gene was obtained from 
genebank. For primers, optimal primer Tm is 59-60°C, less than 2 degree between the 
forward and reverse primers and including 20-80% GC; for probe, optimal Tm is 
69°C or 10°C higher than the Tm of primers, no G on the 5’ end and with less than 4 
contiguous Gs, and have more Gs than Cs. The fluorescent probes contained a 
reporter dye (FAM) covalently attached at the 5’ end and a quencher dye (TAMRA) 
attached at the 3 ’ end. Either one of the primers or probe was designed to span two 
intron-exon boundaries, allowing discrimination between products resulting from 
amplification of cDNA and contamination of genomic DNA. Primers specificity was 
checked against the BLAST® database, found within the PubMed World Wide Web 
site. This was to ensure that there is no significant homology with other genes from 
the same species.
2.10.5 Real-time PCR
Real-Time PCR was performed using an ABI prism 7700 sequence detector 
(PerkinElmer Applied Biosystems, Foster City, CA) according to the manufacturer’s 
instruction, primers and probes are shown in Table 2.6. The principle o f the method is 
outlined in Figure 2.3. Each reaction contained 12.5 pi Master mix (10 mM dNTP 
mix, 5 mM MgCE, 0.625 U AmpliTaqGold™, 0.25 U AmpErase Uracil N- 
Glycosylase, lOx qPCR™ buffer), 1 pi probe, 0.75 pi of each of the primers, 9 pi
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Gene Forward Primer Reverse Primer Probe (5 ’-FAM&3 ’-TAMRA)
T-bet
5 ’-
GCCAGGG AACCGCTT AT  
ATG -3 ’
5 ’-
AACTTCCTGGCGCATCC  
A -3 ’
5 ’-
CCCAGACTCCCCCAACACCGGA
-3 ’
GATA3
5 ’-
TCCTCCTCTACGCTCCTT  
GCTA -3 ’
5 ’-
ACACTGATTCCTTGGCGC  
TC -3 ’
5 ’-
TCGTG ATCGGAAGAGCAACCGT  
CTC -3 ’
HPRT
5 ’-
G CAGTACAG CCCCAAAA
T G G -3’
5 ’-
AACAAAGTCTGGCCTG T  
ATCC A A  -3 ’
5 ’-
TAAG TTGCAAGCTTGCTGGTGA
A A A G G A -3’
Table 2.6 Taqman (real time) PCR primer and probes
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H 2O, 1 jul cDNA template in a total volume of 25 [i\. Amplifications were performed 
in triplicates in a Thermo-Fast 96 Semi-skirt plate (ABgene). The cycling was 
initiated at 50°C for 2 minutes and followed at 95°C for 10 minutes for 1 cycle; 95°C 
for 15 seconds and 60°C for 1 minute for 45 cycles. Data analysis was performed 
using Sequence Detector software (PerkinElmer Applied Biosytems). This represents 
the PCR cycle at which an increase in fluorescence above a set threshold level can 
first be detected (Figure 2.4). Expression of the gene of interest in a sample was 
normalised by comparison to the expression of a reference reporter gene, HPRT. 
Firstly, the ACt was obtained by subtracting the Ct value of HPRT from the Ct value 
of the gene of interest. The formula 2'AACt was then used to calculate a value for the 
fold increase in gene expression relative to HPRT. Multiplication of this value by 100 
gives expression of the gene of interest as a percentage of HPRT. The positive error is 
the standard deviation of the difference, s = V(sj2 + S22) where si and S2 are the 
standard deviations of the Cts of the HPRT and the gene of interest.
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1. Polymerisation
Forward (S) (5)
5- ________________ ■ Y  Pro* Y ,.
3’ ---------------------------------------------------------------------------- 5’
5-  3'
* 5’
2. Strand displacement
4. Polymerisation
\  1  / . fx A /-  ® x -  -  
.. \
Figure 2.3 Taqman real-time RT-PCR.
R e v e r s e
5’ — — -------------
3' ---------------------------------------------------------------------------- 5’
51  3’
«---------------------------------5’
\  1 /3. Cleavage
1 - » ©
5’ ^ ----- ► 3’
3’ ---------------------------------------------------------------------------- 5'
5 - ------------------------------------------------------------- 3-
5’
5’   ► 3’
3’ ---------------------------------------------------------------------------- 5’
5’ ---------------------------------------------------------------------------- 3’
The Taqman probe is an oligonucleotide with a 5’ reporter dye (R) and a 3’ quencher 
(Q). In an intact probe, the proximity of the quencher to the reporter causes 
suppression of reporter fluorescence. During PCR, the probe is cleaved by the 5’ -»  3’ 
exonuclease activity of Taq DNA polymerase separating the reporter from the 
quencher. Reporter fluorescence increases and can be used to determine the quantity 
of specific product generated. The 3’ end of the probe is blocked to prevent extension of 
the probe during PCR.
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Figure 2.4 Typical Taqman amplification plots.
The amplification plot shows how the fluorescence emission (normalised Reporter, 
Rn) varies with the PCR cycle number. Initially the fluorescent signal is below the 
detection limit of the Sequence Detector. As the PCR reaction proceeds the signal can 
be detected as it continues to increase in direct proportion to the amount o f specific 
amplified product. The Rn reaches a plateau when the ratio o f polymerase enzyme to 
PCR product decreases preventing the amount o f PCR product from increasing 
exponentially. The Ct (threshold cycle) is determined during the exponential phase 
(threshold indicated by the black line). The panel above displays plots for three 
triplicate samples (A4-A6, B1-B3 and C1-C3).
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2.11 Statistical analysis
Data were collated and statistical analyses performed using a statistical software 
package (Minitab Statistical Software, Minitab Inc., State College, PA, USA). Power 
calculation to estimate sample size to examine for statistical differences in BAL 
eosinophilia were performed using MINITAB (Fig. 2.5). The Student’s Mest and 
analysis of variance (ANOVA) were used to compare data sets with normal 
distribution. Non-parametric statistics were used (Mann-Whitney U test) for 
comparison between data sets with skewed distribution. *p<0.05 was considered 
significant, and **p<0.01 was deemed highly significant.
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Eosinophil percentage difference we felt was significant is: 10%
Standard deviation of eosinophilia is: 
Significance level is:
Power value is:
5%
0.05
0.95
The calculation below shows that each group in an experiment requires at least 8 mice 
(copied from MINITAB worksheet).
Power and Sample Size
2-Sample t Test
Testing mean 1 = mean 2 (versus not =) 
Calculating power for mean 1 = mean 2 + 1 0  
Alpha = 0.05 Sigma = 5
Sample Target Actual
Size Power Power
8 0.9500 0.9602
Figure 2.5 Power calculation to estimate sample size required to demonstrate 
differences in bronchoalveolar lavage eosinophilia
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Chapter 3
The immunomodulatory effect of Pam3CSK4 in a murine model of
allergic airways disease
Data in this chapter has been published in 
Patel et al (2005), J  Immunol; 174(12):7558-7563.
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3.1 Introduction
The prevalence o f asthma in developed countries has increased approximately 
threefold over the last twenty years, which cannot be explained by changes in genetic 
predisposition. Environmental factors, especially in industrialised countries, are now 
thought to be responsible for this rapid increase (361, 362).
Respiratory infections have been linked to asthma in either a preventative or 
exacerbating role (361, 362). Hence, investigating the components of the immune 
system that initially recognise the respiratory tract pathogens seems imperative to the 
further understanding of this inflammatory disease. Toll-Like receptors (TLRs) are 
pattern recognition receptors, which act as primary sensors of microbial products. 
There are now 10 TLRs identified in humans, in both the innate and adaptive immune 
systems, where they play a pivotal role in the response directed against distinct 
structurally conserved components of pathogens (153, 363). Bacterial endotoxin 
(LPS) is recognised by TLR4, and administration of low dose intranasal LPS in a 
murine model of asthma resulted in an increase in the Th2-mediated allergic 
inflammation (152). However, in the same murine model administration of high dose 
LPS ameliorated airways inflammation. Immunomodulatory oligodeoxynucleotides 
(ISS-ODN) and CpG DNA can reduce allergic inflammation in experimental models 
of asthma, via the activation of TLR9 (364). Thus far, CpG DNA is the only TLR 
agonist that has the ability to reverse established airway inflammation in both acute 
and chronic murine models of asthma (364, 365).
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Recently, it has been demonstrated that TLR2 polymorphism is a major determinant 
of the susceptibility to asthma and allergies in children of farmers in Germany (366). 
TLR2 recognises microbial components by forming a heterodimer with TLR1 or 6 
(78), and studies have examined the effect o f the TLR2 agonists synthetic lipopeptide 
(Pam3CSK4) and peptidoglycan (PGN) on murine models of asthma. The results 
were contradictory. When administered during the sensitisation period, early TLR2 
agonist treatment was reported to worsen asthma (149, 367). In contrast, TLR2 
activation immediately prior to the intranasal challenge was found to reduce allergic 
airways inflammation (368, 369). It is important to note, however, that although PGN 
was thought to activate TLR2/6 heterodimer, recent work suggests that lipoprotein- 
and lipotechoic acid-contamination of PGN may be responsible for its TLR2 
activation (370). All studies to date have examined TLR2 activation prior to the 
airway challenge in these models (149, 367, 368), and none have examined the 
therapeutic potential of TLR2 agonists in established airways inflammation.
We investigated the therapeutic effect of the synthetic TLR2 agonist Pam3CSK4 in a 
murine model of airways inflammation. TLR2 agonists were administered both 
immediately before (termed “prophylactic” administration) and after intranasal 
allergen challenge (termed “established inflammation” administration). We report 
here that intraperitoneal Pam3CSK4 profoundly attenuated OVA-specific asthma in 
mice. Our data therefore provide direct evidence that Pam3CSK4 or other TLR2 
agonists could have potential as a new therapeutic approach in the treatment of 
clinical asthma.
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3.2 Prophylactic intraperitoneal (i.p.) TLR2 agonist ameliorates airways 
inflammation in a murine model of asthma
Initial experiments were performed to determine if the TLR2 agonists - Pam3CSK4 or 
PGN - could influence the development o f allergic airways inflammation. Bacterial 
lipopetides are characterized by unique NH3-terminal lipo-amino acid, A-acyl-iS'- 
diacylglycerol cysteine, and are the found in the outer membrane of gram-positive 
and gram-negative bacteria. Pam3CSK4 (BLP or Pani3CysSerLys4) is a synthetic 
analogue of a bacterial lipopeptide, and is recognised by TLR2/1 heterodimer (371). 
Peptidoglycan (PGN) consists of a glycan backbone with alternating p 1-4 linked 
residues of N-acetyl-D-glucosamine and muramic acid. PGN is a major component of 
gram-positive bacteria, and activates the immune system via TLR2.
BALB/c mice were sensitised and challenged with OVA, as outlined in Figure 3.1, 
and Pam3CSK4 or PGN was given by intraperitoneal injection (i.p.) 2 hours prior to 
the antigen challenge on day 25. OVA control mice were treated with i.p. PBS. PBS 
control mice were sensitised and challenged with PBS. The dose of PGN or 
Pam3CSK4 used was determined by in vivo titration, with the optimal dose being 100 
pg/mouse.
The results for prophylactic i.p. Pam3CSK4 and PGN administration in murine 
asthma are very similar. Hence, to avoid duplication the data for Pam3CSK4 are 
shown and discussed below. Any differences seen between Pam3CSK4 and PGN are 
highlighted in the text.
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Pam 3C SK 4 o r PG N
BALB/c
mice
day Q day 14
100 pg OVA (ip) 
2 mg ALUM
100 pg OVA (ip) 
2 mg ALUM (ip) 
100 pg OVA (ip)
10 pg OVA (in)
BAL
LN
Serum
Histology
Figure 3.1 Experimental protocol to examine the role of prophylactic i.p. TLR2 
agonists on allergic airways disease.
BALB/c mice were injected i.p. with 100 pg OVA and 100 pi 2 % Alum on day 0 and 
14. The mice were boosted i.n. with 100 pg OVA on day 14. All the mice were then 
challenged intranasally (i.n). on 3 consecutive days beginning on day 25. Pam3CSK4 
or PGN (25-100 pg per mouse) was administered i.p only once on day 25. TLR2 
agonist was given 2 h prior to i.n. challenge. Serum, BAL and lymphoid cells were 
collected and lung histology studied on day 28.
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3.2.1 Prophylactic intraperitoneal Pam3CSK4 treatment reduces total 
bronchoalveolar lavage cellularity and eosinophilia
Pam3CSK4 administration prior to i.n. allergen challenge resulted in a marked 
reduction in BAL eosinophil numbers, as compared to untreated OVA-sensitised and - 
challenged mice (Fig. 3.2). BAL cellularity was not significantly affected by TLR2 
agonist administration. BAL cytokines were not detected.
3.2.2 The effect of prophylactic intraperitoneal Pam3CSK4 treatment on OVA- 
induced thoracic lymph node responses in vitro
To investigate the immunological mechanism involved in the Pam3CSK4 treatment, 
thoracic lymphoid node cells were harvested from the Pam3CSK4-treated and 
untreated control mice and cultured with OVA in vitro. Pam3CSK4 therapy did not 
affect the T cell proliferation against OVA in vitro (data not shown). However, the 
lymphoid cells from Pam3CSK4-treated OVA sensitised/challenged mice produced 
significantly more IFNy compared to untreated OVA-sensitised/challenged mice. In 
contrast, Pam3CSK4 treatment led to a marked reduction in IL-4 and IL-5 synthesis 
by the lymphoid cells from OVA-sensitised/challenged mice (Fig. 3.3). Con A- 
induced responses from thoracic cell node cells from mice treated with Pam3CSK4 
showed a similar cytokine profile to that of OVA stimulation. Culture of LN cells 
with medium alone resulted in no cytokines being detected (data not shown).
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Total BAL Count Eosinophils
Pam3CSK4 -
Figure 3.2 BAL eosinophilia fell after prophylactic i.p. Pam3CSK4 therapy.
BAL total cell concentration and eosinophil proportion fell markedly after 
Pam3CSK4 therapy. Mice given i.p. Pam3CSK4 (100 pg/mouse) on day 25 
demonstrated a highly significant fall in their BAL eosinophilia (**p<0.01 compared 
with mice given OVA alone). Data are mean +/- SEM, n=5 and are representative of 3 
experiments.
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Figure 3.3 In vitro OVA-induced IFNy, IL-4, and IL-5 responses after 
prophylactic i.p. Pam3CSK4 therapy.
Lymph node cells were harvested on day 28 and cultured with 1 mg/ml OVA in vitro 
(as described in Materials and Methods, Section 2.6.6, p97). Culture supernatant was 
collected at 96 h and cytokine concentrations assayed by ELISA. IFNy production 
was significantly increased (**p<0.01), and IL-4, and IL-5 production was 
significantly reduced (**p<0.01 compared with mice given OVA alone). Data are 
mean +/- SEM, n=5 and are representative of 3 experiments.
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3.2.3 Histological evidence that prophylactic intraperitoneal Pam3CSK4 
treatment attenuates airways inflammation
Histology demonstrated that mice that had received i.p. Pam3CSK4 therapy prior to 
their i.n. OVA challenges had reduced peri-bronchial and peri-vascular inflammation 
(Fig. 3.4). The degree of airways inflammation seen in TLR2 agonist-treated mice 
appeared to be equivalent to the minimal amount of inflammation associated with 
PBS control mice lungs.
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PBS
OVA Pam3CSK4
Figure 3.4 Histological evidence that airways inflammation is decreased after 
prophylactic i.p. Pam3CSK4 therapy.
H&E sections of lungs (x20 magnification) demonstrate that airways inflammation 
was ameliorated by Pam3CSK4 therapy. Pam3CSK4-treated mice demonstrated 
reduced peri-vascular and peri-bronchial inflammation. Lungs were collected on day 
28 and are representative o f 5 mice per group.
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3.3 Intranasal (i.n.) TLR2 agonist exacerbates allergic airways inflammation 
in a murine model of asthma
Having found that prophylactic i.p. TLR2 agonists attenuated the development of 
allergic airways inflammation, further investigations were performed to examine if 
TLR2 agonists administered by another route could affect allergic inflammation. 
BALB/c mice were sensitised and challenged with OVA, as outlined in Figure 3.5. 
One dose of intranasal (i.n.) Pam3CSK4 or PGN was given at the same time as the 
allergen challenges. Thus i.n. TLR2 agonist was administered on one occassion on 
day 25, 26 or 26. The mice still received all three i.n. OVA challenges. The dose of 
i.n. TLR2 agonist administered was either 25, 50 or 100 pg per mouse. OVA control 
mice were challenged with i.n. OVA alone and PBS control mice were sensitised and 
challenged with OVA. Initial experiments showed that all doses o f i.n. TLR2 agonist 
had a similar detrimental effect on airways inflammation. However, TLR2 agonist 
administration in a dose greater than 25 pg resulted in an unacceptably high mortality 
rate, which appeared to be representative of excessive airways disease, which was 
seen in lungs of the surviving mice treated with higher dose TLR agonists. Hence, 25 
pg was selected for all subsequent experiments.
The data for i.n. Pam3CSK4 and PGN effect on murine asthma are very similar. 
Hence, to avoid duplication the data for Pam3CSK4 are discussed below and any 
differences seen between Pam3CSK4 and PGN are highlighted.
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day 0 day 14
100 pg OVA (ip) 100 pg OVA (ip) 10 pg OVA (in)
2 mg ALUM 2 mg ALUM (ip)
100 pg OVA (ip)
Figure 3.5 Experimental protocol to investigate the effect of intranasal TLR2 
agonist on allergic airways disease.
BALB/c mice were injected i.p. with 100 pg OVA and 100 pi 2 % Alum on day 0 and 
14. The mice were boosted i.n. with 100 pg OVA on day 14. All the mice were then 
challenged i.n. on 3 consecutive days beginning on day 25. Pam3CSK4 or PGN (25- 
100 pg per mouse) was administered i.n. at the same time as the OVA challenges. 
Serum, BAL and lymphoid cells were collected and lung histology studied on day 28
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3.3.1 Intranasal Pam3CSK4 administration increases bronchoalveolar total 
cellularity and eosinophilia
Intranasal Pam3CSK4 administration resulted in a marked increase in total BAL 
cellularity and eosinophil numbers, as compared to untreated OVA sensitised and 
challenged mice (Fig. 3.6). It was noted that mice treated with i.n. PGN displayed the 
same increase in total BAL cell number and eosinophilia, however the proportion of 
BAL neutrophilia also increased, as compared to i.n. Pam3CSK4 treatment. It was 
also noted that higher doses of i.n. PGN resulted in bloody BAL, and macroscopic 
evidence of pulmonary haemorrhage. BAL cytokines were not detected.
3.3.2 Intranasal Pam3CSK4 treatment enhances OVA-induced cytokine 
responses by thoracic lymph node cells in vitro
Pam3CSK4 administration did not affect the T cell proliferation against OVA in vitro 
(data not shown). However, the lymphoid cells from i.n. Pam3CSK4-treated OVA 
sensitised/challenged mice produced significantly more IFNy, IL-4 and IL-5 
compared to untreated OVA-sensitised/challenged mice (Fig. 3.7). Con A-induced 
responses from thoracic cell node cells from mice treated with Pam3CSK4 showed a 
similar cytokine profile to that of OVA stimulation. Culture of LN cells with medium 
alone resulted in no cytokines being detected.
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Figure 3.6 Total bronchoalveolar cell count and eosinophil proportion are 
increased after intranasal (i.n.) Pam3CSK4 administration.
BAL total cell concentration and eosinophil proportion were enhanced after i.n. 
Pam3CSK4 administration. The increase in BAL indices was statistically not 
significant as compared to mice given OVA alone. Data shown are for mice given i.n. 
Pam3CSK4 on day 25 alone, however they are also representative of mice treated 
with Pam3CSK4 on day 26 or day 27. Data are mean +/- SEM, n=5 and are 
representative of 3 experiments.
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Figure 3.7 OVA-induced IFNy, IL-4, and IL-5 in vitro production were 
enhanced after i.n. Pam3CSK4 administration.
Thoracic lymph node cells were harvested on day 28 and cultured with 1 mg/ml OVA 
in vitro (as described in Materials and Methods, Section 2.6.6, p97). Culture 
supernatant was collected at 96 h and cytokine concentrations assayed by ELISA. 
IFNy, IL-4, and IL-5 production was significantly increased (**p<0.01 compared with 
mice given OVA alone). Data shown are for mice given i.n. Pam3CSK4 on day 25 
alone, however are also representative of mice treated with Pam3CSK4 on day 26 or 
day 27. Data are mean +/- SEM, n=5 and are representative of 3 experiments.
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3.3.1 Histological evidence that intranasal Pam3CSK4 administration worsens 
airways inflammation
Histological analysis showed that mice treated with TLR2 agonist had increased peri­
bronchial and peri-vascular inflammation (Fig 3.8). In addition, it was noted that 
peptidoglycan administration resulted in worsened inflammatory infiltrates, with 
intra-pulmonary haemorrhages being evident.
OVA
PamCSK4
Figure 3.8 Histological changes demonstrate that i.n. Pam3CSK4 
administration worsened airways inflammation.
H&E sections of lungs (x20 magnification) demonstrate that peri-bronchial and peri­
vascular inflammation was enhanced by i.n. Pam3CSK4 therapy. Lungs were 
collected on day 28. Histology shown are for mice given i.n. Pam3CSK4 on day 25 
alone, however are representative o f mice treated with Pam3CSK4 on day 26 or day 
27. Sections are representative of 5 mice per group.
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3.4 Intraperitoneal Pam3CSK4 therapy reverses established OVA-induced 
airways inflammation
Having found that prophylactic i.p. TLR2 agonist administration resulted in 
amelioration of murine allergic airways inflammation, the next aim was to establish 
whether i.p. Pam3CSK4 therapy could reverse inflammation that was already 
established? To investigate the potential of TLR2 agonist in reversing inflammation in 
allergic asthma, BALB/c mice were primed and boosted with OVA (as described in 
Materials and Methods, Section 2.6.1 p92). All the mice were challenged i.n. on 3 
consecutive days beginning on day 25. Pam3CSK4 (100 pg per mouse) was 
administered i.p only once on either day 25, 26 or 27. Pam3CSK4 was given 2 h after 
challenge (Fig. 3.9). Thus, mice treated with Pam3CSK4 on day 27 alone would have 
been challenged on the previous 3 days with OVA. In these sets of experiments, PGN 
was not used.
3.4.1 Intraperitoneal Pam3CSK4 treatment reduces BAL total cell count, and 
eosinophilia in established airways inflammation
Pam3CSK4 treatment produced a significant reduction in the BAL total cell count and 
eosinophilia (Fig. 3.10). This decrease in BAL cellularity was observed on all of the 
days that BLP was administered. Even mice that had received all three i.n. OVA 
challenges showed a decrease in their BAL indices, when BLP was administered 2 
hours after their last i.n. allergen dose (see day 27 data). BAL cytokines were not 
detected.
131
BALB/c
mice
day 0 
100 pg OVA (ip) 
2 mg ALUM
day 14 
100 pg OVA (ip) 
2 mg ALUM (ip) 
100 pg OVA (ip)
Pam 3C SK 4 (i.p.)
dav 25.26.27 
10 pg OVA (in)
BAL
LN
Serum
Histology
Penh
Figure 3.9 Experimental protocol to examine the role of intraperitoneal 
Pam3CSK4 in established allergic airways disease.
BALB/c mice were injected i.p. with 100 pg OVA and 100 pi 2 % Alum on day 0 and 
14. The mice were boosted i.n. with 100 pg OVA on day 14. All the mice were then 
challenged i.n. on 3 consecutive days beginning on day 25. Pam3CSK4 (100 pg per 
mouse) was administered i.p only once on either day 25, 26 or 27. Pam3CSK4 was 
given 2 h after challenge. Penh was determined on day 28 and mice were sacrificed 
on day 29. Serum, BAL and lymphoid cells were collected and lung histology 
studied.
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Figure 3.10 BAL total cell concentration and eosinophil proportion fell 
markedly after Pam3CSK4 therapy.
BALB/c mice were challenged i.n. on 3 consecutive days beginning on day 25. 
Pam3CSK4 (100 pg per mouse) was administered i.p only once on either day 25, 26 
or 27, 2 h after i.n. challenge. Mice given Pam3CSK4 after i.n. challenge 
demonstrated a highly significant fall in their BAL indices (**p<0.01 compared with 
mice given OVA alone). Data are mean +/- SEM of individual mice, n= 8 and are 
representative of 3 experiments.
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3.4.2 The effect of intraperitoneal Pam3CSK4 treatment on OVA-induced 
thoracic lymph node responses in vitro
Thoracic lymph node cells were harvested from the Pam3CSK4-treated and untreated 
control mice and cultured with OVA in vitro. Pam3CSK4 did not affect the T cell 
proliferation against OVA in vitro. However, the lymphoid cells from Pam3CSK4- 
treated OVA sensitised/challenged mice produced significantly more IFNy compared 
to untreated OVA-sensitised/challenged mice (Fig. 3.11). Pam3CSK4 treatment led to 
a marked reduction in IL-4 and IL-5 synthesis by the lymphoid cells from OVA- 
sensitised/challenged mice (Fig 3.12). In addition, the lymphoid cells from 
Pam3CSK4-treated OVA sensitised/challenged mice produced significantly more IL- 
10 compared to untreated OVA-sensitised/challenged mice (Fig. 3.13), however as 
expected IL-12 production was not altered after Pam3CSK4 treatment. Con A- 
induced proliferative and cytokine responses from thoracic cell node cells from mice 
treated with Pam3CSK4 were similar to that of OVA stimulation. Culture of LN cells 
with medium alone resulted in no cytokines being detected.
3.4.3 Serum IL-12 levels are increased in mice with established inflammation 
receiving Pam3CSK4 treatment
To further investigate whether the enhanced IFNy production by LN cells was due to 
IL-12 induction by Pam3CSK4 in vivo, serum IL-12 levels were measured. After 
Pam3CSK4 administration the level of serum IL-12 was greatly increased (Fig. 3.14), 
as compared to mice receiving i.p. PBS alone. This elevated IL-12 level peaked at 2 h
134
after Pam3CSK4 therapy and steadily declined until it was not detectable at 24 h (data 
not shown). Serum levels of IFNy, IL-4 and IL-5 were not detected.
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Figure 3.11 OVA-induced proliferation and IFNy production in vitro by 
thoracic lymph node cells taken from mice with established airways 
inflammation and given i.p. Pam3CSK4.
Lymph node cells were harvested on day 29 and cultured with 1 mg/ml OVA in vitro 
(as described in Materials and Methods, Section 2.6.6, p97). Cellular proliferation was 
determined after 8 hours culture with [ H] thymidine. Culture supernatant was 
collected at 96 h and cytokine concentrations assayed by ELISA. Cells from OVA- 
sensitised/challenged mice treated with Pam3CSK4 did not show any change in their 
proliferative response, however IFNy production was signicantly increased (*p<0.05, 
and **p<0.01 compared with mice given OVA alone). Data are mean +/- SEM, n=8 
and are representative o f 3 experiments
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Figure 3.12 In vitro OVA-induced IL-4 and IL-5 production by thoracic lymph 
node cells taken from mice with established airways inflammation that had been 
given i.p. Pam3CSK4 is reduced.
Lymph node cells were harvested on day 29 and cultured with 1 mg/ml OVA in vitro 
(as described in Materials and Methods, Section 2.6.6, p97). Culture supernatant was 
collected at 96 h and cytokine concentrations assayed by ELISA. Cells from mice 
treated with Pam3CSK4 showed a significant reduction in their IL-4 and IL-5 
production (**p<0.01 compared with mice given OVA alone). Data are mean +/- 
SEM, n=8 and are representative of 3 experiments
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Figure 3.13 In vitro OVA-induced IL-10 and IL-12 production in vitro by 
thoracic lymph node cells taken from mice with established airways 
inflammation and given i.p. Pam3CSK4.
Lymph node cells were harvested on day 29 and cultured with 1 mg/ml OVA in vitro 
(as described in Materials and Methods, Section 2.6.6, p97). Culture supernatant was 
collected at 96 h and cytokine concentrations assayed by ELISA. Cells from OVA- 
sensitised/challenged mice treated with Pam3CSK4 did not show any change in their 
IL-12 response, however IL-10 production was markedly increased (**p<0.01 
compared with mice given OVA alone). Data are mean +/- SEM, n=8 and are 
representative of 3 experiments.
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Figure 3.14 Serum total IgE is reduced after i.p. Pam3CSK4 therapy, however 
serum IL-12 levels are elevated.
Sera for IL-12 estimation were collected 2 h after Pam3CSK4 treatment on day 27. 
Pam3CSK4 treatment led to highly enhanced IL-12 synthesis (up to 15 ng/ml). Sera 
collected on day 29 showed a marked reduction in total IgE (**p<0.01 compared with 
mice given OVA alone). OVA-specific IgE showed a similar reduction after 
Pam3CSK4 treatment (data not shown). Data are mean +/- SEM of individual mice, 
n= 8 and are representative of 3 experiments.
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3.4.4 Serum immunoglobulin levels from mice with established inflammation 
receiving Pam3CSK4 treatment
Serum obtained from OVA-sensitised/challenged mice after Pam3CSK4 treatment 
showed a marked reduction in the concentration of total IgE antibody (Fig 3.14). 
OVA-specific IgE also demonstrated a similar after Pam3CSK4 therapy (data not 
shown). Serum IgGl levels were not affected by Pam3CSK4 therapy. The levels of 
serum IgG2a were low and again not significantly affected by i.p. Pam3CSK4 
treatment (Fig. 3.15).
3.4.5 Histological evidence that Pam3CSK4 therapy can reverse established 
airways inflammation
Histological analysis demonstrated a reduction in the inflammatory infiltrates seen in 
the peri-bronchial and peri-vascular areas of the murine lungs treated with Pam3CSK4 
(Fig. 3.16). This decrease in airway inflammation was observed on all of the days that 
Pam3CSK4 was administered. Even mice that had received all three i.n. OVA 
challenges showed a profound decrease in their airways inflammation, when 
Pam3CSK4 was administered 2 hours after their last i.n. allergen dose (see day 27 
data, Fig. 3.16).
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Figure 3.15 Serum OVA-specific IgG l and IgG2a levels are not affected by 
Pam3CSK4 therapy.
Sera collected on day 29 showed little difference in their IgGl and IgG2a levels. Data 
are mean +/- SEM of individual mice, n= 8 and are representative o f 3 experiments.
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Figure 3.16 Histological evidence that Pam3CSK4 therapy ameliorated 
established airways inflammation.
H&E sections o f lungs (x20 magnification) demonstrate that airways inflammation is 
reduced in mice treated with i.p. Pam3CSK4 between days 25 and 27 (panels C-E), 
compared with the inflammation seen in OVA-sensitized and -challenged mice (panel 
B). Pictures are representative o f 8 mice per group.
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3.4.6 Pam3CSK4 therapy reduces airways hyperresponsiveness to 
methacholine in mice with established airways inflammation
Whole Body Plethysmography is a technique that has been used to monitor lower 
airways resistance in unrestrained conscious mice. Enhanced Pause (Penh) was used 
as physiological measure of airways hyperresponsiveness. Penh was measured after 
nebulisation for 2 minute with methacholine on day 28. Mice were challenged with 0, 
12.5, 25, and 50 mg of nebulised methacholine (as described in Materials and 
Methods, Section 2.6.2, p93). Mice that had received Pam3CSK4 treatment showed a 
significant reduction in the airway hyperresponsiveness, as compared to untreated 
OVA-sensitised and -challenged mice (Fig. 3.17).
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Figure 3.17 Pam3CSK4 therapy reduced Penh values in mice with established 
allergic airways inflammation.
Enhanced Pause (Penh), after a 2 min nebulisation with 50 mg/ml methacholine was 
performed on day 28. Mice treated with Pam3CSK4 showed a significant reduction in 
their Penh measurement (*p<0.05 compared with mice given OVA alone). Data are 
mean +/- SEM, n=8 and are representative of 3 experiments.
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3.5 C hapter Discussion
The main findings from the work in this chapter are that:
i) Intraperitoneal Pam3CSK4 or PGN administration immediately prior to 
the i.n. OVA challenges significantly reduces airways inflammation.
ii) Intranasal Pam3CSK4 or PGN given simultaneously with the i.n. OVA 
challenges exacerbates murine asthma, with PGN administration being 
associated with worsened airways inflammation
iii) Intraperitoneal Pam3CSK4 administration after the i.n. OVA challenges 
ameliorates established allergic airways inflammation.
The results of these investigations demonstrate an impressive therapeutic role of 
intraperitoneal Pam3CSK4 in murine asthma. The beneficial effect was immediate 
and sustained, with the effect of i.p. Pam3CSK4 being sustained for at least 5 days 
after treatment (data not shown). The amelioration of allergic airways disease seen 
with i.p. TLR2 agonist treatment was evident in developing and, more importantly, 
established experimental asthma.
Interestingly, i.n. TLR2 agonist administration worsened the allergic phenotype of 
mice in this model. It was felt that i.n. TLR2 agonists may be having a local effect on 
inflammatory cells such as macrophages, neutrophils, mast, and NK cells, whereas i.p. 
TLR2 agonists was having a more systemic effect. Certainly, other investigators have 
found that 15-150 pg i.n. PGN itself can actually induce acute lung injury in mice. 
Peptidoglycan enhanced BAL neutrophilia, and increased the production of pro- 
inflammatory cytokines TNFa, IL-6 and M IP-la from inflammatory cells in the lung
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(372). Work with human mast cells found that TLR2 agonists caused degranulation of 
mast cells which results in a local inflammatory response. Furthermore, it was 
demonstrated that PGN and yeast zymosan (working through TLR 2/6 heterodimer) 
caused greater mast cell degranulation with greater release of inflammatory mediators 
than Pam3CSK4 (working through TLR 2/1 heterodimer) (373). In our studies, we 
observed that i.n. PGN caused a greater degree o f airways inflammation, with a 
greater degree o f BAL neutrophilia, than i.n. Pam3CSK4. It may be that when TLR2 
agonists are given i.n., there is activation and degranulation of airways inflammatory 
cells, such as mast cells, neutrophils and eosinophils, which leads to greater allergic 
airways inflammation. Furthermore, the observation of increased airways 
inflammation seen with i.n. PGN as compared to Pam3CSK4 could be explained by 
worsened local mast cell degranulation through TLR 2/6 signalling. Further studies 
are needed to examine the mechanism(s) o f i.n. TLR2 agonist’s aggravation of 
allergic airways inflammation, and possibly also look at effects of TLR2 
administration by different routes in experimental models o f asthma.
Systemic administration of TLR2 agonists by i.p. route significantly attenuates 
allergic airways inflammation. It was interesting to note that although the serum IgG 
levels remained unchanged, there was a rapid decrease in both the serum OVA- 
specific and total IgE levels. This has also been reported by other investigators (11). 
The mechanism of this rapid IgE reduction is unclear. However, it should be noted 
that the half life of rodent serum IgE can be as short as 12 h (374, 375). The half life 
of rodent IgG is around 4-5 days (376, 377). Despite this, the IgG profile 5 days after 
the last i.n. challenge showed that TLR2 agonists still had little effect on IgG levels.
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Our data demonstrating different outcomes depending on the timing and route of 
administration of agonist is supported by previous studies looking at TLR2 agonists 
and experimental asthma. These papers have produced apparently contradictory 
results. When administered during the sensitisation period (14-21 days prior to i.n. 
OVA challenge), early TLR2 agonist treatment was reported to worsen a Th2- 
mediated asthma (149, 367). In contrast, TLR2 activation immediately prior to the 
intranasal challenge was found to reduce allergic airways inflammation (368, 369). 
Recently, Velasco et al (369) have demonstrated that early administration of PGN (21 
days prior to intratracheal OVA challenge) can also reduce airways inflammation. 
Having observed, in our own studies, that the route of administration is critical to the 
TLR2 agonist effect on airways disease, it is may be that these divergent results are a 
consequence of different routes of administration. However, reviewing the studies 
reveals administration of TLR2 agonist directly into the lungs, by either an intranasal 
or intratracheal route, can both exacerbates and ameliorates airways inflammation 
(367, 369). The action of TLR2 agonists in different murine models of asthma is 
complex and unresolved. The next chapter presents data on potential mechanisms 
involved, and further discussions are made regarding the possible reasons for the 
disparate observations made in Chapters 4 and 6.
Our observation that TLR2 agonist treatment results in a reduced OVA-induced Th2 
cytokine response, with enhanced Thl cytokine production by draining lymph nodes 
suggests that TLR2 agonists are modulating the asthma phenotype by skewing the 
Th2-mediated immune response to a Thl response. As previously discussed, there is 
evidence that Thl lymphocytes are protective in asthma by skewing the immune 
response towards a Thl profile (33). However, in adoptive murine transfer models of
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asthma, Thl cells can actually enhance airways disease once it has been established 
(39-41) It has also been shown that IFNy and Tbet-1 are critical for the attenuation of 
airways eosinophilia in murine models of asthma (35, 36). Hence, there is some 
debate as to the contribution of Thl cells in the pathogenesis of asthma. In our work, 
it was noted that the serum IL-12 levels were significantly increased shortly after 
Pam3CSK4 treatment, which gives further support to the idea that, in our model, 
TLR2 agonists are influencing the Thl/Th2 balance in allergic airways disease.
The enhancing effect o f Pam3CSK4 on IL-10 production also raised the possibility 
that regulatory T cells may play a role in the beneficial outcome of Pam3CSK4 
treatment. Many investigators have observed that regulatory T cells’ (CD4+CD25+, 
Trl and Th3) function is dependent on IL-10 and TGFp in vivo (204, 242, 299, 306). 
It is also known that Tregs express TLRs, and their suppressive function can be 
enhanced by TLR activation (186, 378).
Hence, our observations of the therapeutic effect of i.p. TLR2 agonist in experimental 
asthma may be attributed to enhanced Treg function, or to a skewing of the immune 
response towards a Thl response. The next chapter will further examine the possible 
mechanisms involved in the therapeutic effect of i.p. Pam3CSK4.
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Chapter 4
The mechanisms involved in Pam3CSK4 modulation of inflammation 
in a murine model of allergic airways disease
Data in this chapter has been published in 
Patel et al (2005), JImmunol; 174(12):7558-7563.
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4.1 Introduction
In Chapter 3, we reported that the synthetic TLR2 agonist Pam3CSK4 profoundly 
attenuated allergic airways inflammation in OVA-specific asthma in mice, when 
administered intraperitoneally. This chapter investigates the immunological 
mechanisms involved in i.p. Pam3CSK4 treatment.
Based on our observations of increased IL-10 production by OVA-stimulated LN 
cultures seen in Pam3CSK4-treated mice, we proposed that regulatory T cells (Tregs) 
were one of the cell types important in the beneficial outcome of Pam3CSK4 
treatment. IL-10 and TGFp have been implicated in the effector mechanism of several 
subclasses of regulatory T cells in vivo (204, 242, 299, 306). As such one of the 
primary aims of this chapter is to further examine the role o f IL-10 and TGFp in 
Pam3CSK4 therapy, and to provide evidence as to whether Tregs are important in 
Pam3CSK4 therapy.
Based on our observations of increased serum levels of IL-12, and the enhanced IFNy 
and reduced IL-4 and IL-5 production by OVA-stimulated LN cultures observed in 
Pam3CSK4-treated mice, we propose that a skewing of the Th2 to a Thl response 
contributes to TLR2 agonist treatment. We postulate that Pam3CSK4 may induce IL- 
12 production from APCs (mainly DCs) which can in turn enhance the development 
of Thl cells. The secondary aims of this chapter are to determine if IL-12 and IFNy 
are required for TLR2 agonist therapy in allergic airways disease; and if they are, to 
try and identify the cellular source of these cytokines.
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The data presented below demonstrate that the therapeutic effect of Pam3CSK4 is 
critically dependent on IL-12 and IFNy, but not on IL-10 or TGFp. Our results further 
demonstrate that Pam3CSK4 is capable of inducing DCs to produce IL-12, which in 
turn enhances the development of Thl cells and production of IFNy. This provides 
evidence that Pam3CSK4 therapeutic effect in allergic airways disease is through Thl 
skewing, and is unlikely to involve regulatory T cells.
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4.2 The effect of intraperitoneal Pam3CSK4 therapy on peritoneal 
inflammation
The anti-inflammatory effects of Pam3CSK4, described in the previous chapter, 
demonstrated that TLR2 agonist therapy was dependent on the route of 
administration. Pam3CSK4 therapy profoundly attenuated Th2-mediated 
inflammation when given i.p., whereas i.n. TLR2 agonist administration exacerbated 
the allergic phenotype. Hence, we felt it important to ensure that i.p. Pam3CSK4 
therapy was not a result o f sequestration of inflammatory cells from the lungs into the 
peritoneal cavity.
To investigate this, the murine model of allergic airways inflammation was used as 
described in Fig. 4.1. Mice were sensitised with OVA, and then all the mice were 
challenged i.n. on 3 consecutive days beginning on day 25. Pam3CSK4 (100 pg per 
mouse) or PBS was administered i.p only once on day 25, 2 h after i.n. challenge. 
Mice were sacrificed on day 28, and peritoneal lavage was performed with 5 mis of 
ice cold PBS (as described in Materials and Methods section 2.7, p99). Similar results 
were obtained for mice receiving Pam3CSK4 therapy on day 26 and 27.
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Figure 4.1 Experimental protocol to investigate if i.p. Pam3CSK4 therapy 
sequesters inflammatory cells into the peritoneal cavity.
BALB/c mice were injected i.p. with 100 pg OVA and 100 pi 2 % Alum on day 0 and 
14. The mice were boosted i.n. with 100 pg OVA on day 14. All the mice were then 
challenged i.n. on 3 consecutive days beginning on day 25. Pam3CSK4 (100 pg per 
mouse) or PBS was administered i.p only once on day 25, 2 h after i.n. challenge. 
Mice were sacrificed on day 28, and peritoneal lavage was performed with 5 mis of 
ice cold PBS (as described in Materials and Methods section 2.7, p99).
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4.2.1 Intraperitoneal Pam3CSK4 therapy did not sequester inflammatory cells 
into the peritoneal cavity.
Pam3CSK4 treatment of mice significantly reduced the eosinophil numbers in the 
peritoneal cavity. The number of peritoneal macrophages, neutrophils and 
lymphocytes were not significantly altered after Pam3CSK4 treatment (Fig. 4.2). The 
total number of inflammatory cells in the peritoneum was not affected (Pam3CSK4- 
treated mice total peritoneal cell count 10.75 +/- 2.2 x 105 vs PBS-treated mice total 
peritoneal count 7.05 +/- 5.7 x 105, p=0.38. Data are mean +/- SEM, n=6).
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Figure 4.2 Intraperitoneal Pam3CSK4 therapy is not due to sequestration of 
inflammatory cells into the peritoneal cavity.
Mice were sensitised with OVA, and then all the mice were challenged i.n. on 3 
consecutive days beginning on day 25. Pam3CSK4 (100 pg per mouse) or PBS was 
administered i.p only once on day 25, 2 h after i.n. challenge. Mice were sacrificed on 
day 28, and peritoneal lavage was performed with 3 mis of ice cold PBS. Pam3CSK4 
treatment of mice significantly reduced the eosinophil numbers in the peritoneal 
cavities (*p<0.05 as compared to PBS vehicle control). The number of macrophages, 
lymphocytes, neutrophils was not significantly different. The total numbers of 
inflammatory cells in the peritoneum were not affected. Data are mean +/- SEM, n=6.
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4.3 Pam3CSK4 therapy is not dependent on IL-10
To investigate whether IL-10 is important in Pam3CSK4 therapy, mice were 
sensitised and challenged with OVA using the standard protocol. The animals were 
injected i.p with a blocking anti-mouse IL-10 receptor (R) antibody or control normal 
IgG, 2 h before the i.n. OVA challenge of day 27. Pam3CSK4 therapy was 
administered 2 h after the last i.n. challenge on day 27 (Fig. 4.3). This antibody and 
the amounts administered are routinely found to be effective in abrogating 
CD4+CD25+ regulatory T cells in this laboratory (242).
4.3.1 Anti-IL-IOR antibody does not reverse the therapeutic effect of 
Pam3CSK4 on BAL indices
The total BAL cellularity, eosinophil proportion, and absolute eosinophil numbers 
were consistently reduced in OVA-sensitised and -challenged mice after Pam3CSK4 
therapy. Administration of anti-IL-lOR antibody did not affect the beneficial effect of 
Pam3CSK4 therapy (Fig. 4.4). BAL cytokines were not detected.
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Figure 4.3 Experimental protocol to examine the role of IL-10, TGFp, and IL- 
12 in Pam3CSK4 therapy of established airways inflammation.
Mice were sensitized and challenged as described in Fig. 3.1. Some mice were 
injected i.p. with 1 mg of anti-IL-lOR antibody, anti-TGFp antibody, anti-IL-12 
antibody, or isotype-matched normal control IgG as indicated. The antibodies were 
given 2 h before the last i.n. OVA challenge on day 27. Pam3CSK4 (100 pg/mouse) 
was injected i.p. 2 h after the day 27 i.n. challenge. Penh was determined on day 28 
and mice were sacrificed on day 29. Serum, BAL and lymphoid cells were collected 
and lung histology studied.
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Figure 4.4 The therapeutic benefit of Pam3CSK4 on BAL indices was not 
affected by anti-IL-lOR antibody administration.
Mice were sensitised and challenged with OVA and injected i.p with anti-mouse IL- 
10R antibody or control normal IgG, 2 h before the i.n. OVA challenge of day 27. 
Pam3CSK4 therapy was administered 2 h after the last i.n. challenge on day 27. All 
mice that received Pam3CSK4 therapy demonstrated a highly significant fall in their 
BAL indices (**p<0.01 compared with mice given OVA alone). Administration of 
anti-IL-lOR antibody did not affect total BAL cell count or eosinophil numbers. Data 
are mean +/- SEM, n=8.
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4.3.2 The effect of anti-IL-lOR antibody on Pam3CSK4 therapy of OVA- 
induced thoracic lymph node responses and enhanced pause
Thoracic lymph node cells were harvested from the Pam3CSK4-treated and untreated 
control mice and cultured with OVA in vitro. Pam3CSK4 did not affect the T cell 
proliferation against OVA in vitro from LN cells from mice treated with anti-IL-lOR 
or control IgG. Anti-IL-lOR antibody did not affect the cytokine production from 
thoracic lymph node cells from mice treated with Pam3CSK4 and stimulated in vitro 
with OVA. The IFNy production was still enhanced, with attenuation of IL-4 and IL-5 
(Fig. 4.5). However, the reversal of airway hyperresponsiveness measured by Penh, 
which was associated with Pam3CSK4 therapy, was reversed with anti-IL-lOR 
administration (Fig. 4.5).
4.3.3 Anti-IL-lOR antibody does not reverse histological improvement in 
inflammation seen with Pam3CSK4 therapy
Pam3CSK4 treatment of mice resulted in an attenuation of the histological evidence 
o f airways inflammation, as compared to untreated mice. Anti-IL-lOR antibody 
administration did not alter the reduction in inflammatory cell infiltrate, peri-bronchial 
inflammation, or peri-vascular inflammation demonstrated in the lungs after 
Pam3CSK4 therapy (Fig. 4.6).
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Figure 4.5 The effect of anti-IL-lOR antibody on the OVA-induced IL-4
responses in thoracic lymph node cells in vitro, and Penh values from mice 
treated with Pam3CSK4.
Mice were sensitised and challenged with OVA and injected i.p with anti-mouse IL- 
10R antibody or control normal IgG, 2 h before the i.n. OVA challenge of day 27. 
Pam3CSK4 therapy was administered 2 h after the last i.n. challenge on day 27. Mice 
that received Pam3CSK4 therapy had a significant reduction in IL-4 production by 
draining thoracic lymph node (LN) cells (**p<0.01 compared with mice given OVA 
alone). Administration of anti-IL-lOR antibody did not affect the reduction of IL-4 
production by thoracic lymph node cells treated with Pam3CSK4 therapy (all mice 
that received Pam3CSK4 had a significant reduction, **p<0.01 compared with mice 
given OVA alone). However, anti-IL-lOR antibody did reverse the beneficial effects 
in Penh values seen after Pam3CSK4 therapy. Data are mean +/- SEM, n=8.
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Figure 4.6 Anti-IL-lOR antibody did not affect the histological evidence of 
reduced airways inflammation induced by Pam3CSK4.
Mice were sensitised and challenged with OVA and injected i.p with anti-mouse IL- 
10R antibody or control normal IgG, 2 h before the i.n. OVA challenge of day 27. 
Pam3CSK4 therapy was administered 2 h after the last i.n. challenge on day 27. 
Histology showed that administration of anti-IL-lOR antibody did not affect the 
attenuation o f airways inflammation seen after Pam3CSK4 therapy. H&E sections at 
x20 magnification. Data are representative of 8 mice per group.
161
4.4 Pam3CSK4 therapy is not dependent on TGFp
To investigate the possibility that TGFp is important in Pam3CSK4 therapy, mice 
were sensitised and challenged with OVA using the standard protocol. The animals 
were injected i.p with blocking anti-mouse TGFp antibody or control normal IgG, 2 h 
before i.n. OVA challenge of day 27. Pam3CSK4 therapy (day 27) was administered 
2 h after the last i.n. challenge (Fig. 4.3). This antibody and the amounts administered 
are also routinely found to be effective in abrogating CD4+CD25+ regulatory T cells 
in this laboratory (242).
4.4.1 Anti-TGFp antibody does not reverse the therapeutic effect of Pam3CSK4 
on BAL indices
The total BAL cellularity, and eosinophil proportion and number were consistently 
reduced after Pam3CSK4 therapy. Administration of anti-TGFp antibody did not alter 
this effect of Pam3CSK4 therapy (Fig. 4.7). BAL cytokines were not detected.
4.4.2 The effect of TGFp antibody on Pam3CSK4 therapy of OVA-induced 
thoracic lymph node responses and enhanced pause
Thoracic lymph node cells were harvested from the Pam3CSK4-treated and untreated 
control mice and cultured with OVA in vitro. Pam3CSK4 did not affect the T cell 
proliferation against OVA in vitro, from LN cells from mice treated with anti-TGFp
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or control IgG. Anti-TGFp antibody did not affect the cytokine production from 
thoracic lymph node cells from mice treated with Pam3CSK4 and stimulated in vitro 
with OVA. The IFNy production was still enhanced, with attenuation of IL-4 and IL-5 
(Fig. 4.8). However, the reversal of airway hyperresponsiveness measured by Penh 
which was associated with Pam3CSK4 therapy was reversed with anti-TGFp Ab 
administration (Fig. 4.8).
4.4.3 Anti-TGFp antibody does not reverse histological evidence of anti­
inflammatory action of Pam3CSK4 therapy
Pam3CSK4 treatment of mice resulted in an attenuation of the histological evidence 
o f airways inflammation, as compared to untreated mice. Anti-TGFp antibody 
administration did not alter the reduction in inflammatory cell infiltrate demonstrated 
in the lungs after Pam3CSK4 therapy (Fig. 4.9).
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Figure 4.7 The therapeutic benefit of Pam3CSK4 on BAL indices was not 
affected by anti-TGFp antibody administration.
Mice were sensitised and challenged with OVA and injected i.p with anti-mouse 
TGFp antibody or control normal IgG, 2 h before the i.n. OVA challenge of day 27. 
Pam3CSK4 therapy was administered 2 h after the last i.n. challenge on day 27. All 
mice that received Pam3CSK4 therapy demonstrated a highly significant fall in their 
BAL indices (**p<0.01 compared with mice given OVA alone) Administration of 
anti-TGFp antibody did not affect the reduction in total BAL count or eosinophil 
numbers seen after Pam3CSK4 therapy. Data are mean +/- SEM, n=8.
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Figure 4.8 The effect of anti-TGFp antibody on OVA-induced IL-4 responses 
in thoracic lymph node cells in vitro, and Penh values from mice treated with 
Pam3CSK4.
Mice were sensitised and challenged with OVA and injected i.p with anti-mouse 
TGFp antibody or control normal IgG, 2 h before the i.n. OVA challenge of day 27. 
Pam3CSK4 therapy was administered 2 h after the last i.n. challenge on day 27. Mice 
that received Pam3CSK4 therapy had a significant reduction in IL-4 production by 
draining thoracic lymph node (LN) cells (**p<0.01 compared with mice given OVA 
alone). Administration of anti-TGFp antibody did not affect the reduction of IL-4 
production by thoracic lymph node cells treated with Pam3CSK4 therapy (all mice 
that received Pam3CSK4 had a significant reduction, **p<0.01 compared with mice 
given OVA alone). However, anti-TGFp antibody did reverse the reduction in airway 
hyperreactivity measured by Penh following Pam3CSK4 therapy. Data are mean +/-
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Figure 4.9 Anti-TGFp antibody did not affect the histological evidence of 
reduced airways inflammation induced by Pam3CSK4.
M ice were sensitised and challenged with OVA and injected i.p with anti-m ouse 
TG Fp antibody or control normal IgG, 2 h before the i.n. OVA challenge o f  day 27. 
Pam 3CSK 4 therapy was adm inistered 2 h after the last i.n. challenge on day 27. 
H istology show ed that adm inistration o f  anti-TG Fp antibody did not affect the 
attenuation o f  airways inflam m ation seen after Pam 3CSK 4 therapy. H& E sections at 
x20 m agnification. Data are representative o f  8 mice per group.
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4.5 The therapeutic effect of Pam3CSK4 is IL-12 dependent
We then investigated the role of IL-12 in the therapeutic effect of Pam3CSK4. Mice 
were sensitised and challenged with OVA, as described above, and injected i.p. with 
blocking anti-mouse IL-12 Ab or control rabbit IgG 2 h prior to the i.n. challenge of 
day 27. Pam3CSK4 was than administered 2 h after the allergen challenge on day 27 
(Fig 4.3). The function of this antibody was confirmed in vitro, and is routinely used 
in Th2 cell polarisation.
4.5.1 Anti-IL-12 antibody reverses the therapeutic effect of Pam3CSK4 on 
BAL indices
Fig. 4.10 shows that the therapeutic effect of Pam3CSK4 was completely abrogated 
by blocking IL-12. This was clearly demonstrated by the reversal of the Pam3CSK4 
beneficial effect on BAL cellularity and eosinophila, seen after anti-IL-12 antibody 
administration.
4.5.2 Anti-IL-12 antibody reverses OVA-induced lymph node responses 
induced by Pam3CSK4 therapy
Thoracic lymph node cells were taken from mice treated with Pam3CSK4, and 
stimulated in vitro. The OVA-induced LN proliferative response was not affected by 
Pam3CSK4 treatment. However, the Th2 cytokine (IL-4 and IL-5) production was
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reduced with enhancement of the Thl cytokine (IFNy) production by LN cells taken 
from Pam3CSK4-treated mice. Administration of anti-IL12 antibody completely 
abolished these changes induced by Pam3CSK4 therapy (Fig. 4.11).
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Figure 4.10 The therapeutic benefit of Pam3CSK4 on BAL indices was 
abolished by anti-IL-12 antibody administration.
Mice were sensitised and challenged with OVA and injected i.p with anti-mouse IL- 
12 antibody or control normal IgG, 2 h before the i.n. OVA challenge of day 27. 
Pam3CSK4 therapy was administered 2 h after the last i.n. challenge on day 27. 
Administration of anti-IL-12 antibody significantly reversed the reduction in total 
BAL count or eosinophil numbers seen after Pam3CSK4 therapy (*p<0.05 compared 
with mice given control Ab). Data are mean +/- SEM, n=8.
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Figure 4.11 The effect of anti-IL-12 antibody on OVA-induced IFNy and IL-5 
responses in thoracic lymph node cells in vitro.
Mice were sensitised and challenged with OVA and injected i.p with anti-mouse IL- 
12 antibody or control normal IgG, 2 h before the i.n. OVA challenge of day 27. 
Pam3CSK4 therapy was administered 2 h after the last i.n. challenge on day 27. 
Administration of anti-IL-12 antibody significantly reversed the reduction in IL-5 
production from thoracic lymph node cells by mice given Pam3CSK4 therapy. 
Antibody administration also abrogated the enhanced production of IFNy by cells 
from Pam3CSK4-treated mice (**p<0.01 compared with mice given control Ab). 
Data are mean +/- SEM, n=8.
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4.5.3 Anti-IL-12 antibody reverses the beneficial effect of Pam3CSK4 on 
airway hyperresponsiveness
Anti-IL-12 antibody administration resulted in a significant reversal o f the 
amelioration in Penh values seen in Pam3CSK4-treated mice. Blocking IL-12 resulted 
in Pam3CSK4-treated mice continuing to have increased Penh levels, as seen in 
untreated OVA-sensitised and -challenged mice (Fig. 4.12).
4.5.4 Anti-IL-12 antibody effect on serum immunoglobulin levels of 
Pam3CSK4-treated mice
The beneficial effect of Pam3CSK4 treatment seen in serum total and OVA-specific 
IgE levels was completely abolished after anti-IL-12 antibody administration (Fig. 
4.12). Serum levels of IgGl and IgG2a were unaffected by Pam3CSK4 therapy and 
anti-IL-12 administration (data not shown).
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Figure 4.12 The effect of anti-IL-12 antibody on airway hyperresponsiveness 
measured by Penh and total serum IgE levels from mice treated with 
Pam3CSK4.
Mice were sensitised and challenged with OVA and injected i.p with anti-mouse IL- 
12 antibody or control normal IgG, 2 h before the i.n. OVA challenge o f day 27. 
Pam3CSK4 therapy was administered 2 h after the last i.n. challenge on day 27. 
Administration of anti-IL-12 antibody significantly reversed the beneficial effects on 
Penh values and total serum IgE seen in mice given Pam3CSK4 therapy (**p<0.01 
compared with mice given control Ab). Data are mean +/- SEM, n=8.
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4.5.5 Anti-IL-12 antibody administration abolishes the histological 
improvement in inflammation seen after Pam3CSK4 therapy
Histological examination of the murine lungs demonstrated that anti-IL-12 antibody 
therapy reverses the improvement in lung inflammation seen in mice after Pam3CSK4 
administration (Fig 4.13).
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Figure 4.13 Anti-IL-12 antibody abolished the histological evidence of reduced 
airways inflammation induced by Pam3CSK4.
Mice were sensitised and challenged with OVA and injected i.p with anti-mouse IL- 
12 antibody or control normal IgG, 2 h before the i n. OVA challenge o f day 27. 
Pam3CSK4 therapy was administered 2 h after the last i n. challenge on day 27. 
Histology showed that administration o f anti-IL-12 antibody completely reversed the 
reduction o f airways inflammation seen after Pam3CSK4 therapy. H&E sections at 
x20 magnification. Data are representative of 8 mice per group.
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4.5.6 Pam3CSK4 therapy has no effect on BAL indices in IL-12 deficient mice
To confirm the role o f IL-12 in this model, we sensitised and challenged IL-12 
knockout (ko) mice with OVA, and Pam3CSK4 was then administered 2 h after the 
allergen challenge on day 27. While the wild type (BALB/c) control mice showed the 
expected beneficial effect of Pam3CSK4 treatment, IL-12 ko mice did not. IL-12 ko 
mice exhibited the same degree of eosinophilia (Fig. 4.14) and total BAL cellularity 
(data not shown) as the untreated IL-12 ko or wild-type mice.
4.5.7 Pam3CSK4 therapy has no effect on OVA-induced thoracic lymph node 
cells response taken from IL-12 deficient mice
The wild type mice demonstrated that although the proliferative response to OVA in 
vitro is unaltered after Pam3CSK4 therapy, the Th2 response (IL-4 and IL-5 
production) is attenuated whilst the Thl response (IFNy production) is enhanced. In 
IL-12 ko mice there was no change in the cytokines produced by thoracic lymph 
nodes after Pam3CSK4 therapy (Fig 4.14).
175
10 1
Eosinophils IL - 4
1501
o  5-  X  I I  % 75
WT + + +
IL<12 KO - - - + +
OVA - + + + +
Pam3CSK4 - - + - +
Figure 4.14 Pam3CSK4 had no effect on the eosinophilia or IL-4 synthesis by 
the lymphoid cells of IL-12 deficient mice.
Wild-type and IL-12 ko mice (on a BALB/c background) were sensitized and 
challenged as in Fig. 3.1. Pam3CSK4 was administered i.p. on day 27, 2 h after the 
last i.n. OVA challenge. Pam3CSK4 had no effect on the eosinophilia or IL-4 
synthesis by the lymph node cells of IL-12 ko mice. IFNy was not detectable in the 
culture of cells from the IL-12 ko mice. Data are mean +/- SEM of 5 mice.
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4.5.8 Pam3CSK4 therapy has no effect on histological inflammation in IL-12 
deficient mice
Lung sections stained with H&E demonstrated that IL-12 ko mice showed little 
change in their peri-bronchial and peri-vascular inflammation after Pam3CSK4 
therapy. Wild type mice demonstrated the expected reduction in pulmonary 
inflammation after Pam3CSK4 therapy (Fig. 4.15).
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Figure 4.15 Histological evidence that Pam3CSK4 therapy did not reduce 
airways inflammation in EL-12 deficient mice.
Wild-type and IL-12 ko mice (on a BALB/c background) were sensitized and 
challenged as in Fig. 3.1. Pam3CSK4 was administered i.p. on day 27, 2 h after the 
last i n. OVA challenge. Histology examination of the lungs clearly demonstrated that 
Pam3CSK4 did not prevent inflammatory cell infiltrations in the IL-12 ko mice. Data 
are representative o f 5 mice per group.
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4.6 Pam3CSK4 therapy is Interferon y dependent
The enhanced IFNy production by draining thoracic LN cells from mice treated with 
Pam3CSK4 would suggest that TLR2 agonist therapy may induce Thl cell skewing. 
This hypothesis was further supported by our finding that Pam3CSK4 therapy was 
dependent on IL-12. To confirm the role of IFNy in this model, we sensitised and 
challenged IFNy ko mice (on a 129SV background) with OVA and treated them with 
Pam3CSK4 as above.
4.6.1 Pam3CSK4 therapy has no effect on BAL indices in IFNy deficient mice
While the 129SV wild type mice sensitised and challenged with OVA showed typical 
airway eosinophilia which was reversed by Pam3CSK4 treatment, the IFNy ko mice 
did not demonstrate this reversal. IFNy ko mice exhibited the same degree of 
eosinophilia (Fig. 4.14) and total BAL cellularity (data not shown) as the untreated 
IFNy ko or wild-type mice.
4.6.2 Pam3CSK4 therapy has no effect on OVA-induced lymph node cells 
response taken from IFNy deficient mice
The IFNy ko mice demonstrated no change in the cytokines produced by thoracic 
lymph nodes taken from mice given Pam3CSK4 therapy. This is in contrast to the 
wild type mice that demonstrated increased Thl cytokine (IFNy) production and a
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reduced Th2 response (IL-4 and IL-5 production) by LNs taken from mice given 
Pam3CSK4 therapy (Fig 4.14). IFNy was not detectable in the culture of cells from 
the IFNy ko mice.
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Figure 4.16 Pam3CSK4 had no effect on the eosinophilia or IL-4 synthesis by 
the lymphoid cells of IFNy deficient mice.
Wild-type and IFNy ko mice were sensitized and challenged as in Fig. 3.1. 
Pam3CSK4 was administered i.p. on day 27, 2 h after the last i.n. OVA challenge. 
Pam3CSK4 had no effect on the BAL eosinophilia, or on IL-4 synthesis by the 
lymphoid cells of IFNy ko mice. Data are mean +/- SEM of 6 mice.
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4.6.3 Pam3CSK4 therapy has no effect on histological inflammation in IFNy 
deficient mice
Histological examination demonstrated that IFNy ko mice showed little change in 
their peri-bronchial and peri-vascular inflammation after Pam3CSK4 therapy. Wild 
type mice demonstrated the expected reduction in pulmonary inflammation after 
Pam3CSK4 therapy (Fig.4.17).
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Figure 4.17 Histological evidence that Pam3CSK4 therapy did not reduce 
airways inflammation in IFNy deficient mice.
Wild-type and IFNy ko mice were sensitized and challenged as in Fig. 3.1. 
Pam3CSK4 was administered i.p. on day 27, 2 h after the last i.n. OVA challenge. 
Histology examination o f the lungs clearly demonstrated that Pam3CSK4 did not 
prevent inflammatory cell infiltrations in the IFNy ko mice. Data are representative o f 
6 mice per group.
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4.7 Pam3CSK4 enhances IL-12 and IFNy synthesis in vitro
We have demonstrated above that IL-12 and IFNy are critical for the ability of 
Pam3CSK4 to downregulate airways inflammation associated with reduced 
eosinophilia, IL-4, IL-5, and IgE production. To investigate the cell source and 
mechanism by which Pam3CSK4 induced IL-12 production and Thl cell 
development, we cultured bone marrow derived dendritic cells (BMDCs) and bone 
marrow derived macrophages (BMMs) with graded doses of Pam3CSK4 in vitro.
4.7.1 Pam3CSK4 induces IL-12 production from dendritic cells and 
macrophages in vitro
In response to Pam3CSK4, BMDCs produced significant levels of IL-12, and low but 
detectable levels of IL-10 (Fig. 4.18). IFNy, IL-4 and IL-5 were not detected (data not 
shown). Pam3CSK4 induced BMMs to produce IL-12 and IL-10 (Fig. 4.19), but 
IFNy, IL-4 and IL-5 were not detected (data not shown).
4.7.2 Pam3CSK4-stimulated dendritic cells and macrophages induce 
polarisation of naive CD4+T cells to Thl cells
Pam3CSK4 could enhance IL-12 production from BMDCs and BMMs and IL-10 
production from BMMs. To further investigate the effects on these TLR2 agonist- 
activated APCs on T cell differentiation, Pam3CSK4-stimulated BMDCs and BMMs
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were washed and cultured with highly purified CD4+ T cells from OVA-TcR 
transgenic mice (DO10.11), in the presence of OVA peptide and Pam3CSK4. CD4+ T 
cells cultured in the presence of Pam3CSK4-stimulated BMDCs produced significant 
amounts of IFNy, but little or no detectable IL-4 (Fig. 4.20). CD4+ T cells cultured 
with Pam3CSK4-stimulated BMMs produced a small amount of IFNy but no IL-4 
(Fig. 4.21). These results demonstrate that Pam3CSK4 is capable of inducing APCs 
(mainly DCs) to produce IL-12, which in turn enhanced the development of Thl cells 
and the production of IFNy.
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Figure 4.18 Pam3CSK4 enhanced IL-12 production by DCs in vitro.
BMDC were cultured with 10 or 100 ng/ml Pam3CSK4 for 12 h. Cytokine 
concentrations in the culture supernatant were assayed by ELISA. No cytokine was 
detected in the cultures without Pam3CSK4. In the presence of Pam3CSK4, BMDC 
produced IL-12 (*p<0.05 compared to cultures without Pam3CSK4). IL-10, IFNy, IL- 
4 and IL-5 were not detected in significant amounts. Data are mean +/- SEM, n=3 and 
are representative of 3 experiments.
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Figure 4.19 Pam3CSK4 enhanced IL-12 and IL-10 production by 
macrophages in vitro.
BMMs were cultured with 10 or 100 ng/ml Pam3CSK4 for 12 h. Cytokine 
concentrations in the culture supernatant were assayed by ELISA. No cytokine was 
detected in the cultures without Pam3CSK4. In the presence of Pam3CSK4, BMMs 
produced low levels of IL-12 and IL-10 (*p<0.05 compared to cultures without 
Pam3CSK4). IFNy, IL-4 and IL-5 were not detected. Data are mean +/- SEM, n=3 
and are representative of 3 experiments.
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Figure 4.20 Pam3CSK4-stimulated DCs enhanced IFNy synthesis by T cells in 
vitro.
CD4+ T cells were purified from DO 11.10 mice and cultured in a 5:1 ratio with 
BMDCs, in the presence of OVA peptide and Pam3CSK4 for 72 h. Cytokine 
concentrations in the culture supernatant were assayed by ELISA. Pam3CSK4 
significantly enhanced IFNy (*p<0.05 compared to cultures without Pam3CSK4) but 
not IL-4 synthesis. Data are mean +/- SEM, n=3 and are representative of 3 
experiments.
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Figure 4.21 Pam3CSK4-stimulated macrophages enhanced IFNy synthesis by 
T cells in vitro.
CD4+ T cells were purified from DO 11.10 mice and cultured in a 5:1 ratio with 
BMMs, in the presence of OVA peptide and Pam3CSK4 for 72 h. Cytokine 
concentrations in the culture supernatant were assayed by ELISA. Pam3CSK4 
significantly increased IFNy production (**p<0.01 compared to cultures without 
Pam3CSK4) but had no detectable effect on IL-4 synthesis. Data are mean +/- SEM, 
n=3 and are representative of 3 experiments.
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4.7.3 Pam3CSK4 directly enhances T h l and Th2 differentiation of CD4+ cells
Having found Pam3CSK4 could influence Thl differentiation via APCs, we were 
interested to investigate the direct effect of Pam3CSK4 on Th differentiation. CD4+ T 
cells were purified from OVA-TcR transgenic mice (DO10.11) and stimulated twice 
with OVA peptide under neutral (ThO), Thl or Th2 polarising conditions in the 
presence of Pam3CSK4 (as described in Materials and Methods, Section 2.5.3, p90). 
CD4+ cells cultured under all three conditions showed enhanced IFNy and IL-5 
production in the presence of Pam3CSK4 treatment after 1 round of polarisation (Fig. 
4.22). This enhanced Thl and Th2 cytokine production was not evident after the 2nd 
round of stimulation.
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Figure 4.22 Pam3CSK4 enhanced in vitro production of IFNy and 11-5 by CD4+ 
T cells directly.
CD4+ T cells were purified from DO 11.10 mice and cultured with OVA peptide under 
neutral (ThO), Thl or Th2 polarising conditions in the presence of 10 ng/ml 
Pam3CSK4. Cytokine concentrations in the culture supernatant were assayed by 
ELISA. Pam3CSK4 increased IFNy and IL-5 production from ThO cells (**p<0.01 
compared to cultures without Pam3CSK4). Pam3CSK4 also enhanced IFNy and IL-5 
synthesis from Thl and Th2 cells respectively (**p<0.01 compared to cultures 
without Pam3CSK4). Pam3CSK4 also increased both IFNy and IL-5 production from 
ThO cells. Data are mean +/- SEM, n=3 and are representative of 2 experiments.
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4.8 C hapter Discussion
The main findings from the work in this chapter are that:
iv) Intraperitoneal Pam3CSK4 therapy does not sequester eosinophils into the
peritoneal cavity
v) Pam3CSK4 therapy is dependent on IL-12 and IFNy in vivo
vi) Pam3CSK4 therapy is independent of IL-10 or TGFp in vivo
vii) Pam3CSK4 can induce IL-12 synthesis from APCs, which in turn can
enhance Thl differentiation of CD4+ cells in vitro
viii) Pam3CSK4 can directly enhance early Thl and Th2 differentiation of 
CD4+ cell in vitro.
The immunomodulatory effect of Pam3CSK4 therapy in allergic airways disease 
appears to be based, at least in part, on its ability to induce IL-12 synthesis by DCs. 
The heightened levels of IL-12 in turn enhance a specific Thl response and decrease 
Th2 activity. The therapeutic effect is independent of IL-10 and TGFp and, by 
extension, unlikely to involve regulatory T cells.
In an equivalent study in asthma patients, it has been shown that recombinant IL-12 
administration could reduce blood and sputum eosinophilia, but did not significantly 
change airway hyperresponsiveness (379). The reasons for these observations are 
difficult to explain. It may be that the short term administration of IL-12 was 
sufficient to attenuate acute indices of allergic inflammation, however therapy that 
alters the Thl/2 profile in a more prolonged fashion is required to alter parameters 
like airway hyperresponsiveness. It is known that IFNy or IL-12 can reverse Th2-
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mediated airways hyperresponsiveness and inflammation in murine models of allergic 
airways inflammation (380). However, once disease has been established it has also 
been reported that high levels of IFNy and IL-12 can promote Th2-induced 
eosinophilic inflammation, and that a strong Thl response (independent of Th2 
involvement) can induce airway hyperresponsiveness (381-383). This is perhaps not 
surprising since at high concentrations, IFNy is a well-recognised pro-inflammatory 
cytokine that appears to have a role in airways inflammation. In as much as Th2 
cytokines are a dominant detrimental feature in airways diseases, the key therapeutic 
approach is perhaps to achieve a balance between the Th2 and Thl cytokines, where 
there is a decrease in the Th2 cytokines without a large increase in the Thl response. 
The role of TLR2 signalling in the induction of Thl and Th2 cell development from 
naive T cells remains unresolved. TLR2 activation has been reported to lead to the 
initiation of both Thl and Th2 differentiation (149, 384, 385). It is likely that whether 
the TLR signalling predominantly activates the Thl or the Th2 pathway depends on 
the timing (relative to specific antigenic stimulation), dose and nature of TLR2 
agonists, and the genetic background of the responding hosts. In our model, although 
there is a mild increase in the Thl cytokines after TLR2 agonist therapy, the levels do 
not appear to be high enough to exacerbate airway hyperresponsiveness, or increase 
the Thl-dominant IgG2a antibody subtype. Our data is supported by recent reports 
investigating the effect of a TLR2 agonist in the sensitisation phase (369), and the 
effect of a TLR 2/4 agonist in the challenge phase (386) o f murine models of asthma 
which have shown that TLR activation could lead to a beneficial decrease in airways 
disease by down-regulating the Th2 response, with a mild non-detrimental increase in 
Thl response.
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Several contradictory reports have been made on the effect of TLR2 agonist 
administration in the sensitisation phase of airways disease induction. Investigators 
(149, 367) have shown that early TLR2 agonist administration worsens the 
development of murine asthma, whilst others (369) have demonstrated early TLR2 
agonist therapy can ameliorate allergic airways disease. One possible explanation for 
these observations is that different strains of mice were used by different 
investigators, and therefore the nature of the T-helper response that predominates in 
different strains of mouse may influence the effect of TLR2 activation. The majority 
of work to date has been performed using BALB/c mice, which have a dominant Th2 
immune system. However, administration of TLR2 agonist therapy to BALB/c mice 
has resulted in both amelioration (368, 369) and aggravation (367) of allergic airways 
disease. Furthermore, Redecke et al (149) used 129SV mice which have a dominant 
Thl immune system, and showed that Pam3CSK4 administration in the sensitisation 
phase of airways disease induction resulted in a worsening of experimental asthma. 
Interestingly, our own work utilised 129SV mice as wild type controls for the IFNy ko 
studies, and demonstrated that Pam3CSK4 administration had a therapeutic role in 
allergic airways disease in this strain of mouse. Hence, it is unlikely that strain 
differences alone will fully explain the different results reported for TLR2 agonist 
treatment in murine models o f asthma. The amount and route of administration o f 
TLR2 agonist have been proposed as alternative explanations for the differences 
observed. With 129SV mice, Redecke et al administered 500 pg of Pam3CSK4 per 
mouse by a subcutaneous route, whereas I administered only 100 pg of Pam3CSK4 
per mouse by an intraperitoneal route. Although this might partly explain the different 
observations observed with TLR2 agonist administration in 129SV mice, it does not 
account for all the observations made in BALB/c mice (367, 369). These differences
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and the mechanisms behind TLR2 agonist administration in different experimental 
asthma models remain unresolved and require further investigation. Possible 
explanations for the different action of TLR2 agonists observed in murine models of 
asthma are further discussed in Chapter 6.
There are other possible roles for TLR agonist in the lung. TLR activation of 
inflammatory cells and respiratory epithelial cells increase their adhesion molecule 
expression and migration into sites of inflammation (387, 388). In Chapter 3, we 
demonstrated that Pam3CSK4 administration by i.p. injection ameliorates airways 
disease, whilst TLR2 agonists given by the i.n. route exacerbate inflammation. One 
mechanism that may account for this difference is that i.p. Pam3CSK4 therapy could 
be creating a local inflammatory response in the peritoneal cavity, and sequestering 
inflammatory cells (such as eosinophils) away from the lung to the peritoneum. 
However, in this chapter we have demonstrated that this is not the case. Mice that had 
received i.p. Pam3CSK4 displayed a reduction in the eosinophil numbers in the 
peritoneum. In addition, mice that had received i.p. Pam3CSK4 therapy demonstrated 
little difference in their peritoneal lymphocyte, neutrophil and macrophage numbers; 
did not look unwell; and macroscopically their intestines and peritoneal cavities 
looked normal. It may be that the timing of the peritoneal washes at 24h, 48h and 72h 
after Pam3CSK4 therapy did not detect an acute peritonitis. However, any detrimental 
effects that may have occurred in the peritoneal cavity out with these times are 
certainly not long-lived, whereas the beneficial effects of TLR2 agonist treatment on 
airways inflammation is seen up to 5 days after the last i.n. challenge.
195
Another possible explanation for the attenuation airways eosinophilia observed after 
TLR2 agonist i.p. administration may relate to increased cell death through increased 
apoptosis and/or necrosis. Necrosis seems unlikely, as increased cell death would 
result in increased release in inflammatory mediators which would in turn enhance 
inflammation. We are currently examining the migration and activation status, 
including markers of apoptosis, in immune cells in the mouse after TLR2 agonist 
therapy. This will further add to our knowledge of how TLR2 agonists are functioning 
in this murine model of allergic airways disease.
The enhancing effect of Pam3CSK4 on IL-10 production in vivo and in vitro raised 
the possibility that regulatory T cells may play a role in Pam3CSK4 treatment. Many 
investigators have observed that regulatory T cells (CD4+CD25+, Trl and Th3) 
function is dependent on IL-10 and TGFp (204, 242, 299, 306). It is also known that 
Tregs express TLRs, and their suppressive function can be enhanced by TLR 
activation (186, 378). Using blocking antibodies, we demonstrate here that the anti­
inflammatory effect of Pam3CSK4 appears to be independent of IL-10 or TGFp, and 
hence Treg cells are unlikely to play an important role in Pam3CSK4 therapeutic 
effect.
The beneficial effect of Pam3CSK4 in murine allergic airways disease and its 
mechanism of action appear to be akin to the TLR9 agonist, CpG oligonucleotides. 
TLR9 activation also led to an increase in IL-12 production from DCs and an 
enhancement o f IFNy synthesis by T cells, resulting in decreased Th2 cell 
differentiation and attenuated eosinophilic airways inflammation (365). However, it 
has been reported that CpG could enhance the risk of aggravation of autoimmune
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disorder in immunocompetent hosts (170). Thus TLR2 agonists, such as synthetic 
Pam3CSK4, may represent additional and alternative potential reagents for 
controlling allergic diseases.
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C h a p t e r  5
The role of Glucocorticoid-induced tumour necrosis factor receptor 
(GITR) in a murine model of allergic airways disease
Data in this chapter has been submitted for publication.
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5.1 Introduction
Glucocorticoid-induced tumour necrosis factor receptor (GITR, TNFRSF 18), is a 
receptor belonging to the TNFR superfamily (TNFRSF), which was cloned in 1997 in 
a hybridoma T cell line treated with dexamethasone (389). GITR is expressed at low 
levels on naive T cells (264, 265, 291), and is abundant on CD4+CD25+ T regulatory 
(Treg) cells (264, 265). GITR was proposed as a cytological marker for CD4+CD25+ 
Tregs, however, GITR expression is up-regulated after activation of CD4+CD25* 
effector T cells (264, 265).
Its ligand, GITRL, is a 173 amino acid transmembrane protein and is expressed on 
macrophages, DCs, and B cells, but not on T cells (390-392). The interaction of GITR 
with its ligand provides an early co-stimulatory signal for CD4+ T cells, enhancing 
proliferation and cytokine production of both CD4+CD25+ and CD4+CD25' 
populations (390, 393, 394). CD4+CD25+ Tregs have a direct inhibitory effect on the 
proliferation of CD4+CD25' effector T cells, and this suppressive activity is reversed 
by an agonistic anti-GITR mAb. Thus, GITR is an important molecule that modulates 
both regulatory and effector T cell functions. However, the role o f GITR in disease, 
especially Th2- mediated disorders, has not yet been investigated and is still poorly 
understood. We have investigated the role of GITR in the function of Thl and Th2 
cells in vitro and in a murine model of asthma in vivo.
The aims of the work in this chapter are to investigate the role of GITR in the 
polarisation of Thl and Th2 cells in vitro by activating cells with anti-CD3 and anti- 
GITR mAb, and then examine cytokine production and expression of the key
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transcription factors T-bet (Thl) and GATA3 (Th2). We then aim to subsequently 
examine the role of GITR in murine asthma in vivo.
We report here that anti-GITR antibody enhanced both Type 1 (IFNy) and Type 2 (IL- 
5) cytokine production by anti-CD3-activated CD4+, and CD4+CD25' T cells cultured 
under neutral, Thl or Th2 polarising conditions in vitro. Consistent with this, anti- 
GITR antibody treatment also significantly increased the expression of the key 
transcription factors T-bet (Thl) and GATA3 (Th2) by CD4+CD25’ T cells cultured 
with anti-CD3 antibody in vitro. In vivo, GITR activation led to disease exacerbation 
of asthma with concomitant elevation of Typel and Type 2 cytokine synthesis. Thus, 
our study suggests that GITR is a potential therapeutic target for both T hl- and Th2- 
mediated inflammatory diseases.
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5.2 The effects of anti-G ITR antibody on Th polarisation in vitro
Our experiments to examine the role of GITR in lymphocyte function started with in 
vitro studies to investigate the effect of anti-GITR mAb treatment on Thl and Th2 
differentiation from naive CD4+ T cell precursors. Previous work has demonstrated 
that anti-GITR mAb can abrogate CD4+CD25+ Treg suppressor function (264, 265), 
and that GITR is an early co-stimulatory signal for CD4+ T cells - enhancing 
proliferation and cytokine production of both CD4+CD25+ and CD4+CD25' 
populations (390, 393, 394). Given the importance of Thl and Th2 cells in infectious 
and inflammatory diseases, we therefore investigated the role of GITR in the 
development of these two key subsets of T cells.
5.2.1 Anti-GITR mAb partially abrogates the suppressor function of 
CD4+CD25+ T regulatory cells
In vitro experiments were performed to re-confirm that anti-GITR mAb abrogated the 
suppressor function of regulatory T cells. These experiments were performed as 
originally described by Shimuzu et al (264), and then performed with graded doses of 
anti-CD3 and anti-GITR antibody (as described in Materials and Methods, Section 
2.5.2, p89). CD4+CD25' and CD4+CD25+ cells from naive BALB/c mice were 
purified by MACS. CD4+CD25+ cells were pre-incubated for 30 minutes with either 
anti-GITR or control Ab. CD4+CD25' and CD4+CD25+ cells (1:1 ratio) were then 
cultured with soluble anti-CD3 Ab, and mitomycin C-treated CD4' cells (acting as 
APC) for 72 hours. Cellular proliferation was determined for the last 8 hours of
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culture by [3H] thymidine incorporation. CD4+CD25' T cells showed typical 
proliferation under these conditions, but CD4+CD25+ T cells did not proliferate above 
background. The regulatory function o f the CD4+CD25+ T cells was demonstrated by 
their suppression of proliferation of the CD4+CD25' cells in co-culture experiments. 
Anti-GITR mAb partially abrogated the suppressor function of CD4+CD25+ cells, as 
demonstrated by the recovery of proliferation of CD4+CD25'/CD4+CD25+ T cell co­
cultures to the proliferation level seen by CD4+CD25' T cells alone (Fig. 5.1). APC 
cells did not proliferate in the presence of anti-CD3 mAb. Anti-GITR mAb did not 
significantly affect the proliferation of CD4+CD25+T cells (data not shown).
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Figure 5.1 Anti-GITR mAb partially abrogated the suppressor function of 
CD25+ T regs in vitro.
CD4+CD25* and CD4+CD25+ cells from BALB/c mice were purified by MACS. 
CD4+CD25+ cells were pre-incubated for 30 minutes with either 10 pg/ml anti-GITR 
or control Ab in vitro. CD4+CD25' and CD4+CD25+ cells (1:1 ratio) were then 
cultured with soluble anti-CD3 Ab (1 pg/ml), and mitomycin C-treated CD4' cells (as 
APC) for 72 hours. Cellular proliferation was determined for the last 8 hours of 
culture by [ H] thymidine incorporation. Anti-GITR mAb partially abrogated the 
suppressor function of CD4+CD25+ T cells (*p<0.05). Data are representative o f 7 
independent experiments, and are shown as mean +/- SEM.
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5.2.2 Anti-GITR mAb enhances proliferation and IFNy and IL-5 production 
from naive CD4+ T cells
To examine the effect of GITR activation of CD4+ cells as a whole, CD4+ cells were 
purified from the lymph nodes o f naive BALB/c mice. These CD4+ cells, which have 
a physiological ratio of CD4+CD25+ and CD4+CD25' cells o f approximately 1:20, 
were stimulated with anti-CD3 mAb and either anti-GITR or control Ab, in the 
presence of mitomycin C-treated CD4' cells (acting as APC) for 72 h (as described in 
Materials and Methods, Section 2.5.3, p90). Proliferation o f CD4+ T cells was 
enhanced in the presence of anti-GITR mAb. Both IFNy and IL-5 production from 
CD4+ cells was significantly increased after anti-GITR mAb treatment (Fig. 5.2). 
APCs did not proliferate or produce cytokines.
5.2.3 Anti-GITR mAb enhances IFNy and IL-5 production from purified 
CD4+CD25' T cells
To examine the effect o f GITR activation on CD4+CD25' effector cells alone, CD4+ 
cells were separated in to CD4+CD25+ and CD4+CD25' populations. CD4+CD25' cells 
were stimulated with anti-CD3 Ab under neutral, Thl or Th2 polarising conditions in 
the presence of anti-GITR or control IgG for 72 h (as described in Materials and 
Methods, Section 2.5.3, p90). Under neutral conditions, CD4+CD25' cultured with 
anti-GITR mAb showed significantly enhanced Thl and Th2 cytokine production 
compared to control Ab, after the 1st and 2nd round of stimulation (Fig. 5.3). 
Proliferation of CD4+CD25* cells was enhanced by culture with anti-GITR mAb. 
Anti-GITR mAb treatment of CD4+CD25+ cells did not significantly alter the
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proliferative response or cytokine production, as compared to control antibody (data 
not shown).
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Figure 5.2 Anti-GITR mAb enhanced proliferation, and IFNy and IL-5 
production by CD4+ cells in vitro.
Naive CD4+ cells from BALB/c mice were cultured with plate-bound anti-GITR or rat 
IgG Ab (10 pg/ml), soluble anti-CD3 Ab (1 (ig/ml), and mitomycin C-treated CD4' 
cells (as APC) for 72 h. Culture supernatant was collected and cytokine 
concentrations assayed by ELISA. Cellular proliferation was determined for the last 8 
hours of culture by [ H] thymidine incorporation. Anti-GITR mAb significantly 
increased proliferation and IFNy and IL-5 production from CD4+ T cells (**p<0.01 as 
compared to control IgG). Data are representative o f 3 independent experiments, and 
are shown as mean +/- SEM.
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Figure 5.3 IFNy and IL-5 production by CD4+CD25* cells in vitro is enhanced 
by anti-GITR mAb.
Naive CD4+CD25' cells were stimulated by anti-CD3 antibody (plate bound 1 pg/ml) 
and anti-GITR or control antibody (soluble 10 pg/ml), without Th skewing agents. 
Culture supernatant was collected at 72 h and cytokine concentrations assayed by 
ELISA. Naive CD4+CD25' showed enhanced Thl and Th2 cytokine production in the 
presence of anti-GITR mAb (**p<0.01 as compared to control antibody). Data are 
representative of 3 independent experiments, and are shown as mean +/- SEM.
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5.2.4 Anti-GITR mAb enhances early Thl and Th2 polarisation by purified 
CD4+CD25‘ T cells in vitro
Having found that anti-GITR mAb can enhance both Thl and Th2 cytokine 
production from CD4+ and CD4+CD25' effectors T cells under neutral conditions, we 
then further investigated the effect of GITR activation on CD4+CD25' effector cells 
under Thl and Th2 polarising conditions. CD4+CD25' cells purified from BALB/c 
mice were stimulated with plate bound or soluble anti-CD3 Ab (0.5-5 pg/ml), and 
anti-GITR or control Ab (10 pg/ml), under Thl or Th2 skewing conditions. After the 
1st round of polarisation, IFNy and IL-5 production was significantly enhanced by Thl 
and Th2 cells respectively, cultured in the presence of anti-GITR mAb (Fig. 5.4). 
Proliferation of Thl and Th2 cells was not affected by culture with anti-GITR mAb 
(data not shown). Flow cytomeric analysis was performed to check the GITR 
expression on CD4+CD25‘ T cells. Consistent with earlier reports (264, 265, 394), 
GITR expression on naive CD4+CD25' T cells was up-regulated within 24 h of CD3 
engagement.
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Figure 5.4 IFNy and IL-5 production in vitro by CD4+CD25' cells cultured in 
Th polarising conditions is enhanced by anti-GITR mAb.
CD4+CD25' cells from BALB/c mice were purified by MACS, and stimulated with 
soluble anti-CD3 Ab (1 pg/ml), and anti-GITR or control Ab (10 pg/ml), under Thl or 
Th2 skewing conditions for 72 h. Culture supernatant was collected and cytokine 
concentrations assayed by ELISA. After the 1st round of polarisation, IFNy and IL-5 
production was significantly enhanced by Thl and Th2 cells respectively in the 
presence of anti-GITR mAb (**p<0.01 as compared to control IgG). Data are 
representative of 3 independent experiments, and are shown as mean +/- SEM.
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5.2.5 A nti-G ITR mAb has no effect on Th polarisation of m ature effector cells
in vitro
We then investigated the effect of anti-GITR antibody on established T cell lines. Thl 
and Th2 cell lines polarised above were then subjected to a second round of 
polarisation in the presence of anti-GITR antibody or normal IgG. Anti-GITR 
antibody had no significant effect on the proliferation or cytokine production of these 
cell lines (data not shown). An earlier report showed that anti-GITR antibody 
enhanced the cytokine production of cloned Thl and Th2 cells (390). We therefore 
investigated the effect of anti-GITR antibody on a more established cell line, cloned 
Thl (X I2) and cloned Th2 (X9) cells. Again, anti-GITR antibody had no effect on the 
proliferation or cytokine production by these cells following CD3 activation (Fig. 
5.5). Flow cytometric analysis was performed to check the GITR expression of the 
cloned Th cells. GITR expression on cloned Th cells was up-regulated within 24 h of 
CD3 engagement. Anti-GITR mAb treatment did not significantly alter the 
proliferative response or cytokine production by CD4+CD25+ T cells (data not 
shown).
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Figure 5.5 IFNy and IL-5 production in vitro by Th clones is not altered by 
anti-GITR mAb.
Thl (X9) and Th2 (X I2) clones were stimulated with anti-CD3 antibody (plate bound 
1 pg/ml) and anti-GITR or control antibody (soluble 10 jig/ml) for 72 h. Culture 
supernatant was collected and cytokine concentrations assayed by ELISA. The 
presence of anti-GITR mAb did not result in significant differences in proliferation, or 
IFNy or IL-5 produced by cloned T cells. Data are mean +/- SEM, and are 
representative of 3 independent experiments.
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5.2.6 Anti-GITR mAb enhances T-bet and GATA3 mRNA expression in early 
Th polarisation
We then explored the mechanism for the anti-GITR antibody mediated enhancement 
o f Type 1 and Type 2 cytokine synthesis in the naive or early polarised cells. Since T- 
bet and GAT A3 are the master switches of Thl and Th2 development respectively 
(10, 23), we investigated the effect o f anti-GITR antibody on the expression of these 
two transcription factors.
5.2.6.1 Anti-GITR mAb enhances early T-bet and GATA3 mRNA expression of 
purified CD4+CD25' T cells
Naive CD4+CD25' cells from BALB/c mice were purified and stimulated by anti-CD3 
antibody and anti-GITR or control antibody, without Th skewing agents for 48 h. Real 
time PCR analysis shows that both T-bet and GATA3 messages were markedly 
enhanced in naive CD4+CD25' T cells cultured with anti-CD3 antibody under neutral 
condition in the presence of anti-GITR antibody compared with normal IgG control 
(Fig. 5.6).
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Figure 5.6 Anti-GITR mAb enhanced the expression of T-bet and GATA3 
mRNA by ThO cells.
Naive CD4+CD25' cells from BALB/c mice were purified by MACS and stimulated 
by anti-CD3 antibody (plate bound 1 pg/ml) and anti-GITR or control antibody 
(soluble 10 pg/ml), without Th skewing agents for 48 h. The expression of T-bet and 
GATA3 were determined by quantitative PCR. CD4+CD25' cells showed a significant 
increase in their T-bet and GATA3 expression, when stimulated in the presence of 
anti-GITR mAb (**p<0.01 and *p<0.05 compared with control Ab). Data are 
representative o f 2 independent experiments, and are shown as mean +/- SEM.
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5.2.6.2 Anti-GITR mAb enhances early T-bet and GATA3 mRNA expression in 
polarised Thl and Th2 cells
CD4+CD25' cells from BALB/c mice were purified and stimulated by anti-CD3 
antibody, and anti-GITR or control antibody. Cells had one round of polarisation 
toward Thl and Th2 phenotypes for 48 h (as described in Material and Method, 
Section 2.5.3, p90). Anti-GITR mAb enhanced T-bet expression in CD4+CD25* T 
cells cultured under Thl polarising conditions (Figs. 5.7), and GAT A3 expression in 
CD4+CD25' T cells stimulated under Th2 polarising conditions (Fig. 5.8).
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Figure 5.7 T-bet mRNA expression is enhanced by anti-GITR mAb treatment 
of Thl cells.
Naive CD4+CD25' cells from BALB/c mice were purified by MACS and stimulated 
by anti-CD3 antibody (plate bound 1 pg/ml) and anti-GITR or control antibody 
(soluble 10 pg/ml). Cells were polarised toward Thl and Th2 phenotypes for 48 h. 
The expression o f T-bet was determined by quantitative PCR. Anti-GITR mAb 
increased the T-bet mRNA expression of CD4+CD25* cells polarised under Thl 
skewing conditions (**p<0.01 compared with control Ab). Data are representative of 
2 independent experiments, and are shown as mean +/- SEM.
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Figure 5.8 GATA3 mRNA expression is enhanced by anti-GITR mAb 
treatment of Th2 cells.
Naive CD4+CD25' cells from BALB/c mice were purified by MACS and stimulated 
by anti-CD3 antibody (plate bound 1 pg/ml) and anti-GITR or control antibody 
(soluble 10 pg/ml). Cells were polarised toward Thl and Th2 phenotypes for 48 h. 
The expression of GAT A3 was determined by quantitative PCR. Anti-GITR mAb 
increased the GATA3 mRNA expression of CD4+CD25' cells polarised under Th2 
skewing conditions (**p<0.01 compared with control Ab). Data are representative of 
2 independent experiments, and are shown as mean +/- SEM.
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5.3 Anti-GITR monoclonal antibody administration exacerbates allergic 
airways inflammation in a murine model of asthma
We have established that anti-GITR mAb can augment the early Thl and Th2 
responses of CD4+ T cells and CD4+CD25’ T cells. This enhancing effect is likely to 
involve the transcription factors T-bet and GAT A3. Previous work has demonstrated 
that anti-GITR mAb can abrogate CD4+CD25+ Treg suppressor function (264, 265) 
We then proceeded to investigate the relevance of the anti-GITR antibody on a Th2 
(asthma) models o f inflammatory disease in vivo.
To investigate the potential role o f an activating anti-GITR mAb in murine allergic 
airways inflammation, we used an OVA-induced murine asthma model. BALB/c mice 
were primed and boosted with OVA (as described in Materials and Methods, Section 
2.6.1, p92). All the mice were challenged i.n. on 3 consecutive days beginning on day 
25. Anti-GITR mAb or control IgG (1 mg per mouse) was administered i.p on day 24 
and 26 (Fig. 5.9). The dose of anti-GITR mAb used was determined by preliminary in 
vivo titration.
Several control groups were used in these experiments. The group labelled below as 
“PBS” represent mice that were sensitised and challenged with PBS (to control for 
OVA), and also given i.p. PBS was on days 24 and 26 in place of anti-GITR mAb. 
The group labelled “Rat IgG” represent mice that were sensitised and challenged with 
OVA, and received control rat IgG i.p. on day 24 and 26.
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One further control group was examined to ensure the effect of anti-GITR mAb was 
not antigen-independent. Here, mice were sensitised with OVA, received anti-GITR 
mAb i.p. on days 24 and 26, and were challenged with i.n. PBS on days 25, 26, and 
27. This last group of control mice did not develop any features of allergic airways 
disease (data not shown).
Initial experiments were carried out with varying doses of i.n. OVA challenge. The 
amount o f i.n. OVA administered was between 1 to 50 micrograms per mouse. The 
i.n. OVA challenge dose was titrated at 2 pg per mouse, which induced a moderate 
amount of airways inflammation that still had the potential to be enhanced.
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Figure 5.9 Experimental protocol to investigate the role of anti-GITR mAb in 
a murine model of allergic airways disease.
BALB/c mice were injected i.p. with 100 pg OVA and 100 pi 2 % Alum on day 0 and 
14. The mice were boosted i.n. with 100 pg OVA on day 14. All mice were then 
challenged i.n. on 3 consecutive days beginning on day 25. Anti-GITR mAb or 
control Rat IgG (1 mg per mouse) was administered i.p on day 24, and 26. Antibody 
was given 1 h prior to i.n. challenge. Penh was determined on day 28 and mice were 
sacrificed on day 29. Serum, BAL and lymphoid cells were collected and lung tissue 
was harvested for histology.
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5.3.1 Anti-G ITR antibody increases BAL eosinophilia
Mice treated with anti-GITR mAb but not control rat IgG showed a profound increase 
in their BAL eosinophilia, without affecting the BAL total cell count (Fig. 5.10).
5.3.2 Anti-GITR antibody administration enhances OVA-induced thoracic 
lymph node responses in vitro
To investigate the immunological mechanism involved in anti-GITR mAb treatment 
which resulted in the increased airway eosinophilia, thoracic lymph node cells were 
harvested from the anti-GITR-treated and rat IgG-treated mice, and cultured with 
OVA in vitro. Lymphocytes from mice treated with anti-GITR mAb had augmented 
OVA-specific T cell proliferation compared to those treated with control rat IgG (Fig. 
5.11). The lymphoid cells from anti-GITR mAb-treated OVA sensitised/challenged 
mice produced significantly more IL-2, IL-4, IL-5, IL-10, and IFNy compared to cells 
from mice treated with control antibody (Fig. 5.11 -  Fig. 5.13).
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Figure 5.10 Anti-GITR mAb exacerbated BAL eosinophilia in murine allergic 
airways disease.
BAL total cell concentration remained unchanged, however the total eosinophil 
numbers and proportion increased markedly after anti-GITR mAb administration 
(*p<0.05 compared with control Ab). Data are mean +/- SEM, n=10 and are 
representative o f 3 independent experiments.
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Figure 5.11 Anti-GITR mAb enhanced the proliferative and T hl cytokine 
response in murine asthma.
Thoracic lymph node cells were harvested on day 29 and cultured with 1 mg/ml OVA 
in vitro. Culture supernatant was collected at 96 h and cytokine concentrations 
assayed by ELISA. Cellular proliferation was determined after 8 hours culture with 
[3H] thymidine. Anti-GITR mAb administration resulted in enhanced cellular 
proliferation, and IFNy production (*p<0.05 and **p<0.01 compared with control 
Ab). Data are mean +/- SEM, n=10 and are representative of 3 experiments.
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Figure 5.12 Anti-GITR mAb enhanced the Th2 cytokine response in murine 
asthma.
Thoracic lymph node cells were harvested on day 29 and cultured with 1 mg/ml OVA 
in vitro. Culture supernatant was collected at 96 h and cytokine concentrations 
assayed by ELISA. Anti-GITR mAb administration resulted in significantly increased 
production of IL-4 and IL-5 (**p<0.01 compared with control Ab). Data are mean +/- 
SEM, n=10 and are representative of 3 experiments.
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Figure 5.13 Anti-GITR mAb enhanced IL-10 and IL-2 production in murine 
asthma.
Thoracic lymph node cells were harvested on day 29 and cultured with 1 mg/ml OVA 
in vitro. Culture supernatant was collected at 96 h and cytokine concentrations 
assayed by ELISA. Anti-GITR mAb administration resulted in enhanced IL-10 and 
IL-2 production (**p<0.01 compared with control Ab). Data are mean +/- SEM, n=10 
and are representative of 3 experiments.
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5.3.3 A nti-G ITR antibody adm inistration increases serum  IgE levels
Serum obtained from mice after anti-GITR mAb treatment showed significantly 
raised titres of OVA-specific IgE antibody (Fig. 5.14), and total IgE (data not shown). 
The level of serum OVA-specific IgGl was not significantly altered by anti-GITR 
mAb treatment (Fig. 5.14). Serum IgG2a levels were low in both groups and 
unaffected by anti-GITR administration (data not shown), which reflects the strong 
Th2 bias in this model.
5.3.4 Anti-GITR antibody increases airway hyperresponsiveness measured by 
enhanced pause
On day 28, the airway hyper-reactivity (a physiological index measure of asthma) was 
assessed by whole body plethysmography. Enhanced pause (Penh) was measured after 
a 2 min nebulisation with 50 mg/ml methacholine (as described in Materials and 
Methods Section 2.6.2, p93). Anti-GITR mAb-treated mice demonstrated increased 
Penh, however this difference was not statistically significant when compared to 
control IgG-treated mice (Fig. 5.15). The p value of 0.055 suggests that the difference 
may have reached statistical significance if the number of mice in each group was 
increased.
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Figure 5.14 Anti-GITR mAb enhanced the OVA-specific IgE levels in murine 
asthma.
Sera were collected on day 29. Anti-GITR mAb treatment led to a significant increase 
in OVA-specific IgE (*p<0.05 compared to control rat IgG) but no significant 
difference in OVA-specific IgGl production. Data are mean +/- SEM of individual 
mice, n= 10 and are representative of 3 experiments.
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Figure 5.15 Anti-GITR mAb modulates airway hyperresponsiveness in murine 
asthma.
Enhanced Pause (Penh) measurement after a 2 min nebulisation with 50 mg/ml 
methacholine was performed on day 28. A non-significant increase in airways hyper­
reactivity was seen in the anti-GITR mAb-treated mice. Data are mean +/- SEM of 
individual mice, n= 10 and are representative of 2 experiments.
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5.3.5 Anti-GITR antibody administration exacerbates histological evidence of 
inflammation in murine lungs
Histological analysis demonstrated an amplification of the inflammatory infiltrates 
seen in the peri-bronchial and peri-vascular areas of the lungs treated with anti-GITR 
mAb (Fig. 5.16).
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Figure 5.16 Histological evidence tha t anti-G ITR  mAb exacerbated m urine 
allergic airways disease.
H&E sections of lungs (x20 magnification) demonstrate that peri-bronchial and peri­
vascular inflammation was increased after anti-GITR mAb administration. Pictures 
(day 29) are representative o f 10 mice per group.
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5.4 CD4+G ITR + cells attenuate allergic airways inflammation in SCID mice
Previous studies have demonstrated that CD4+GITR+ cells which consist mainly of 
CD4+CD25+ Tregs but also contain CD4+CD25‘ Tregs, suppress Thl-mediated 
inflammatory bowel disease (IBD) in the mouse (395). To investigate whether 
CD4+GITR+ cells could exert a regulatory effect in a Th2 driven allergic airways 
disease, we adoptively transferred CD4+GITR+, CD4+GITR', or a combination of 
CD4+GITR+ and CD4+GITR' cells into SCID mice, which then had airways 
inflammation induced by the standard protocol (Fig. 5.17).
5.4.1 CD4+GITR+ cells attenuates BAL eosinophilia induced in SCID mice
Mice transferred with CD4+GITR' cells developed marked eosinophilia after airway 
challenge with OVA, whereas mice transferred with CD4+GITR+ cells failed to show 
eosinophilia. Furthermore co-transfer of both cell types demonstrated that the 
CD4+GITR+ T cells completely suppressed CD4+GITR'-induced eosinophilia (Fig. 
5.18). There was no significant difference in the total BAL cell count among the three 
groups o f mice.
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Figure 5.17 Experimental protocol for the adoptive transfer of CD4+ GITR+ 
and CD4'GITR+ cells into SCID mice with subsequent induction of allergic 
airways disease.
CD4+GITR+, CD4+GITR\ or equal numbers o f CD4+GITR+ and CD4+GITR* cells 
were transferred i.p. into SCID mice, and allergic airways inflammation was induced. 
SCID mice were injected i.p. with 100 pg OVA and 100 pi 2 % Alum on day 0 and 
14. The mice were boosted i.n. with 100 pg OVA on day 14. All mice were then
challenged i.n. on 3 consecutive days beginning on day 25. Mice were sacrificed on
day 28. Serum, BAL and lymphoid cells were collected and lung histology studied.
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Figure 5.18 CD4+GITR+cells suppress BAL eosinophilia in SCID mice.
CD4+GITR+, CD4+GITR\ or equal numbers of CD4+GITR+ and CD4+GITR* cells 
were transferred i.p. into SCID mice, and allergic airways inflammation was induced. 
There was no significant difference in the total BAL cell count among the three 
groups o f mice. However, co-transfer of both cell types demonstrated that the 
CD4+GITR+ T cells completely suppressed CD4+GITR'-induced eosinophilia 
(*p<0.05 compared to CD4+GITR' cell transfer alone). Data are mean +/-SEM, n=5.
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5.4.2 The effect of CD4+GITR+ adoptive cell transfer on OVA-induced lymph 
node cell responses in vitro
Thoracic lymph node cells were harvested and cultured with OVA in vitro. The 
proliferative response of CD4+GITR' cells was unaffected by CD4+GITR+ cells. 
CD4+GITR+ cells alone did not proliferate (data not shown). Cells from CD4+GITR'- 
transferred mice produced significant levels of IL-5 and IFNy, whilst cells from 
CD4+GITR+ transferred mice did not. Interestingly CD4+GITR+ cells significantly 
suppressed the production of IL-5 but enhanced the synthesis of IFNy by CD4+GITR* 
T cells ex vivo (Fig. 5.19). IL-10 was not detected in appreciable amounts in culture 
supernatants.
5.4.3 CD4+GITR+ cell transfer attenuates histological evidence of inflammation
Histological analysis demonstrated that SCID mice reconstituted with CD4+GITR' but 
not CD4+GITR+ cells developed airways inflammation. The airway inflammation in 
mice reconstituted CD4+GITR' cells was completely abolished by co-transfer of 
CD4+GITR+ cells (Fig. 5.20).
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Figure 5.19 OVA-induced LN culture responses in SCID mice adoptive 
transfer experiments.
Lymph node cell culture supernatant, collected at 96 h, shows that the IL-5 produced 
by CD4+GITR' recipients was significantly suppressed in the presence of CD4+GITR+ 
cells. However, IFNy production by LN cultures from CD4+GITR'-treated mice was 
markedly enhanced when CD4+GITR+ cells were co-transferred. Data are mean +/- 
SEM, n=5.
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Figure 5.20 Histological evidence tha t CD4+GITR+ cells suppressed allergic 
airways inflammation in SCID mice.
H&E sections of lungs (x20 magnification) demonstrate that airways inflammation 
was increased after CD4 GITR' cell transfer. This allergic airway inflammation was 
ameliorated if C D 4G ITR  cells were co-transferred with the CD4 GITR' cells. 
Pictures (day 29) are representative o f 5 mice per group.
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5.5 C hapter Discussion
The work in this chapter demonstrates that:
(i) Activating anti-GITR mAb enhances Thl and Th2 differentiation o f naive 
CD4+ and CD4+CD25’ T cells in vitro
(ii) Anti-GITR mAb elevates the expression of the transcription factors, T-bet 
in Thl cells and GATA3 in Th2 cell
(iii) Anti-GITR mAb exacerbates murine asthma, associated with an increase 
of both the Thl and Th2 response
(iv) Passively transferred CD4+GITR+ cells can attenuate murine asthma 
induced in SCID mice reconstituted with CD4+GITR* cells.
These results therefore demonstrate that activation of GITR not only enhances Thl 
and Th2 development in vitro, but has profound effect on Th2-mediated disease in 
vivo.
Regulatory T cells have a pivotal role in asthma pathogenesis (350-352), and GITR is 
an important factor in controlling Treg function. GITR is expressed at high levels in 
murine and human CD4+CD25+ Treg cells, and to a lesser degree on nai've 
CD4+CD25' cells (238, 264, 265, 394-396). Extensive work has demonstrated that the 
addition o f anti-GITR mAb to co-cultures of murine responder (CD4+CD25‘) and 
suppressor (CD4+CD25+) cells completely abrogates the suppressive function of these 
regulatory cells (264, 265). Our study demonstrates that apart from abrogating the 
suppressive effect of Treg cells reported previously, the reversal o f suppression by
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anti-GITR antibody in this culture system could also be due to a direct enhancing 
effect on the CD4+CD25' effector cells.
Anti-GITR mAb administration in experimental murine asthma made it worse, and 
was associated with an increase o f both Thl and Th2 cytokines production. In 
addition, separate in vitro data demonstrates that anti-GITR mAb markedly increased 
both Thl and Th2 cytokine production from antigen-nai've CD4+CD25' cells. The 
mechanism of this enhancing effect on CD4+CD25' cells is likely due to the ability of 
the antibody to elevate T-bet and GATA3, the master switch of Thl and Th2 cells 
respectively. The effect of anti-GITR antibody in this Thl and Th2 driven system is 
likely secondary to the TcR activation and the polarisation cytokines. Thus, anti-GITR 
antibody elevates the expression of these transcription factors following their initial 
induction by the polarising conditions, suggesting that there is a common pathway by 
which GITR signalling enhances the expression of these two opposing transcription 
factors. Given the importance of T-bet and GATA3 in Th cell differentiation, the 
mechanism by which GITR signalling enhances the expression of these transcription 
factors merits further investigation.
It is intriguing that GITR signalling had little or no effect on established Thl and Th2 
cell lines or clones. This is in apparent contrast to a previous report showing that a 
murine recombinant GITR ligand (rmGITR) was able to activate Thl and Th2 cell 
clone (390). The difference may be due to the relative strength of GITR signalling 
delivered by a cross-linking antibody versus GITR ligand. Naive CD4+CD25’ cells 
express a low level of GITR whereas polarised Thl and Th2 cell have high density of 
GITR. It may be that the cross-linking antibody had no further effect on the already
237
densely packed GITR on highly activated T cell lines or clones. Similar reasoning 
may also apply to the lack of an enhancing effect o f the anti-GITR antibody on 
CD4+CD25+ Treg cells which express constitutively high density of GITR and are 
regarded as memory T cells (264, 265). To ensure that this lack of enhancement in 
primed cells was not due to differential cell surface expression, the GITR was 
quantified by flow cytometry. The GITR surface expression was found to be 
upregulated on T cell clones and on established Th cell lines after TcR stimulation, as 
previously described (264, 265). Thus, our results show that cross-linking GITR with 
an agonist anti-GITR antibody enhances the differentiation of naive T cells into Thl 
and Th2 cells, but has little or no effect on the proliferation or cytokine production of 
established Thl or Th2 cells or CD4+CD25+ Treg cells.
In order to further examine the role of GITR activation on established Th2 cells and 
Tregs, in vivo studies were carried out in a murine model of asthma. The 
administration o f anti-GITR mAb in our experiments was relatively late (day 24 and 
day 26). In this setting, anti-GITR mAb is likely to engage cells that are antigen 
primed, and are likely to be Th2 committed as a consequence of alum adjuvant 
administration. Our in vitro data, showing the lack o f enhancement of proliferation or 
cytokine production from primed CD4+CD25' cells, would suggest that anti-GITR 
mAb would not augment the function on these Ag-primed effector T cells in vivo. It 
has been demonstrated that anti-GITR mAb abrogates the suppressive function of 
Tregs in vitro and in vivo (264, 265, 395). Therefore, it may be that the exacerbation 
of allergic airways disease seen in our murine model is mainly a consequence of 
abrogation of Treg function. This explanation may be an over-simplification of the T 
cell-mediated processes that will be involved in our murine model, and it is more than
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likely that antigen-naive CD4+CD25* cells as well as other cell types are involved in 
the worsened Th2-mediated phenotype observed in anti-GITR mAb-treated mice. The 
contribution made by individual T cell populations in the worsened experimental 
asthma observed in anti-GITR mAb-treated mice could be further clarified by 
carrying out adoptive transfer experiments. Here, one could transfer effector and 
regulatory T cells from wild type and GITR-deficient mice into SCID mice, and 
thereafter induce allergic airways disease. Any difference observed between transfer 
groups may elucidate the cells responsible for the GITR-mediated worsening of 
murine asthma.
As previously discussed, many inflammatory cells and mediators are involved in 
asthma pathogenesis. The aims of this study were to examine key mechanisms that 
were involved in many of these complex effector systems. For this reason, the 
investigations outlined in this chapter have primarily concentrated on T cells, which 
are integral to the initiation, propagation and regulation of asthma. As well as T 
lymphocytes, GITR is also expressed on other immune cells, for example 
macrophages and B cells, and it is possible that GITR activation of these cells may 
contribute to aggravation of Th2-mediated inflammation observed in vivo. It would be 
important to investigate the role of GITR activation o f these non-T cells in murine 
models o f asthma. One experimental approach would be to use distinct cell 
populations from GITR-deficient or GITR-over-expressing mice and transfer them 
into SCID mice, with subsequent induction of allergic airways disease. This technique 
and further in vitro studies could further define the role of GITR on different cell 
populations and their modulation of asthma and other inflammatory disorders.
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As well as being a marker for regulatory T cells in the CD4+CD25+ population, 
several investigators have found that GITR is also expressed on naive CD4+CD25‘ T 
cells. Furthermore, it has also been demonstrated that GITR may be a surface marker 
o f CD4+CD25' Treg cells (395, 397). To investigate the role of CD4+GITR+ cells in 
murine asthma, we used an adoptive transfer asthma model. The results demonstrate 
that CD4+GITR+ cells suppressed allergic airways inflammation induced in SCID 
mice reconstituted by CD4+GITR* T cells. The disease-suppressing effect was 
associated with a decrease in the Th2 cytokine and an increase in the Thl cytokine 
production. We have not used anti-GITR mAb treatment in this model, as it would not 
be possible to differentiate the effect of the antibody on CD4+ Treg cells and the 
CD4+CD25‘ effector cells in vivo. Previously it has been reported that CD4+GITR+ 
cells could adoptively suppress inflammatory bowel disease (IBD), induced in SCID 
mice reconstituted with CD4+CD45RBhlgh cells (395). In this IBD system, 
CD4+GITR+ cells reduced IFNy synthesis, and had no effect on the minimal level of 
IL-4. Thus, although CD4+GITR+ T cells have a general beneficial effect on a range 
of inflammatory diseases, the immunological parameters affected by these cells could 
differ, depending perhaps on the prevailing pro-inflammatory cytokine presence in the 
disease milieu. In our study, it is not completely clear why the OVA-induced LN 
production of IFNy is increased when CD4+GITR+ cells are co-transferred into SCID 
mice. It may be that CD4+GITR+ are mainly inhibiting Th2 cells in vivo and the 
balance between the Th2 and Thl cytokines has been disrupted, leading to an 
enhanced Thl profile. It is known that IFNy can reverse Th2-mediated airways 
inflammation if given early during the induction phase of disease (380), however, in 
some models, IFNy have been reported to promote eosinophilic inflammation if given 
late in established disease (381). The low level o f IFNy, produced by LN cells after
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CD4+GITR+ cells transfer, does not appear to affect the degree of airways 
inflammation in our model. Thus, CD4+GITR+ cells appear to effectively suppress the 
predominant Th2-mediated response in murine asthma without significantly 
increasing the Thl profile, and would appear to be a promising candidate for a new 
therapy for inflammatory diseases.
In summary, we demonstrate here that GITR activation results in an exacerbation of 
Th2-mediated inflammatory diseases through the activation of Thl as well as Th2 
cytokines. This is due to the activation of a pathway common to T-bet and GATA3. 
Thus, our results suggest that GITR may be a potential novel target for a range of Thl 
and Th2 mediated inflammatory diseases. Therapeutic potential of reagents such as 
soluble recombinant GITR receptor is currently being explored in our laboratory.
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6.0 General Discussion
6.1 Extrapolating information from murine models of allergic airways 
inflammation to human asthma
In this thesis, a murine model of allergic airways inflammation has been used to 
investigate the immunological processes involved in asthma. This in vivo system 
displays many of the key features seen in acute atopic asthma clinically, such as 
airway eosinophila, elevated serum IgE, allergen-induced production of Th2-mediated 
cytokines by lymph node cells, and histological evidence of allergic inflammation. 
This murine model has allowed the mechanisms of allergic airways inflammation to 
be examined, and more importantly has permitted initial investigation of 
immunomodulatory agents, such as TLR2 agonists and anti-GITR mAb, to be carried 
out with no risk to human subjects. Although this experimental model has been used 
extensively by many investigators and is robust and reproducible I had minor 
concerns over two of the many endpoint parameters used to assess inflammation in 
this model: whole body plethysmography, and the objective interpretation of lung 
histology.
Enhanced pause (Penh) was used as a physiological marker o f airways
hyperresponsiveness. The advantage of using whole body plethysmography is that the
mice are alive, unrestrained and the measurement of Penh is non-invasive. There is
substantial evidence showing Penh is a valid measure of airway hyperresponsiveness,
which also correlates strongly with BAL eosinophilia, and serum IgE levels (359, 398,
399). However, there have also been criticisms of the validity of Penh as a measure of
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airways hyperreactivity (400, 401). These investigators have demonstrated that Penh 
does not always relate to invasive measures of airways resistance and lung 
compliance. Furthermore, it has been suggested that Penh might be a measure of nasal 
passage smooth muscle contraction in response to methacholine (400, 401). 
Additional studies suggest that association between Penh and airways resistance in 
mice may be strain related. It was shown that Penh correlates well with invasive 
measures of airways hyperreactivity in BALB/c mice, however this correlation was 
not as strong in C57BL/6 (402, 403). Enhanced pause is generally, but not universally, 
accepted as an accurate measure of airways hyperresponsiveness. The main concern 
regarding Penh is that it is a derived ratio of expiratory to inspiratory pressures, and 
not an absolute physiological measure. Nevetheless, with this limitation in mind we 
have used a whole body plethysmography in our studies as one of the multiple 
outcomes of allergic airways disease.
In this thesis, representative histological pictures have been used to demonstrate 
changes in allergic airways inflammation. Although many histological scoring 
systems for inflammatory changes are used, there is no universally agreed technique 
in murine allergic airways disease. With the help o f a veterinary experimental 
pathologist, Dr Hal Thompson, we have made initial investigations into the 
inflammatory changes that occur at different stages in our murine model o f allergic 
airways disease. This work is preliminary however we propose to develop this as a 
validated histology scoring system for the allergic murine lung.
Although there is considerable homology between the human and murine genome, 
with only about 300 genes unique to one or the other species (404), there are
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significant differences between their immune systems (405). As such, murine models 
can only approximate to the complex mechanisms of spontaneous and variable airflow 
obstruction, disease exacerbations, or naive airway hyperresponsiveness associated 
with the spectrum of clinical asthma [reviewed in (406, 407)]. Although experimental 
models have their limitations, the information gained by their use is invaluable in 
unravelling the intricacies involved in a disease as complicated as asthma. In 
particular, the manipulations possible with murine models are far greater than is 
possible in humans. Therefore, murine models of asthma are important as one of 
preliminary in vivo methods for gaining further knowledge into the pathogenesis of 
diseases, such as asthma. However, extrapolation of experimental asthma work to the 
pathophysiology of human disease needs caution, for example murine models 
generally use inbred strains and this potential bias may not translate to outbred human 
populations. For this reason, additional experimental animal and human studies will 
be required to support the main findings of this thesis which suggest that the 
manipulation o f TLR2 and GITR results in therapeutic modulation of the 
inflammatory response in asthma.
6.2 TLRs, Regulatory T cells and allergic airways inflammation
The prevalence of asthma and allergies has increased dramatically over the last twenty 
years in developed countries, which cannot be explained by changes in genetic 
predisposition (361, 362, 408). Environmental factors are now thought to be 
responsible for this rapid increase in asthma. The “Hygiene Hypothesis” was 
proposed as a possible explanation for the decreasing prevalence of asthma with 
increasing numbers of siblings. This hypothesis was extended to suggest that with
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improved public health measures and through the use of vaccinations and antibiotics, 
there has been a reduction in childhood exposure of viral and bacterial infections. This 
has lead to reduced development of Thl immunity, leading to a predisposition to Th2- 
mediated conditions, such as asthma (361). However, there is some debate over the 
validity o f this thesis. It has been shown that childhood Th2-dominated immune 
responses against helminths are also associated with protection against atopic diseases 
in adulthood [reviewed in (409)]. Furthermore, it has been shown that the increase in 
prevalence of Thl-mediated autoimmune diseases, such as Type I diabetes mellitus, 
has also risen in parallel with atopic diseases (410). This would suggest that a lack of 
Thl-stimulating immune responses is not the full explanation as to why the 
prevalence of asthma, and other inflammatory disorders, is increasing.
With both Thl- and Th2-mediated inflammatory diseases increasing, it was proposed 
that an immuno-regulatory system that controls both these effector immune responses 
may be affected by environmental changes. Regulatory T cells (Treg) have been 
suggested as a susceptible immunoregulatory system. It has been shown that 
microbial pathogens can influence Treg development and function (411-413). Studies 
have demonstrated that microbial pathogens may induce regulatory T cell 
development through Toll-like receptors (TLRs). Tregs express TLRs, and their 
suppressive function can be enhanced by TLR activation (186, 378). This effect itself 
may be further controlled because TLR signalling can induce DCs to produce soluble 
mediators, such as IL-6, that can make effector T cells resistant to Treg suppressor 
action (187). The importance of TLRs in Treg development in vivo was suggested in 
animal model studies using Mycobacterium vaccae. It was shown that mice treated 
with heat-killed M. vaccae during allergen sensitisation resulted in reduced airway
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hyperresponsiveness, eosinophila, IgE and Th2 cytokine production. The attenuation 
of this Th2-mediated disease was dependent on the production of IL-10 and TGFp by 
regulatory T cells (183). It is known that mycobacteria are recognised by T cells via 
TLR2 and TLR4.
6.3 The role of TLRs in allergic airways inflammation
In our study, the down-regulatory effect of the synthetic TLR2 ligand (Pam3CSK4) 
on airways inflammation was associated with enhanced production of IL-10. This 
raised the possibility that regulatory T cells may play a role TLR2 agonist therapy. 
Many investigators have observed that regulatory T cells’ (CD4+CD25+, Trl and Th3) 
function is dependent on IL-10 and TGFp in vivo (204, 242, 299, 306). Using 
blocking antibodies, we demonstrate in Chapter 4 that the anti-inflammatory effects of 
Pam3CSK4 are mainly independent of IL-10 or TGFp. The only endpoint measure 
that suggested IL-10 and TGFp had a role in the beneficial effect of Pam3CSK4 
therapy was Penh. This apparent disassociation o f airways hyperresponsiveness with 
other immunological measures of acute inflammation has been demonstrated before 
(414-416), and may imply that bronchial hyperreactivity may reflect more established 
airways changes. Overall, it would appear that regulatory T cells are unlikely to be 
involved in the beneficial effects o f Pam3CSK4 therapy in acute allergic airways 
inflammation. Although in this model, it would appear Treg cells do not play an 
important role in the therapeutic effect o f TLR2 agonists, this does not necessarily 
infer that TLR2 or other TLRs will not influence Treg function in other inflammatory 
disorders. Observations in our laboratory suggest that Pam3CSK4 treatment of
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CD4+CD25+ Tregs can transiently abrogate their suppressor action in a murine model 
of inflammatory bowel disease (unpublished data).
It is important to remember that, in addition to Tregs, many other cells of both the 
innate and adaptive immune system express TLRs. It has been demonstrated that 
several APCs express multiple TLRs. In Chapter 4, it was demonstrated that in vitro 
stimulation of BMDCs and BMMs with Pam3CSK4 could modulate the cytokines 
produced, which can influence the polarisation of naive CD4+ T cells. In addition, 
previous studies have demonstrated that TLR activation up regulates the expression of 
surface co-stimulatory molecules on DCs (128-132). Thus, it is likely that TLR 
activation of cells of the innate immune system can influence their APC function by 
changing their cytokine production, and their surface co-stimulatory signals. In the 
context of asthma, APCs other than DCs that express multiple TLRs include epithelial 
cells, fibroblasts, eosinophils, and B cells. In addition, the effector cells of asthma, 
such as NK cells, smooth muscle cells, and mast cells express TLRs, and may also be 
influenced through TLR activation. In our laboratory, investigations into the effect of 
TLR activation on these cells are in progress and will provide important insights into 
how TLR activation may affect inflammatory diseases such as asthma.
The effect of TLR2 activation in asthma is under intense investigation. Chisholm et al 
and Redecke et al (149, 367) have shown that early TLR2 agonist administration 
worsens the development of murine asthma, whilst Velasco et al (369) have 
demonstrated early TLR2 agonist therapy can ameliorate allergic airways disease. 
These apparently contradictory findings cannot be attributed to single factors such as 
the amount or route of administration of TLR2 agonist, or the strain of mouse used -
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as discussed in Chapter 4. However, we propose that a combination of factors may 
determine whether TLR2 agonists attenuates or aggravates allergic airways 
inflammation. Work in our laboratory has demonstrated that TLR2 can act as co­
stimulatory molecule for T cell activation (153). Furthermore, data presented in 
Chapter 4 showed that direct TLR2 activation of Th cells resulted in enhanced Thl 
and Th2 cytokine production in vitro. This TLR2-dependent augmentation of Th 
polarisation is only seen when naive CD4+ are stimulated. Thus, whether TLR 
signalling predominantly activates the Thl or the Th2 pathway depends on a 
combination of factors such as timing (relative to specific antigenic stimulation), dose 
and nature of TLR2 agonists; dose and nature of antigen and adjuvant used; and the 
genetic background of the responding hosts. These factors will then determine if 
TLR2 agonists predominantly activate T cells, or DCs. Although it has been shown 
that TLR activation of CD4+ T cells can enhance Thl responses (153), we postulate 
that under certain in vivo condition, for example in the presence of Alum adjuvant, 
TLR2 agonists may act on T cells directly and enhance Th2 cytokine production by 
CD4+ T cells. This may then explain why some investigators found TLR2 agonist 
administration aggravated allergic murine asthma (149, 367). However, if  TLR2 
agonists are used in a manner so that DCs are mainly activated, then as shown by our 
in vitro work IL-12 production by the APCs will be increased. This will favour Thl 
cell differentiation de novo, and will not only increase the number of Thl cells but 
will also increase the amount of Thl cytokines being produced, which in turn will 
antagonise naive and antigen-primed Th2 cells. Therefore, as long as the levels of 
IFNy induced are not excessive, allergic airways inflammation may then be 
ameliorated by disrupting the Thl/2 balance. This hypothesis is illustrated in Figure 
6 . 1.
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Figure 6.1 Possible explanation for the different action of TLR2 agonists in 
m urine models of allergic airways disease
Depending on factors such as timing (relative to specific antigenic stimulation), dose 
and nature of TLR2 agonists; dose and nature of antigen and adjuvant used; and the 
genetic background of the responding hosts, TLR2 activation may directly enhance 
Thl and Th2 cytokine production from naive CD4+ T cells. This will result 
aggravating allergic murine asthma. However, under different circumstances TLR2 
agonists may influence DC function to enhance their production of IL-12, which in 
turn will favour Thl cell differentiation. As long as the Thl response is not excessive, 
airways inflammation will then be attenuated.
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The hypothesis suggested above and the conclusions o f the data presented in Chapters 
3 and 4 suggest that TLR2 agonists can ameliorate airways inflammation by skewing 
the immune response from a Th2 profile to a Thl profile. In addition to the murine 
work discussed in Chapter 4, studies in humans have shown that Thl cytokines cannot 
only ameliorate allergic disease, but may also exacerbate it. For example, human 
asthma may be characterized by increased expression of both Th2 and Thl cytokines 
by T cells (417), and the airway o f human asthmatics is characterised by 
constitutively increased activation o f the Thl-dependent transcription factor STAT1 
(418), and enhanced expression of IL-12 p40 (419) compared to tissue from non- 
atopic individuals. However, studies examining patients who had received effective 
allergen-desensitisation immunotherapy have demonstrated a shift from a Th2 
cytokine profile into Thl cytokine profiles, which correlated with symptomatic 
benefit in atopic patients (420-422). Thus, although the central requirement for Th2 
cytokines in the pathogenesis o f allergic disease remains clear, Thl and Th2 responses 
are not necessarily mutually exclusive or antagonistic in the context of chronic 
inflammatory responses to allergens. This might partly account for the disappointing 
results from administration o f subcutaneous IL-12 in asthma patients who exhibited 
no improvement in airway hyperresponsiveness to histamine, no significant effect on 
the late asthmatic reaction after inhaled allergen challenge, and experienced a high 
frequency of serious side effects (379).
Although direct administration o f Thl cytokines or Thl-inducing cytokines (such as 
IL-12) have had poor results in human studies, preliminary results using CpG- 
containing DNA vaccines for the treatment of allergic asthma in humans have been 
reported as being promising. CpG-containing vaccines are composed o f DNA with
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immunostimulatory sequences (ISS) containing unmethylated cytosine residues 
adjacent to guanine residues [CpG motif; (423)]. These sequences activate DCs to 
induce robust Thl responses, which is dependent on TLR9 (106). 
Oligodeoxynucleotides that incorporate these ISS (known as CpG-ODNs) are highly 
effective at preventing or ameliorating allergen-induced pulmonary disease and Th2 
responses in mice (423, 424), and these studies have demonstrated that TLR9 
signalling can attenuate allergic airways inflammation by skewing a Th2-dominant 
immune response to a Thl-dominant response. In addition, studies using CpG- 
containing DNA vaccines in human allergic diseases have reported very few side 
effects (425). The reasons why TLR9 activation induces a Thl response in allergic 
disease with few side effects, whilst Thl cytokine administration causes systemic 
upset remains unclear. Hence, targeting TLR9 and other TLRs that induce Thl 
responses would appear to be a novel therapy for Th2-mediated diseases.
Although the clinical trials have initially shown CpG-containing DNA vaccines to 
have few side effects in asthmatic patients, concerns have been raised over the use of 
CpG-containing vaccines in patients with a predisposition to autoimmune diseases, 
such as systemic lupus erythematosus (SLE). SLE is a non-organ specific disease 
characterised by inefficient removal o f apoptotic cells, and the normally sequestered 
nucleoproteins exposed on apoptotic cell membranes that can trigger auto-reactive B 
cells to produce IgG auto-antibody. This process appears to involve antigen 
presentation by dendritic cells using a TLR9-dependent pathway (169). It has been 
suggested that CpG-containing vaccines could enhance the risk of aggravating 
autoimmune disorder in a small number of immunocompetent hosts (169, 170). In our 
model, the total IgG level in Pam3CSK4-treated and -untreated mice, and found to be
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similar. Although this does not exclude the development of autoreactive antibodies, it 
does show that the total level of immunoglobulin does not increase after TLR2 agonist 
therapy. Thus TLR2 agonists, such as synthetic Pam3CSK4, may represent additional 
and alternative potential reagents for controlling allergic diseases.
Together the results obtained here using TLR agonists suggest that established Th2- 
mediated inflammation could be ameliorated by TLR agonists, probably by skewing 
towards a Thl response. Further studies are needed to elucidate the mechanism of 
TLR agonist therapy in inflammation, and several suggestions will be discussed in the 
prospective studies paragraph below. However, synthetic lipopeptide, or other TLR2 
agonists have minimal toxicity and may have potential as therapeutic agents in human 
asthma.
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6.4 The role of G ITR and allergic airways inflammation
Glucocorticoid-induced tumour necrosis factor receptor (GITR) was described as a 
surface molecule involved in regulatory T cell function, and our initial experiments 
were designed to investigate this in a murine model of asthma. Subsequent work has 
demonstrated that GITR activation not only abrogate CD4+CD25+ Treg function, but 
also act as a co-stimulatory signal of CD4+CD25‘ effector T cells, and thus broadened 
our experimental approach to studying this molecule in asthma. In addition, it has 
since been shown that GITR expression may represent a marker for all naive CD4+ 
regulatory T cells. Our preliminary work initially focused on regulatory T cells in 
asthma, however, as our knowledge of GITR increased the direction of our efforts 
moved towards how GITR activation affected effector cells, in particular Th 
polarisation. Furthermore, we investigated whether isolated CD4+GITR+ cells could 
suppress allergic airways disease by passive transfer in vivo.
Our results demonstrate that an activating anti-GITR mAb enhances both Thl and 
Th2 differentiation of naive CD4+CD25' effector T cells in vitro. The work also 
demonstrates that anti-GITR mAb causes an impressive exacerbation of murine 
asthma, which is associated with an increase of both the Thl and Th2 response in 
vivo.
There is conflicting published data regarding the role of CD4+CD25+ regulatory T 
cells in experimental allergic disease in mice. Some investigators have demonstrated 
that passive transfer of CD4+CD25+ T cells worsened the allergic phenotype in mice, 
and suggested that this was due to the preferential inhibition of Thl cells by the Tregs
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(349). Others have found that CD4+CD25+ regulatory T cells could suppress Th2- 
mediated inflammation, without affecting airways hyperresponsiveness (350, 351). 
The explanation for these different findings is not completely clear, however these 
were just three studies and a consensus will probably emerge in time with more 
experimental work. It may also reflect the complex interplay of different 
inflammatory mechanisms that are involved in airway hyperresponsiveness, only 
some o f which may be under the control of Tregs.
In human studies, CD4+CD25+ cells isolated from peripheral blood of atopic patients 
are less effective than the same cells from non-atopic control subjects in their 
suppressive function and in their ability to regulate Th2 responses (352, 426, 427). 
Proposed explanations for this finding include reduced numbers of Tregs, 
dysfunctional Tregs, a higher proportion of CD4+CD25' effector T cells, or 
refractoriness of effector cells to regulation of activated CD4+CD25+ T cells. Ling et 
al (352) showed that the peripheral blood CD4+CD25+ T cell count was normal in 
atopic patients, but the function of these Tregs seemed reduced. This was shown when 
purified CD4+CD25+ Tregs from healthy non-atopic individuals had a greater ability 
to suppress allergen-specific Th2 responses in vitro than observed from CD4+CD25+ 
Tregs from atopic individuals. Furthermore, suppression was further diminished when 
CD4+CD25+ T cells were isolated from grass pollen allergic patients during hayfever 
season. This reduced Treg function offers a plausible alternative explanation to the 
hygiene hypothesis for the increased prevalence of autoimmune and allergic disease 
observed over the last 20-30 years. If Tregs, that normally can suppress T hl- and 
Th2-mediated responses, became dysfunctional as a consequence of some
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environmental change, this would then account for the increase in prevalence of both 
Thl - and Th2-mediated inflammatory diseases.
There is a condition in nature that illustrates this hypothesis. A mutation in the gene 
coding the transcription factor FOXP3 results in the immunodysregulation, 
polyendocrinopathy, and enteropathy, X-linked (IPEX) syndrome. This is also 
associated with allergic symptoms including severe eczema, increased serum IgE 
levels, eosinophilia, and food allergies. This implies that dysfunction of the Treg 
population results in multiple diseases, including Th2-mediated allergy (272) 
Furthermore, it has been demonstrated that an imbalance between IL-10-secreting 
Tregs and Th2 cells are responsible for the occurrence of allergic symptoms (428). 
Consisitent with this, Akdis et al demonstrated an increased frequency of IL-4 
secreting, allergen-specific T cells in atopic patients and an increased frequency of IL- 
10-secreting, allergen-specific T cells in non-atopic individuals (428).
Tregs have also been found to be important in the induction of airways tolerance to 
inhaled allergen. Murine work has indicated a role for foxp3  and membrane bound 
TGFp-expressing CD4+ Tregs in induction of airways tolerance elicited by low dose 
inhaled antigen (429). Studies by Umetsu and colleagues (52, 53) have shown that, in 
a murine model o f allergic airways disease, tolerance can be induced by intranasal 
administration of high dose allergen. This tolerance is dependent on IL-10-producing 
DCs, which in turn promote the induction of IL-10-secreting regulatory T cells. These 
Tr cells also produce IL-4 early in their development, and are dependent on IL-10 
production by DCs and the inducible T-cell co-stimulator (ICOS) molecule expressed
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on DCs for their suppressive function. Subsequent studies have shown these Tr cells 
to be T-bet and/ox/?3-positive (278).
Hence, Tregs have been shown to inhibit allergic inflammation in animal models, and 
ex vivo experiments suggest that human Tregs may be dysfunctional in atopic 
individuals. To further support the notion that Tregs are important in the pathogenesis 
of allergic disease, there is evidence showing that treatments commonly used for 
asthma and allergy may promote Treg numbers and/or function. Allergen- 
desensitisation immunotherapy is used for patients with IgE-mediated diseases, such 
as allergic rhinitis, asthma and bee venom anaphylaxis. Effective allergen 
immunotherapy is associated with immune deviation from a Th2 profile to a Thl 
response (422, 430). However, not all reports agree that immune deviation is 
necessary for allergen-desensitisation immunotherapy to be successful (431). In this 
case, it was shown that immunotherapy to insect venom is associated with a decrease 
in allergen-specific Th2 response, and the induction of IL-10-secreting T regulatory 
cells (432, 433). Another line of evidence is that an important therapy for asthma and 
allergic disease is glucocorticoids. It has been shown that glucocorticoid-induced 
synthesis o f IL-10 by human T cells is associated with a suppressive effect on CD4+T 
cells (434). More importantly, steroid-resistant asthmatics have CD4+ T cells with a 
reduced capacity to synthesise IL-10 in response to glucocorticoids in vitro (435). 
Glucocorticoids and Vitamin D3 can induce IL-10 producing Tregs (301, 436) which 
can reduce Th2 cytokine production by human T cells in vitro. Furthermore, pre­
incubating CD4+CD25+ regulatory T cells from the peripheral blood of atopic patients 
with the steroid fluticasone propionate resulted in enhancement of Treg function 
(437). Thus, Tregs appear to have an important regulatory role in the pathogenesis of
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asthma and allergy, and current treatments may work by inducing Treg numbers and 
function.
CD4+CD25+ regulatory T cells constitutively express GITR at high levels, and 
moreover the suppressive function of these Tregs is abrogated by the activating anti- 
GITR antibody. If GITR signalling could be blocked, this would lead to an 
enhancement of the regulatory function of CD4+CD25+ T cells and potentially new 
therapies for inflammatory diseases could be developed. In Chapter 5, it was 
demonstrated the OVA-induced IL-10 production in vitro from thoracic LN cells was 
enhanced in mice that had been treated with anti-GITR mAb. In this situation, one 
would expect anti-GITR mAb treatment to abrogate CD4+CD25+ Treg function, with 
an associated reduction of IL-10 production. If anti-GITR mAb were activating other 
Tregs, for example CD4+CD25' IL-10-producing Trl cells, again an increase in IL-10 
production would not correlate with the observed exacerbation o f murine asthma. 
However, it has been demonstrated that GITR is also expressed on CD4+CD25' 
effector T cells and macrophages, and we suggest that anti-GITR mAb may be 
inducing IL-10 production from these cells. Thus, macrophages or CD4+CD25' 
effector T cells may be producing IL-10 in response to anti-GITR mAb treatment in 
vivo, and this may even be enhanced if Treg function is abrogated by GITR activation. 
It would be important to further investigate this by examining the effects of GITR 
activation on these cells in vitro, as well as examining possibly isolating the role of 
GITR on other cells such as Trl cells which are known to produce large quantities of 
IL-10.
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Regulatory T cells have been shown to have suppressive effects on CD4+, CD8+, B 
cells and APCs. However, there have been no reports o f Tregs directly influencing 
other cells of the innate system, for example mast cells, NK(T) cells or eosinophils. It 
would be interesting to investigate the effects of Tregs (and GITR) on the effector 
function o f cells of the innate system, as well as other cells important in airway 
remodelling of chronic asthma such as fibroblasts and smooth muscle cells. One 
murine study has demonstrated the importance of CD4+CD25+ Tregs in suppressing 
Th2-mediated immune responses, but not bronchial hyperresponsiveness, in a model 
o f chronic asthma (351). Having demonstrated that GITR has an important role in a 
mouse model of acute asthma, it would be of interest to examine the role of GITR in a 
chronic model of murine asthma, which may resemble more closely the human 
disease. It would then be important to determine whether CD4+CD25+ T cells have a 
role in regulating chronic airways inflammation in humans.
It is important to remember that GITR is also expressed at low levels on CD4+CD25' 
effector T cells. Upon TcR engagement, GITR expression is upregulated on effector T 
cells, and has been shown to act as a co-stimulatory molecule (390, 394). Our study 
demonstrates that activating anti-GITR mAb enhances Thl and Th2 differentiation of 
naive CD4+ and CD4+CD25* T cells in vitro. The mechanism of the enhancing effect 
on CD4+CD25’ cells is likely due to its ability to elevated T-bet and GATA3, the two 
master switches o f Thl and Th2 cells. Given the importance of T-bet and GATA3 in 
Th cell differentiation, the mechanism by which GITR signalling enhances the 
expression of these transcription factors merits further investigation. The mechanism 
by which GITR activation inhibits Treg function, but co-stimulates effector T cells 
also requires further elucidation. Shimuzu et al showed that NF-kB expression was
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increased in CD4+CD25+ T cells after GITR cross-linking. Ronchetti et al, using 
GITR-deficient mice, found that GITR'7' effector T cells proliferated more than wild 
type control T cell in response to anti-CD3 stimulation (438). The same investigators 
also found that GITR provided a signal to T cells that protected them from activation- 
induced cell death (AICD) (389, 438). However, other investigators suggest that 
GITR ligation can induce both AICD and apoptosis (396, 439). Therefore the role for 
GITR as a cell survival signal is unresolved, and recently, it has been shown that 
GITR cross-linking on naive and activated T cells resulted in activation of MAPKs 
and NF-kB. However these signals were not sufficient to directly inhibit AICD of T 
cells (440). Recently, it has been demonstrated that TNFR-associated factor 2 
(TRAF2) plays an inhibitory role in GITR-triggered NF-kB activation, which is not 
observed in other TNFRs, and may represent a target for GITR manipulation (441). 
Hence, GITR signalling is incompletely understood, and further studies are required 
to elucidate the mechanisms o f GITR activation o f immune cells, which may lead to 
novel targets for GITR modulation.
Recent studies carried out in our laboratory have shown that GITR activation can also 
exacerbate a Thl-mediated murine model of arthritis in vivo (unpublished data). 
Hence, GITR activation by monoclonal antibody increases both Thl- and Th2- 
mediated diseases in vivo. Although this would not be beneficial in inflammatory 
disease, it could potentially have a clinical use when enhancement of the immune 
system was required, for example in tumour cell or microbial pathogen clearance (Fig. 
6.2, lb). Developing soluble recombinant GITR receptor or increasing TRAF2 signals 
are potential targets for inhibiting the GITR signal, which could be used in many 
inflammatory disorders (Fig. 6.2, la). The balancing of an over-active immune system
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Figure 6. 2 Potential therapeutic interventions with GITR modulation
Manipulation o f GITR function could possibly lead to new therapeutic approaches. 
We hypothesise that blocking GITR signal could increase Treg function and reduce 
the co-stimulatory signal to effector T cells. If the GITR signal could be blocked 
sufficiently to dampen the immune system without inducing immunosuppression, then 
the clinical application in inflammatory and related disorders would be o f value (panel 
la). The opposite would then apply if the GITR signal was enhanced (panel lb). 
Furthermore, the transfer (panel II) or depletion of GITRf cells could potentially 
induce suppression or activation of the immune response.
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without over-suppressing it represents a considerable future challenge. In addition to 
suppressing or enhancing GITR function, GITR expression may represent a marker 
for all naive CD4+ regulatory T cells. Our study demonstrated that passively 
transferred CD4+GITR+ cells could attenuate murine asthma induced in SCID mice 
reconstituted with CD4+GITR' cells. The transfer or induction of CD4+GITR+ cells 
could possibly dampen an overactive immune response (Fig. 6.2, II), or the removal 
o f these cells could “boost” the immune system when required. The potential 
difficulty of using GITR as marker of Tregs is that, like CD25, it is also upregulated 
upon activation of other cells. Therefore in the peripheral blood of humans, who are 
continuously exposed to antigen, GITR+ cells will be a heterogeneous mix of Tregs 
and activated effector cells.
Although these potential problems exist, GITR is an exciting new molecule that is 
important in the function of both regulatory and effector T cells, and through its 
modulation may develop into new therapies for many inflammatory disorders.
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6.5 Future w ork
Based on the results of the work presented in this thesis I would like to suggest that 
our initial hypothesis can be advanced and that several new experimental lines of 
investigation have been opened.
1. One possible target is GITR, which has been shown to be a molecule that is 
important in the function of CD4+CD25+ Tregs and effector T cells. The potential 
exists for manipulating GITR function that may lead to therapies in human diseases. 
Again, before translating findings from our murine model of allergic inflammation 
into clinical diseases such as asthma, extensive in vitro and in vivo work will be 
required to determine if GITR activation can be controlled so as not to induce 
unacceptable adverse effects, and to also examine the effect of GITR activation on 
other cells of the immune system. These studies could also be designed to examine the 
role of GITR activation on cells of the innate and adaptive immune system, such as 
macrophages and B cells. Furthermore, the role of GITR activation on other Treg 
populations, for example Trl and Th3 cells, could be performed. These investigations 
would hopefully not only provide further information into the cellular and molecular 
mechanisms behind GITR in acute models of murine asthma, but also address 
hypotheses regarding the role of GITR and Tregs in chronic asthma pathogenesis as 
well. Further knowledge into the mechanisms o f GITR activation of immune cells 
would hopefully direct future work into modulating GITR function, which would 
hopefully lead to safe manipulation of the immune response, as summarised in Figure 
6 .2 .
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2a. Our work shows that TLR2 agonist therapy in a BALB/c model of asthma was 
effective in attenuating Th2 inflammation by reducing a Th2 response and inducing a 
mild Thl response. Further work is required to investigate the detailed mechanisms 
involved in TLR2 activation of APCs and T cells in Th2-mediated inflammation. In 
particular, examining the molecular basis of TLR2 agonist action on these cells would 
be of interest. As well as investigating the effect of TLR2 activation on APCs and T 
cells, it would be important to carry out experiments designed to address whether 
TLR2 activation of other cells, such as eosinophils, mast cells, epithelial cells, 
fibroblasts, smooth muscle cells, B cells and NK cells, influenced their function and 
as to whether this had a bearing on asthma pathogenesis. This experimental approach 
would also be of value in investigating why different routes and different timing of 
TLR2 agonist administration resulted in apparently contradictory results. A secondary 
aim of this work could also address whether these TLR2 agonists had a role in airway 
remodelling, seen in patients with chronic irreversible asthma, and may also be 
extended to investigate the role of TLR2 activation in non-allergic airways 
inflammatory disease such as non-atopic asthma, COPD or Acute Lung Injury.
2b. As TLR2 activation induces a mild Thl response in our model, it would be 
important to ensure that side effects from such a therapy are not evident. In our 
preliminary studies, we showed that TLR2 agonist therapy did not appear to increase 
IgG levels, did not induce peritonitis, and the mice did not look sick. The primary aim 
of this work was to examine the potential benefits o f TLR2 agonist administration, 
and was not designed to investigate potential adverse effects. Having demonstrated a 
potential use for TLR2 agonists in experimental asthma, it would be important to 
address whether TLR2 activation induces symptoms such as fever, peritonitis over a
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longer time scale, or even induced Thl-mediated inflammatory disease. Such work 
has been performed for TLR9-mediated CpG DNA vaccine therapy in Th2-mediated 
disease, and appears to have minimal side effects.
3. Further work is required to examine the effects o f TLR2 agonists and GITR 
manipulation in our murine model o f acute asthma, and in models o f chronic asthma. 
Airway hyperreactivity was assessed in our work using enhanced pause. Some 
investigators have found that in some strains of mouse, Penh does not always 
correlate with invasive measures of airway hyperresponsiveness. It would be 
important to ensure that our assessment of airway hyperreactivity using whole body 
plethysmography was validated. This could be performed by running an experiment 
where non-invasive whole body plethysmography was performed on the same mice 
that had invasive physiological measures taken. It would also be useful to devise a 
lung histology score that could be used as validated measure of allergic airways 
inflammation.
4. If further experimental animal work indicates that TLR2 agonists and GITR 
have important roles in asthma pathogenesis, and more importantly are safe, then the 
ultimate aim of this work would be conduct clinical studies in human asthmatics. 
These studies would initially be aimed at examining the expression of GITR and 
TLR2 on different cell groups obtained from peripheral blood, sputum, 
bronchoalveolar lavage (BAL), and lung biopsy specimens from asthmatic and normal 
healthy individuals. This work could then be taken forward by examining the effect of 
these immunomodulatory agents on the cells isolated from the peripheral blood and 
lung samples ex vivo. It is noted that the number of cells obtained, especially T cells,
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is poor from sputum and BAL samples, and hence lung biopsies may be necessary 
when examining the role of TLR2 and GITR on pulmonary cells. If  TLR2 and GITR 
were found to have a role in either the protection from asthma in healthy individuals, 
or in the development of disease in asthmatics then the potential for conducting 
clinical trials investigating the safety and the therapeutic benefits of these novel 
immunomodulatory agents should be considered.
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6.6 Conclusions
TLR2 agonists appear to represent a novel approach to treat established Th2-mediated 
inflammation by skewing the immune response towards a Thl response. GITR 
activation activates the immune system by abrogating regulatory T cell function, and 
enhancing effector T cell response. GITR manipulation may lead to new therapies, 
especially if the benefits of activating or suppressing the immune system are 
maximised, with minimal induction of side effects. Both TLR2 agonists and GITR 
merit further investigation, and may result in novel therapies not only for asthma, but 
a range of many inflammatory disorders.
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